<allTrials totalCount="61" xmlns="http://www.67bricks.com/isrctn"><fullTrial>
  <trial lastUpdated="2006-12-29T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2006-12-28T00:00:00.000Z">33364178</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>PREvention of Migraine In Adolescents</title>
      <scientificTitle/>
      <acronym>PREMIA</acronym>
      <studyHypothesis>Based on systematic reviews concerning effective treatments in children with migraine a medical treatment (propanolol) as well as a non-medical treatment (relaxation therapy) appear to be effective compared to no treatment or placebo. However their relative effectiveness is unknown.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Perceived effect and change of intensity
2. Frequence and duration of migraine attacks</primaryOutcome>
      <secondaryOutcome>1. Change in 'quality of life'- experience
2. Number of schooldays missed
3. Medical consumption</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN33364178</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, placebo controlled, parallel group, triple blinded trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-10-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-07-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="e4c0feb5-a3e9-457d-a4f0-e73dd773a62d">
	  <name>Erasmus Medical Centre</name>
	  <address/>
	  <city>Alkmaar</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>3016 AH</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Migraine patients
2. Aged 13 to 18 years
3. Living in Rotterdam</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Years" value="13.0"/>
      <upperAgeLimit unit="Years" value="18.0"/>
      <gender>Not Specified</gender>
      <targetEnrolment>160</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>160</totalTarget>
      <exclusion>1. Patients suffering from asthma, allergies and diabetes
2. Using propanolol and/or relaxation therapy as a treatment less then six months before the start of the trial</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-10-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-07-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Migraine</description>
	<diseaseClass1>Nervous System Diseases</diseaseClass1>
	<diseaseClass2>paroxysmal disorders</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Group 1: Propanolol treatment and placebo relaxation treatment
Group 2: Placebo medical treatment and relaxation therapy</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Propanolol</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder15966-0</funderId>
      <contactId>Contact53912_15966</contactId>
      <sponsorId>Sponsor52461</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53912_15966">
    <title>Dr</title>
    <forename>D</forename>
    <surname>Noordzij</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Erasmus Medical Centre
Department of General Practice
Westzeedijk 112-114</address>
      <city>Alkmaar</city>
      <country>Netherlands</country>
      <zip>3016 AH</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor52461">
    <organisation>Erasmus Medical Center (The Netherlands)</organisation>
    <website>http://www.erasmusmc.nl/#http://www.erasmusmc.nl/</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Department of General Practice
P.O. Box 1738</address>
      <city>Rotterdam</city>
      <country>Netherlands</country>
      <zip>3000 DR</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.5645.2</gridId>
    <rorId>https://ror.org/018906e22</rorId>
  </sponsor>
  <funder id="Funder15966-0">
    <name>Nuts/Ohra (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2006-12-28T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2006-12-28T00:00:00.000Z">97133543</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Levetiracetam for Treatment of Non-psychotic and Non-depressive behavioural symptoms of dementia</title>
      <scientificTitle/>
      <acronym>LaTiNN</acronym>
      <studyHypothesis>Specific behavioural symptoms of dementia needs specific treatment. In cases, levetiracetam seems to be effective in non-psychotic and non-depressive behavioural symptoms of dementia.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Effect on week four and 13 compared to base-line on:
1. Behavioural symptoms (NPI and Cohen-Mansfield Agitation Inventory [CMAI])
2. Care-giver burden (CBI) 
3. Clinical impression (Global Clinical Impression [GCI])</primaryOutcome>
      <secondaryOutcome>Effect on week four and 13 compared to base-line on:
1. Cognition (Mini Mental State Examination [MMSE])
2. Activities in Daily Living (ADL) (Interview for Deterioration in Daily living activities in Dementia [IDDD])</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN97133543</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Non-randomised, clinical trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Single-centre</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-08-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-04-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="30d8fe24-9f46-40b3-a16f-84880f1a29d4">
	  <name>Jeroen Bosch Hospital</name>
	  <address/>
	  <city>Den Bosch</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>5200 ME</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Ambulant patients with dementia, level Reisberg four to six
2. Informant available
3. Six weeks stable treatment of dementia, anti-psychotics and anti-depressants</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>25</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>25</totalTarget>
      <exclusion>1. Neuropsychiatric Inventory (NPI) item hallucinations, delusions and depression more than one
2. Epilepsia
3. Alcoholism
4. Diabetes Mellitus (DM) or thyroid disease not under control</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-08-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-04-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Dementia</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Mental disorders</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>500 mg Levetiracetam/day to a maximum 1500 mg Levetiracetam/day.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Levetiracetam</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2005 Results article in https://doi.org/10.1017/s1041610205212061</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="5548b06a-36f9-4769-9a32-f0b970d5f1cd" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2005-06-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://doi.org/10.1017/s1041610205212061"/>
	<description/>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder15983-0</funderId>
      <contactId>Contact53929_15983</contactId>
      <sponsorId>Sponsor52478</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53929_15983">
    <title>Dr</title>
    <forename>P L J</forename>
    <surname>Dautzenberg</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Jeroen Bosch Hospital
Department of Geriatrics
P.O. Box 90153</address>
      <city>Den Bosch</city>
      <country>Netherlands</country>
      <zip>5200 ME</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)73 699 8629</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">p.dautzenberg@jbz.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52478">
    <organisation>Jeroen Bosch Hospital (The Netherlands)</organisation>
    <website>http://www.jeroenboschziekenhuis.nl/jbz/jbz_patient</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Department of Geriatrics
P.O. Box 1101</address>
      <city>Den Bosch</city>
      <country>Netherlands</country>
      <zip>5200 BD</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.413508.b</gridId>
    <rorId>https://ror.org/04rr42t68</rorId>
  </sponsor>
  <funder id="Funder15983-0">
    <name>Not provided at time of registration</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2006-12-28T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2006-12-28T00:00:00.000Z">42881741</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Conform and non conform glenoid components in total shoulder replacements</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Conform components are beneficial for motion coordination and reducing high rim-loads, while non-conform components are beneficial in reducing high humerus-to-scapula impulses (impact forces).</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Component fixation (Rontgen Stereophotographic Analysis [RSA])
2. Shoulder functioning (Range of Motion [RoM], Questionnaires for shoulder functioning)</primaryOutcome>
      <secondaryOutcome>1. Glenohumeral translation (Fluoroscopy)
2. Pain (Visual Analogue Scale [VAS])
3. Maximum arm force
4. Shoulder coordination (Principal action)
5. Proprosepsis (mirroring)</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN42881741</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>p06.017</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, controlled, parallel group, double blinded trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-11-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2010-11-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="016732e9-41b6-463c-afe0-eb7621501149">
	  <name>Leiden University Medical Center</name>
	  <address/>
	  <city>Leiden</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>2300 RC</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Individuals requiring primary arthroplasty as a result of osteoarthritis or rheumatoid arthritis.</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>20</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>20</totalTarget>
      <exclusion>1. Rotator cuff tear, pre-operatively diagnosed by means of Magnetic Resonance Imaging (MRI)
2. Humeral component with a radius of 20 mm
3. Prior history of shoulder surgery</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-11-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2010-11-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Shoulder disorders</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Shoulder disorders</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Total shoulder replacement</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16001-0</funderId>
      <contactId>Contact53947_16001</contactId>
      <sponsorId>Sponsor52496</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53947_16001">
    <title>Dr</title>
    <forename>F</forename>
    <surname>Steenbrink</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Leiden University Medical Center
Departement of Orthopaedics
Laboratory for Movement Analysis
P.O. Box 9600</address>
      <city>Leiden</city>
      <country>Netherlands</country>
      <zip>2300 RC</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31(0)71 526 2581</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">f.steenbrink@lumc.nl </email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52496">
    <organisation>Leiden University Medical Center (LUMC) (The Netherlands)</organisation>
    <website>http://www.lumc.nl/english/start_english.html#http://www.lumc.nl/english/start_english.html</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Department of Orthopaedics
Laboratory for Movement Analysis
P.O. Box 9600</address>
      <city>Leiden</city>
      <country>Netherlands</country>
      <zip>2300 RC</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.10419.3d</gridId>
    <rorId>https://ror.org/05xvt9f17</rorId>
  </sponsor>
  <funder id="Funder16001-0">
    <name>Reumafonds (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2006-12-29T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2006-12-28T00:00:00.000Z">42343515</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Effect of milk containing lactium on subjective sleep parameters</title>
      <scientificTitle/>
      <acronym>"slaap-onderzoek" (sleep study)</acronym>
      <studyHypothesis>Milk containing lactium significantly increases duration and quality of sleep in persons with mild sleeping disorders.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Sleep quality (assesed with the "Groningen Sleep Questionnaire") and sleep quantity.</primaryOutcome>
      <secondaryOutcome>Quality of Life and Sleepiness.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN42343515</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, placebo controlled, parallel group, double blinded trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-04-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="5d427a1a-af94-4b70-83a7-c385c98cdaaa">
	  <name>Friesland Foods</name>
	  <address/>
	  <city>Ede</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>6710 BD</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Healthy adults 20 to 60 years of age
2. With regular and normal Dutch eating habits (consuming mostly three main meals including breakfast)
3. A regular lifestyle
4. With sleeping problems present during more than one month prior to the start of the study and during three or more nights a week
5. Having given their written informed consent
6. Willing to comply with the study procedures
7. Willing to accept use of all nameless data, including publication, and the confidential use and storage of all data for at least 15 years
8. Sleeping problems are defined as more than 30 minutes awake after lights out or more than three times awake at night or during more than 45 minutes awake at night</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>200</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>200</totalTarget>
      <exclusion>1. Participation in any clinical trial including blood sampling and/or administration of substances up to 90 days before the start of this study
2. Participation in any non-invasive clinical trial up to 30 days before the start of this study, including no blood sampling and/or oral, intravenous, inhalatory administration of substances
3. Mental status that is incompatible with the proper conduct of the study
4. Intended vacation in the study period
5. Having a history of medical or surgical events that may significantly affect the study outcome
6. Use of medication for sleeping problems within three months prior to the study, and during the study
7. Alcohol consumption more than 21 units/week
8. Frequent intense sport practice (more than ten hours a week)
9. Reported participation on night shift work
10. Pregnant or lactating or wishing to became pregnant in the period of the study
11. Not having a general practitioner
12. Not willing to accept information-transfer concerning participation in the study, or information regarding her health, like findings at anamnesis and eventual adverse events to and from her general practitioner
13. Depression, restless legs, sleep apnoea syndrome</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-04-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Sleep Disorders</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Physiological disturbances</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Semi-skimmed milk with lactium compared to semi-skimmed milk without lactium.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Lactium</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder16002-0</funderId>
      <contactId>Contact53948_16002</contactId>
      <sponsorId>Sponsor52497</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53948_16002">
    <title>Dr</title>
    <forename>Astrid</forename>
    <surname>Bakker-Zierikzee</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Friesland Foods
P.O. Box 159</address>
      <city>Ede</city>
      <country>Netherlands</country>
      <zip>6710 BD</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor52497">
    <organisation>Friesland Foods (The Netherlands)</organisation>
    <website>http://www.fcdf.com/</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>P.O. Box 159</address>
      <city>Ede</city>
      <country>Netherlands</country>
      <zip>6710 BD</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.434547.5</gridId>
    <rorId>https://ror.org/025mtxh67</rorId>
  </sponsor>
  <funder id="Funder16002-0">
    <name>Friesland Foods (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2006-12-21T00:00:00.000Z" version="19">
    <isrctn dateAssigned="2006-12-21T00:00:00.000Z">27093749</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Rituximab in Rheumatoid Arthritis in patients who failed therapy with tumour necrosis factor-blockers: a multi-centre clinical observational real-life study (phase IIIb)</title>
      <scientificTitle/>
      <acronym>RIRA</acronym>
      <studyHypothesis>To investigate the efficacy of treatment in real life (routine clinical care) with rituximab (MabThera®) in patients with active Rheumatoid Arthritis (RA) whose current treatment with a Tumour Necrosis Factor (TNF)-blocker (Etanercept - Enbrel®, Infliximab &#150; Remicade® or Adalumimab - Humira®) in combination with Methotrexate (MTX) is insufficient.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Primary outcome measure will be the frequency of reaching low disease activity or remission as measured by the Clinical Disease Activity Index (CDAI) (less than or equal to ten).</primaryOutcome>
      <secondaryOutcome>1. Major CDAI response of -13.9
2. Moderate CDAI response of -6.7
3. Disease Activity Score based on 28 joints (DAS28)
4. Simplified Disease Activity Index (SDAI)
5. American College of Rheumatology (ACR) response criteria (20%, 50%, 70%)
6. Health Assessment Questionnaire (HAQ)
7. Short Form Health Sruvey (SF-36)</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethical committee and internal review board of the Medical University of Vienna (reference Number 049/2006), date of approval: 14/03/2006.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN27093749</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>3.1</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>A clinical observational real-life study investigating the effect of Rituximab</studyDesign>
      <primaryStudyDesign>Observational</primaryStudyDesign>
      <secondaryStudyDesign>Multi-centre</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-09-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-09-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Austria</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="60bd1245-c3cf-443a-b251-0cb0f90effc8">
	  <name>Medical University of Vienna</name>
	  <address/>
	  <city>Vienna</city>
	  <state/>
	  <country>Austria</country>
	  <zip>1090</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Women or men 18 years of age or older
2. Diagnosis of RA according to the revised 1987 criteria of the American Rheumtololgy Association (ARA) for at least three months prior to first administration of study medication
3. The current treatment with Etanercept, Infliximab or Adalimumab in combination with MTX is insufficient. The patient&#146;s disease is considered to be active despite Disease Modifying Anti-Rheumatic Drug (DMARD) treatment
4. Active disease at the time of screening as defined by:
a. more than or equal to six swollen joints on a 66/68 joint count
b. more than or equal to six tender joints on a 66/68 joint count
c. and one out of the following three categories:
i. Erythrocyte Sedimentation Rate (ESR) more than or equal to 28 mm/h
ii. C-Reactive Protein (CRP) more than or equal to 1.5 mg/dl
iii. Morning stiffness more than or equal to 45 minutes
d. and one out of the following three categories:
i. bone erosion by x-ray prior to first administration of study medication
ii. Anti-Cyclic Citrullinated Peptide (Anti-CCP) antibody-positive
iii. Rheumatoid Factor (RF)-positive at screening
5. If using Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) or other analgesics for RA, must be on a stable dose for at least two weeks prior to the first administration of study agent
6. If using oral corticosteroids, must be on a stable dose equivalent to less than or equal to 10 mg of prednisone/day for at least two weeks prior to first administration of study agent. If currently not using corticosteroids, the subject must not have received oral corticosteroids for at least two weeks prior to first administration of study medication
7. Women of childbearing potential or men capable of fathering children must be using adequate birth control measures (e.g., abstinence, oral contraceptives, intrauterine device, barrier method with spermicide, surgical sterilisation) during the study and for six months after receiving the last administration of study agent
8. Female subjects of childbearing potential must test negative for pregnancy. A pregnancy test will be performed at the beginning and at the end of the study
9. The screening laboratory test must meet the following criteria:
a. haemoglobin more than or equal to 8.5 g/dl providing the low haemoglobin level is not due to other diseases than anemia of chronic inflammation
b. White Blood Cells (WBC) more than or equal to 3500/µl
c. neutrophils more than or equal to 1500/µl
d. platelets more than or equal to 100,000/µl
e. serum transaminase less than or equal to two times the Upper Limit of Normal (ULN)
f. serum creatinine less than or equal to 1.7 mg/dl
10. The patient must be able to adhere the study visit schedule and other protocol requirements and must have given informed consent prior to any screening procedures</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>20</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>20</totalTarget>
      <exclusion>Patients are excluded if they meet one of the following criteria:
1. Pregnant women, nursing mothers or a planned pregnancy within six months after last scheduled treatment
2. Patients with other inflammatory diseases that might interfere with the evaluation of the RA
3. Patients with fibromyalgia syndrome
4. Use of IntraMuscular (IM), IntraVenous (IV), IntraArterial (IA) corticosteroids within four weeks prior to screening
5. Treatment with any investigational drug within three months prior to screening
6. A history of known allergy to murine proteins, e.g. allergy to Infliximab
7. History of infected joint prothesis within the previous five years
8. Chronic infections
9. History of active tuberculosis requiring treatment within the previous three years, or history of opportunistic infections within two months, uncontrolled active infection or documented Human Immunodeficiency Virus (HIV) infection. Also excluded are patients with evidence of latent tuberculosis and patients with old tuberculosis (TB) without documented adequate therapy if they will not be treated according to the local TB guidelines
10. Current signs or symptoms of other severe uncontrolled disease which in the investigators opinion would put the patient at an unacceptable risk
11. History of lymphoproliferative disease, any current malignancies or history of malignancy within five years other than successfully treated basal cell carcinoma or squamous cell carcinoma of the skin
12. History of drug abuse</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-09-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-09-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Rheumatoid Arthritis (RA)</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Rheumatoid Arthritis (RA)</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Infusion with rituximab (MabThera®)</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Phase II/III</phase>
	<drugNames>Rituximab (MabThera®), Etanercept (Enbrel®), Infliximab (Remicade®), Adalumimab (Humira®) and Methotrexate (MTX)</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder15355-0</funderId>
      <contactId>Contact53286_15355</contactId>
      <sponsorId>Sponsor51833</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53286_15355">
    <title>Prof</title>
    <forename>Josef</forename>
    <surname>Smolen</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Medical University of Vienna
Waehringer Guertel 18-20</address>
      <city>Vienna</city>
      <country>Austria</country>
      <zip>1090</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+43 (0) 1 40 400 4381</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">josef.smolen@wienkav.at</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51833">
    <organisation>Medical University of Vienna (Austria)</organisation>
    <website>http://www.meduniwien.ac.at/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>c/o Prof. Dr. Josef Smolen
Waehringer Guertel 18-20</address>
      <city>Vienna</city>
      <country>Austria</country>
      <zip>1090</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+43 (0) 1 40 400 4381</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">josef.smolen@wienkav.at</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.22937.3d</gridId>
    <rorId>https://ror.org/05n3x4p02</rorId>
  </sponsor>
  <funder id="Funder15355-0">
    <name>The trial is an investigator driven study without any grant support, Roche provides the medication.</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2006-12-21T00:00:00.000Z" version="19">
    <isrctn dateAssigned="2006-12-21T00:00:00.000Z">76859006</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Rituximab In Psoriatic Arthritis: a multi-centre randomised placebo-controlled double blind pilot-study of rituximab in patients with active psoriatic arthritis</title>
      <scientificTitle/>
      <acronym>RIPA</acronym>
      <studyHypothesis>To investigate the efficacy and safety of treatment with rituximab in patients with active Psoriatic Arthritis (PsA) who showed at last one Disease Modifying Anti-Rheumatic Drug (DMARD) failure (phase IIb, efficacy and dose finding).</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Primary endpoint is the Psoriatic Arthritis Response Criteria (PsARC): improvement of 30% of tender and swollen joint count or if only one fulfilled, then plus 30% improvement of Visual Analogue Scale (VAS) patient global or physican global.</primaryOutcome>
      <secondaryOutcome>1. Psoriasis Area and Severity Index
2. Disease Activity Score based on 28 joints (DAS28)
3. Simplified Disease Activity Index (SDAI)
4. Clinical Disease Activity Index (CDAI)
5. Disease Activity index for the assessment of Reactive Arthritis (DAREA)
6. Health Assessment Questionnaire (HAQ)
7. Short Form health survey (SF-36)</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethical committee and internal review board of the Medical University of Vienna (reference number 049/2006), date of approval: 14/03/2006.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN76859006</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>1.1</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>A multi-centre placebo-controlled, double blind randomized study of Rituximab (MabThera®) in patients with active Psoriatic Arthritis</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-09-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-09-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Austria</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="efe59ec8-44c1-4056-8526-56c8cfd19969">
	  <name>Medical University of Vienna</name>
	  <address/>
	  <city>Vienna</city>
	  <state/>
	  <country>Austria</country>
	  <zip>1090</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients diagnosed with PsA according to the following criteria: psoriasis or family history of psoriasis plus any one of the following criteria:
a. clinical inflammatory enthesitis
b. radiographic enthesitis
c. distal interphalangeal joint disease
d. sacroiliitis or spinal inflammation
e. dactylitis
f. monoarthritis
g. oligoarthritis (four or less swollen joints)
2. Aged 18 years or older
3. Negative rheumatoid factor
4. The disease should at least have been diagnosed six months prior to screening
5. Active disease at the time of screening as defined by:
a. two out of the following three criteria:
i. more than or equal to four swollen on a 66/68 joint count
ii. more than or equal to six tender joints on a 66/68 joint count
iii. presence of dactylitis
b. and one out of the following two categories:
i. Erythrocyte Sedimentation Rate (ESR) more than or equal to 28 mm/h
ii. C-Reactive Protein (CRP) more than or equal to 1.0 mg/dl
6. Insufficient response to MTX in maximum tolerated dose
7. All patients use MTX and must be on a stable dose prior to screening
8. Patients must be receiving concurrent therapeutic folic acid
9. Patients using oral corticosteroids must have been on a stable dose of less than or equal to 10 mg/day for two weeks prior to screening. If using Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), patients must be on a stable dose for two weeks prior to screening
10. Women of childbearing potential or men capable of fathering children must be using adequate birth control measures (e.g., abstinence, oral contraceptives, intrauterine device, barrier method with spermicide, surgical sterilisation) during the study and for six months after receiving the last administration of study agent
11. Female subjects of childbearing potential must test negative for pregnancy. A pregnancy test will be performed at the beginning and at the end of the study
12. The screening laboratory test must meet the following criteria:
a. haemoglobin more than or equal to 8.5 g/dl providing the low haemoglobin level is not due to other diseases than anemia of chronic inflammation
b. White Blood Cells (WBC) more than or equal to 3500/µl
c. neutrophils more than or equal to 1500/µl
d. platelets more than or equal to 100,000/µl
e. serum transaminase less than or equal to two times the Upper Limit of Normal
f. serum creatinine less than or equal to 1.7 mg/dl
13. The patient must be able to adhere the study visit schedule and other protocol requirements and must have given informed consent prior to any screening procedures</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>40</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>40</totalTarget>
      <exclusion>Patients are excluded if they meet one of the following criteria:
1. Pregnant women, nursing mothers or a planned pregnancy within six months after last scheduled treatment
2. Patients with other inflammatory diseases that might interfere with the evaluation of the psoriatic arthritis
3. Patients with fibromyalgia syndrome
4. Use of Rituximab prior to screening
5. Treatment with Tumor Necrosis Factor (TNF)-Blockers prior to screening
6. Use of IntraMuscular (IM), IntraVenous (IV), Intra-Arterial (IA)  corticosteroids within four weeks prior to screening
7. Treatment with any investigational drug within three months prior to screening
8. Use of cyclosporine or tacrolimus within four weeks prior to screening
9. A history of known allergy to murine proteins, e.g. allergy to Infliximab
10. History of infected joint prosthesis within the previous five years
11. Chronic infections
12. History of active TuBerculosis (TB) requiring treatment within the previous three years, or history of opportunistic infections within two months, uncontrolled active infection or documented Human Immunodeficiency Virus (HIV) infection. Also excluded are patients with evidence of latent TB and patients with old TB without documented adequate therapy if they will not be treated according to the local TB guidelines
13. Current signs or symptoms of other severe uncontrolled disease which in the investigators opinion would put the patient at an unacceptable risk
14. History of lymphoproliferative disease, any current malignancies or history of malignancy within five years other than successfully treated basal cell carcinoma or squamous cell carcinoma of the skin
15. History of drug abuse</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-09-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-09-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Psoriatic Arthritis (PsA)</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Psoriatic Arthritis (PsA)</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Infusion with Rituximab (MabThera®)</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Phase II/III</phase>
	<drugNames>Rituximab (MabThera®), methotrexate (MTX)</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder15356-0</funderId>
      <contactId>Contact53287_15356</contactId>
      <sponsorId>Sponsor51834</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53287_15356">
    <title>Prof</title>
    <forename>Josef</forename>
    <surname>Smolen</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Medical University of Vienna
Waehringer Guertel 18-20</address>
      <city>Vienna</city>
      <country>Austria</country>
      <zip>1090</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+43 (0) 1 40 400 4381</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">josef.smolen@wienkav.at</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51834">
    <organisation>Medical University of Vienna (Austria)</organisation>
    <website>http://www.meduniwien.ac.at/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>c/o Prof. Dr. Josef Smolen
Waehringer Guertel 18-20</address>
      <city>Vienna</city>
      <country>Austria</country>
      <zip>1090</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+43 (0) 1 40 400 4381</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">josef.smolen@wienkav.at</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.22937.3d</gridId>
    <rorId>https://ror.org/05n3x4p02</rorId>
  </sponsor>
  <funder id="Funder15356-0">
    <name>The trial is an investigator driven study without any grant support, Roche provides the medication.</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2006-11-28T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2006-11-22T00:00:00.000Z">72604310</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Mannitol inhalations as faster procedure for testing of airways hyper-responsiveness</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Measurement of airways hyperresponsiveness by mannitol (Aridol©) as compared to methacholine saves time to the lung function technician, while being as sensitive to discern hyperresponsive from normo-responsive, and being at least equally acceptable to patients presenting at a pulmonary out-patient clinic.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Time involved in measurement of hyper-responsiveness (including technician time for preparation and cleaning).</primaryOutcome>
      <secondaryOutcome>1. Patient reported adverse events.
2. Patient preference.
3. Technician preference.
4. Borg score during test.
5. Exhaled Breath Condensate (EBC).
6. Bronchial Hyper-Reactivity questionnaire (BHR)</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Medisch Ethische Toetsingscommissie Universitair Medisch Centrum Groningen (Medical Ethical Committee University Medical Center Groningen), approval received on October 3rd 2006.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN72604310</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>Griac001</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-09-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-08-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="452590d2-edd0-4a01-9b74-7aabdf220233">
	  <name>Head Department of Respiratory Medicine</name>
	  <address/>
	  <city>Groningen</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>9700 RB</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Asthmatics:
1. 	Episodic symptoms of dyspnea, and/or wheezing, and/or cough
2. 	Allergic or non-allergic
3. 	Non current smokers (more than 0.5 years)
4. 	Provocation Concentration that causes a decrease in forced expiratory volume in one second of 20% (PC20) for MethaCholine (MCh) less than 8 mg/ml

Chronic Obstructive Pulmonary Disease (COPD) patients: 
1. 	Age more than 40 years
2. 	Active or former smokers, with a smoking history of more than ten pack years
3. 	Continuous symptoms of cough/sputum and/or dyspnea on exertion
4. 	No history of asthma
5. 	Forced expiratory volume in one second (FEV1)/Forced Vital Capacity (FVC) less than 70% and FEV1 between 50 and 80% predicted

Controls: 
1. 	No history of asthma or COPD
2. 	PC20 MCh more than 8 mg/ml
3. 	FEV1/FVC more than 70% and FEV1 more than 90% predicted</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>120</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>120</totalTarget>
      <exclusion>1. 	Age less than 18 years
2. 	Inability to perform acceptable-quality spirometry or to understand directions given by personnel
3. 	Severe airflow limitation (FEV1 less than 50% of predicted or less than 1.0 L)
4. 	Heart attack or stroke in last three months
5. 	Uncontrolled hypertension, systolic Blood Pressure (BP) more than 200 mmHg, or diastolic BP more than 100 mmHg
6. 	Known aortic aneurysm
7. 	Pregnancy
8. 	Nursing mothers
9. 	Current use of cholinesterase inhibitor medication (for myasthenia gravis)</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-09-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-08-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Asthma, Chronic Obstructive Pulmonary Disease (COPD)</description>
	<diseaseClass1>Respiratory</diseaseClass1>
	<diseaseClass2>Chronic lower respiratory diseases</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Measurement of bronchial hyper-responsiveness with mannitol and methacholine.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Mannitol and methacholine</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder15837-0</funderId>
      <contactId>Contact53777_15837</contactId>
      <sponsorId>Sponsor52330</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53777_15837">
    <title>Prof</title>
    <forename>H A M</forename>
    <surname>Kerstjens, MD, PhD </surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Head Department of Respiratory Medicine 
University Medical Center Groningen 
Postbox 30001</address>
      <city>Groningen</city>
      <country>Netherlands</country>
      <zip>9700 RB</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)50 3612357 </telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">h.a.m.kerstjens@int.umcg.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52330">
    <organisation>University Medical Center Groningen (UMCG) (The Netherlands)</organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Department of Respiratory Medicine
P.O. Box 30001</address>
      <city>Groningen</city>
      <country>Netherlands</country>
      <zip>9700RB</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.4494.d</gridId>
    <rorId>https://ror.org/03cv38k47</rorId>
  </sponsor>
  <funder id="Funder15837-0">
    <name>Pharmaxis Ltd.</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2006-12-04T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2006-11-22T00:00:00.000Z">03447252</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The prediction of short-term and long-term treatment response to sertraline in panic disorder</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Baseline variables such as harm avoidance and other personality, biological and electrophysiological measures will predict treatment outcome to an Selective Serotonin Reuptake Inhibitor (SSRI).</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>To identify variables mentioned above (at baseline) that can predict short-term and long-term response to treatment with sertraline in Panic Disorder.</primaryOutcome>
      <secondaryOutcome>1. To establish whether Autonomous Nervous System (ANS) functioning is a state marker of illness severity.
2. To establish whether treatment with sertraline has an affect on the functioning of the ANS.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN03447252</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>STL-NL-96-002</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-06-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="33fbb252-c3ea-496f-a855-42e65038aa46">
	  <name>University Medical Center Groningen</name>
	  <address/>
	  <city>Rotterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>9700 RB</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Panic Disorder According to Diagnostic and Statistical Manual of mental disorders (DSM-IV)
2. Two panic attacks in medication-free run-in period
3. Outpatients more than 18 years</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Not Specified</gender>
      <targetEnrolment>57</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>57</totalTarget>
      <exclusion>1. Co-morbid psychotic disorder, alcohol abuse, major affective disorder or personality disorder in the last year
2. Participation in other drug trial 30 days prior to selection
3. Serious medical illness
4. History of hepatitis
5. Risk of suicidality
6. History of drug allergy of hypersensitivity to SSRIs
7. Pregnancy, lactation or childbearing potential during the study</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-06-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Panic disorder</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Anxiety disorders</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Intervention:
Treatment with Sertraline (50 mg) for a period of 57 weeks

Investigators Assessments: 
Hamilton Anxiety Scale
Hamilton Depression Scale
Clinical Global Impression

Subject&#146;s assessments: 
Frequency of panic attacks
Fear Questionnaire
Patient Global Evaluation
Symptoms CheckList (SCL-90)
Temperament and Character Inventory
NEO-Neuroticism subscale
Rand 36-item health survey
Rosenberg Self-esteem list

Biochemical assessments:
Plasma 3-Methoxy-4-HydroxyPhenylGlycol (MHPG) level
Plasma Sertraline level

Electrophysiology: 
Heart Rate Variability</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Sertraline</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder15854-0</funderId>
      <contactId>Contact53794_15854</contactId>
      <sponsorId>Sponsor52347</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53794_15854">
    <title>Dr</title>
    <forename>P P</forename>
    <surname>Mersch</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>University Medical Center Groningen
Department of Psychiatry
P.O. Box 30001</address>
      <city>Rotterdam</city>
      <country>Netherlands</country>
      <zip>9700 RB</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor52347">
    <organisation>University Medical Center Groningen (The Netherlands)</organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Room 5.29
Department of Psychiatry
P.O. Box 30001</address>
      <city>Groningen</city>
      <country>Netherlands</country>
      <zip>9700 RB</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.4494.d</gridId>
    <rorId>https://ror.org/03cv38k47</rorId>
  </sponsor>
  <funder id="Funder15854-0">
    <name>Pfizer</name>
    <fundRef>http://dx.doi.org/10.13039/100004319</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2006-12-05T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2006-11-22T00:00:00.000Z">23778671</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Ultraviolet related deoxyribonucleic acid damage in skin of patients with atopic dermatitis and atopic status in relation to the use of Myfortic®</title>
      <scientificTitle/>
      <acronym>Effect of Myfortic® on UV-induced DNA-damage and atopic status</acronym>
      <studyHypothesis>Our hypothesis is that in patients with atopic dermatitis which use topical tacrolimus 0.1% the repair of DeoxyriboNucleic Acid (DNA)-damage in the skin is delayed. The repair of DNA-damage in the skin of patients with atopic dermatitis which use a class II corticosteroid is not delayed.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The difference between the percentage in repair of Cyclobutane Pyrimidine Dimers (CPD's) before and after treatment with Myfortic® is the primary study outcome.</primaryOutcome>
      <secondaryOutcome>1. The atopic state before and after treatment with Myfortic®. 
2. The evaluation of the efficacy of initial high dosing with Myfortic® in order to induce rapid improvement of the disease.</secondaryOutcome>
      <trialWebsite>http://www.dermatologyutrecht.nl/</trialWebsite>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN23778671</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>14196</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Clinical Trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Single-centre</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-10-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-05-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="baf62f7c-31df-4b22-971a-13037b1e87b8">
	  <name>University Medical Center Utrecht</name>
	  <address/>
	  <city>Utrecht</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>3508 GA</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Age from 18 years
2. Atopic dermatitis according to the criteria of Hanifin and Rajka
3. Insufficient response to topical therapy alone
4. The physician estimates that treatment with oral immunosuppressive agents is indicated</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Not Specified</gender>
      <targetEnrolment>10</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>10</totalTarget>
      <exclusion>1. Patients with any known hypersensitivity to mycofenolic acid or other components of the formulation
2. Oral immunosuppressive treatment in the last six weeks
3. Concomitant Ultraviolet (UV) therapy or UV therapy in the last two months
4. Contact with UV on the lesional skin for the last two months
5. Patients with thrombocytopenia (less than 75,000/mm^3), with an absolute neutrophil count less than 1,500/mm^3 and/or leukocytopenia (less than 2,500/mm^3) and/or haemoglobin less than 6.0 g/dl prior to enrolment
6. Patients who have received an investigational drug within two weeks prior to screening
7. Patients with a history of malignancy within the last five years
8. Females of childbearing potential who are planning to become pregnant, who are pregnant and/or lactating, who are unwilling to use effective means of contraception
9. Patients with an immunologic disorder (like Rheumatoid Arthritis [RA], Systemic Lupus Erythematosus [SLE] or M. SjÖgren) or a pre-existent dermatologic disorder that worsens in combination with UV (like LE or photosensitive eczema)
10. Presence of clinically significant infection requiring continued therapy, severe diarrhoea or uncontrolled diabetes mellitus that would interfere with the appropriate conduct of the study</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-10-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-05-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Atopic dermatitis</description>
	<diseaseClass1>Skin and Connective Tissue Diseases</diseaseClass1>
	<diseaseClass2>Skin condition</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Ten patients in total with atopic dermatitis are to be included in the study. The inclusion takes place after the physician has indicated that treatment with oral immunosuppressive drugs is necessary. The informed consent intake will be performed by the researcher. At inclusion a screening will be done to evaluate the severity of the eczema and the atopic state (total and specific Immunoglobulin E [IgE], skin-prick test and atopy patch test) of the patient.

Subsequently we will compare UV-irradiated, non-lesional skin prior to treatment (control) to UV-irradiated, non-lesional skin treated with Myfortic® during 12 weeks (intervention). The Minimal Erythema Dose (MED) will be determined prior to actual irradiation. Punch biopsies will be taken immediately after irradiation with two MED and after 24 hours. A reference biopsy will be taken from skin that is not irrradiated. The whole process will be repeated after 12 weeks of treatment. 

To evaluate the atopic status after 12 weeks of treatment, we will repeat the skin-prick test and atopy patch test. The final clinical evaluation of therapy will be performed after 16 weeks.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Myfortic®</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder15834-0</funderId>
      <contactId>Contact53774_15834</contactId>
      <sponsorId>Sponsor52327</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53774_15834">
    <title>Dr</title>
    <forename>M S</forename>
    <surname>de Bruin-Weller</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>University Medical Center Utrecht 
Department of Dermatology
HPN G02 124
P.O. Box 85500</address>
      <city>Utrecht</city>
      <country>Netherlands</country>
      <zip>3508 GA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)30 2509111</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">m.s.debruin-weller@umcutrecht.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52327">
    <organisation>University Medical Center Utrecht (UMCU) (The Netherlands)</organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Department of Dermatology and Allergology
P.O. Box 85500</address>
      <city>Utrecht</city>
      <country>Netherlands</country>
      <zip>3508 GA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.7692.a</gridId>
    <rorId>https://ror.org/0575yy874</rorId>
  </sponsor>
  <funder id="Funder15834-0">
    <name>Novartis Pharma B.V.</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2006-11-20T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2006-11-20T00:00:00.000Z">05214203</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A prospective Longitudinal trial of the effect of Atomoxetine on cognitive, educational, behavioural, social and emotional wellbeing in students with Attention Deficit Hyperactivity Disorder</title>
      <scientificTitle/>
      <acronym>LAtADHD</acronym>
      <studyHypothesis>It is hypothesised that over a period of 26 weeks' administration of atomoxetine, students with Attention Deficit Hyperactivity Disorder (ADHD) will demonstrate:
1. Improvement in the cognitive functions of working memory, verbal ability and cognitive efficiency
2. Improved executive functioning capacity
3. Improvement in their educational achievements in reading, mathematics, spelling and written compostion.
4.Improvement in their depression and anxiety ratings.
5. Improvement in their social skills and perceptions of the classroom learning environment.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Cognitive functioning, working memory, verbal ability and cognitive efficiency
2. Executive functioning (teacher and parent ratings)
3. Educational achievement</primaryOutcome>
      <secondaryOutcome>1. Depression (child, parent, teacher ratings)
2. Anxiety (child and parent ratings)
3. Social skills (teacher and parent ratings)
4. Perceptions of learning environment (child ratings)</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The study has been approved by the Curtin University Human Research Ethics Committee, (Approval Ref No. 28/2005), and complies with all requirements of the Australian National Health and Medical Research Committee.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN05214203</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>LP0349029</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Prospective longitudinal study, with a control group of children without ADHD, matched for age and gender and within the same school class as the children with ADHD</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-11-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-11-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Australia</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="de1f0067-62e7-4025-8984-9513ab821ff1">
	  <name>Department of Education</name>
	  <address/>
	  <city>Perth, WA</city>
	  <state/>
	  <country>Australia</country>
	  <zip>6845</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Boys and girls aged seven to 15 years
2. Meet the Diagnostic and Statistical Manual of Mental Disorders - Fourth Edition (DSM-IV) criteria for ADHD, as determined by the referring paediatrician or child psychiatrist
3. Participants are naive to atomoxetine medication</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Years" value="7.0"/>
      <upperAgeLimit unit="Years" value="15.0"/>
      <gender>Both</gender>
      <targetEnrolment>144</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>144 (72 participants with ADHD and 72 control children)</totalTarget>
      <exclusion>1. A history of bipolar or psychotic disorder
2. Tourette&#146;s syndrome
3. Substance abuse
4. Serious medical illness
5. Intellectual disability (Intelligence Quotient [IQ] less than 70)
6. Pregnancy
7. Non compliance with research protocol</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-11-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-11-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Attention Deficit Hyperactivity Disorder</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Behavioural and emotional disorders</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Administration of atomoxetine for 26 weeks.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Atomoxetine</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder15772-0</funderId>
      <funderId>Funder15772-1</funderId>
      <funderId>Funder15772-2</funderId>
      <funderId>Funder15772-3</funderId>
      <funderId>Funder15772-4</funderId>
      <funderId>Funder15772-5</funderId>
      <contactId>Contact53712_15772</contactId>
      <sponsorId>Sponsor52264</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53712_15772">
    <title>Dr</title>
    <forename>Heather</forename>
    <surname>Jenkins</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Education
Curtin University of Technology
GPO Box U1987</address>
      <city>Perth, WA</city>
      <country>Australia</country>
      <zip>6845</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">h.jenkins@curtin.edu.au</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52264">
    <organisation>Australian Research Council (Australia)</organisation>
    <website>http://www.arc.gov.au/arc_home/default.htm</website>
    <sponsorType>Research council</sponsorType>
    <contactDetails>
      <address>Department of Education, Science and Training
GPO Box 2702</address>
      <city>Canberra, ACT</city>
      <country>Australia</country>
      <zip>2601</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">info@arc.gov.au</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.413452.5</gridId>
    <rorId>https://ror.org/05mmh0f86</rorId>
  </sponsor>
  <funder id="Funder15772-0">
    <name>Australian Research Council (ARC) linkage grant (ref LP0349029), which includes:</name>
    <fundRef/>
  </funder>
  <funder id="Funder15772-1">
    <name>ARC funding (AUD 173,000)</name>
    <fundRef/>
  </funder>
  <funder id="Funder15772-2">
    <name>West Australian Dept of Education (AUD 15,000)</name>
    <fundRef/>
  </funder>
  <funder id="Funder15772-3">
    <name>Association of Independent School of Western Australia (AUD 15,000)</name>
    <fundRef/>
  </funder>
  <funder id="Funder15772-4">
    <name>Westmead Children's Hospital Education Research Institute (AUD19,500)</name>
    <fundRef/>
  </funder>
  <funder id="Funder15772-5">
    <name>Eli Lilly Australia Pty Ltd (AUD 45,000)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2006-10-25T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2006-10-25T00:00:00.000Z">21593740</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Randomised controlled trial of the benefits of oral essential amino acids in haemodialysis patients at high risk for hospitalisation</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Can health parameters be improved in patients on maintenance haemodialysis by oral supplementation with essential amino acids?</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The primary outcome was comparing the time of the composite primary outcome of :
1. Hospitalisation, other than for uncomplicated dialysis access procedure
2. Prolonged Emergency Room (ER) visit (more than 16 hours)
3. Out of hospital death</primaryOutcome>
      <secondaryOutcome>Secondary efficacy analyses, for the following outcomes comparing the change in the given parameter from baseline to the last available study measurement:
1. Change in subjective global assessment
2. Change in grip strength
3. Change in quality of life measures (using Short Form 12 instrument)
4. Change in lowest post dialysis weight</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Western Institutional Review Board (USA) approved on 27 November 2002 (Study number: 1033247, Invest. number: 67275).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN21593740</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>CT 00-AMI-003</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, multicentre, double-blind, parallel, placebo-controlled study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-01-09T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-01-20T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Ireland</country>
	<country>United States of America</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="bbf1a3a6-7be2-4191-aa9f-6d5d1a4d4cf2">
	  <name>Department of Nephrology</name>
	  <address/>
	  <city>Cork</city>
	  <state/>
	  <country>Ireland</country>
	  <zip>-</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients on maintenance haemodialysis  for at least four months at high risk of hospitalisation. This is defined as:
a. no more than two weeks post discharge from an acute hospitalisation and a serum albumin below 4.0 g/dl 
b. a serum albumin below 3.8 g/dl</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>400</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Patients planned for approximately 400. Patients obtained 84</totalTarget>
      <exclusion>1. Patients who have difficulties in taking pills, due to problems swallowing or intractable vomiting
2. Patients who have a short time life expectancy or are awaiting non-cadaveric kidney transplantation</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-01-09T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-01-20T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>End Stage Renal Disease (ESRD), and haemodialysis</description>
	<diseaseClass1>Urological and Genital Diseases</diseaseClass1>
	<diseaseClass2>Renal Disease</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Essential amino acid supplementation/placebo treatment in haemodialysis patient for six months or until a primary end-point is reached.</description>
	<interventionType>Supplement</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Essential amino acid supplementation</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder15385-0</funderId>
      <funderId>Funder15385-1</funderId>
      <funderId>Funder15385-2</funderId>
      <contactId>Contact53317_15385</contactId>
      <sponsorId>Sponsor51864</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53317_15385">
    <title>Dr</title>
    <forename>Joseph</forename>
    <surname>Eustace</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Nephrology
Cork University Hospital</address>
      <city>Cork</city>
      <country>Ireland</country>
      <zip>-</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor51864">
    <organisation>Recip AB (Sweden)</organisation>
    <website>http:// www.recip.se</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Lagervägen 7  </address>
      <city>Haninge</city>
      <country>Sweden</country>
      <zip>SE -136 50</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.496608.5</gridId>
    <rorId>https://ror.org/01apnjb23</rorId>
  </sponsor>
  <funder id="Funder15385-0">
    <name>National Institute of Diabetes and Digestive and Kidney diseases (NIDDK), National Institutes of Health (USA)</name>
    <fundRef/>
  </funder>
  <funder id="Funder15385-1">
    <name>Recip AB (Sweden)</name>
    <fundRef/>
  </funder>
  <funder id="Funder15385-2">
    <name>Gambro Corporate Research</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2006-10-12T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2006-10-12T00:00:00.000Z">43525354</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Anti-CD20 therapy for the treatment of chronic Graft Versus Host Disease</title>
      <scientificTitle/>
      <acronym>R'mabcGVHD</acronym>
      <studyHypothesis>B cells contribute to the development of chronic Graft Versus Host Disease (cGVHD).</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Proportion of complete and partial responses: 
A complete response will be defined as a complete resolution of clinical evidence of chronic GVHD. 
A partial response will be defined by an improvement in any of the affected organs.</primaryOutcome>
      <secondaryOutcome>Proportion of patients with a histological response.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN43525354</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Non-randomised trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Single-centre</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-07-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-07-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="b80eee3c-5dac-437f-a269-d1bc882fa536">
	  <name>University Medical Center Utrecht</name>
	  <address/>
	  <city>Utrecht</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>3508 GA</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Aged over 18 years
2. Steroid refractory chronic GVHD, including skin localisation
3. No other treatment apart from steroids and when applicable standard GVHD prevention</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>30</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>30</totalTarget>
      <exclusion>1. Relapse with a life expectancy of less than six months
2. Severe infections</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-07-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-07-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Chronic Graft Versus Host Disease (cGVHD)</description>
	<diseaseClass1>Injury, Occupational Diseases, Poisoning</diseaseClass1>
	<diseaseClass2>Failure and rejection of transplanted organs</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Treatment with Rituximab once a week, for four weeks.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Rituximab</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder15720-0</funderId>
      <funderId>Funder15720-1</funderId>
      <contactId>Contact53655_15720</contactId>
      <sponsorId>Sponsor52211</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53655_15720">
    <title>Dr</title>
    <forename>Ellen</forename>
    <surname>Meijer</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>University Medical Center Utrecht
Department of Hematology/H03.102
P.O. Box 85500</address>
      <city>Utrecht</city>
      <country>Netherlands</country>
      <zip>3508 GA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)30 2507230</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">e.meijer@umcutrecht.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52211">
    <organisation>University Medical Center Utrecht (UMCU) (The Netherlands)</organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>P.O. Box 85500</address>
      <city>Utrecht</city>
      <country>Netherlands</country>
      <zip>3508 GA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.7692.a</gridId>
    <rorId>https://ror.org/0575yy874</rorId>
  </sponsor>
  <funder id="Funder15720-0">
    <name>Koningin Wilhelmina Fonds (KWF) (The Netherlands)</name>
    <fundRef/>
  </funder>
  <funder id="Funder15720-1">
    <name>Roche Nederland BV (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2006-10-12T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2006-10-12T00:00:00.000Z">15823716</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The effectiveness of cognitive behavioural therapy in groups for patients with Chronic Fatigue Syndrome (CFS): a randomised controlled study</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>There are two research questions: 
1. Does Cognitive Behavioural Therapy (CBT) in groups lead to a significant decrease of fatigue and functional impairment of Chronic Fatigue Syndrome (CFS) patients compared to a waiting list condition?
2. For which patient is group therapy a suitable treatment method?</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Fatigue severity (measured with the CIS subscale fatigue severity).
2. Disabilities (measured with the Sickness Impact Profile (SIP) total score and the Short form health survey (SF-36) subscale 'physical functioning'). The CIS-f, SIP and SF-36 are used in two assessments, a baseline and a post-treatment (or post-waiting list) assessment. The change score between post-treatment and baseline of each of the treatment conditions is compared with the difference score between post-waiting list and baseline assessment of the waiting list condition.</primaryOutcome>
      <secondaryOutcome>Psychological distress measured with the Symptom Checklist 90 (SCL 90).</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN15823716</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>CMO 2006/030</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-12-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="92066fc9-128b-47b6-8f81-823882d46cc8">
	  <name>University Medical Center St. Radboud</name>
	  <address/>
	  <city>Nijmegen</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>6500 HB</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Over 18 years old
2. Being able to speak and read Dutch
3. Meeting the 1994 research criteria for CFS as formulated by the US Center for Disease Control
4. Severely fatigued (having a Checklist Individual Strength (CIS)-fatigue severity score of more than or equal to 35)
5. Severely disabled (weighted total score on the Sickness Impact Profile of more than or equal to 700)
6. Motivated for treatment of CFS with CBT
7. Having functioned good in groups before (self-report) and willing to follow a group treatment for CFS
8. Given written informed consent for participation in the study</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>204</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>204</totalTarget>
      <exclusion>1. Patient does not meet the previously mentioned inclusion criteria
2. Patient is currently engaged in a legal procedure concerning disability-related financial benefits</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2008-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-12-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Chronic Fatigue Syndrome (CFS)</description>
	<diseaseClass1>Nervous System Diseases</diseaseClass1>
	<diseaseClass2>Disorders of the brain</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>After a basline assessment patients are randomly assigned to one of three conditions. There are two treatment conditions: small group (four patients and one therapist) and large group (eight patients and two therapists). Both group treatments consist of 16 sessions of two hours in a period of about six months. There is a second assessment after the treatment. The third condition is a waiting list condition. After the waiting period of at least six months, patients get a second assessment.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder15725-0</funderId>
      <contactId>Contact53660_15725</contactId>
      <sponsorId>Sponsor52216</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53660_15725">
    <title>Professor</title>
    <forename>G</forename>
    <surname>Bleijenberg</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>University Medical Center St. Radboud
Expert Center Chronic Fatigue
P.O. Box 9011</address>
      <city>Nijmegen</city>
      <country>Netherlands</country>
      <zip>6500 HB</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)24 3610030</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">g.bleijenberg@nkcv.umcn.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52216">
    <organisation>University Medical Center St. Radboud (The Netherlands)</organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>P.O. Box 9101 </address>
      <city>Nijmegen</city>
      <country>Netherlands</country>
      <zip>6500 HB </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)24 3611111</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">info@ozi.umcn.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.10417.33</gridId>
    <rorId>https://ror.org/05wg1m734</rorId>
  </sponsor>
  <funder id="Funder15725-0">
    <name>University Medical Center St. Radboud (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2006-10-05T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2006-10-05T00:00:00.000Z">16400909</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Tianeptine for the treatment of fibromyalgia: a prospective double-blind, randomised, single-centre, placebo-controlled, parallel group study</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Fibromyalgia (FM) is a common illness that affects approximately 2.5 to 13% of the general population, of which the majority (10/1) are female. FM is characterised by chronic widespread pain and sleeping problems. Patients with FM frequently have other symptoms such as headaches, nocturnal jaw tightness, morning stiffness, tingling and numbness of arms and legs, irritable bowel, urinary urgency, dryness in the mouth and eyes, cold swollen hands, anxiety and/or depression. Another characteristic of FM is tenderness at palpation in defined points at the neck and lower back areas. 

Tianeptine is an antidepressant agent with a novel neurochemical profile. It increases serotonin (5-HydroxyTryptamine [5-HT]) uptake in the brain (in contrast with most antidepressant agents), promotes neuroplasticity and reduces stress-induced atrophy of neuronal dendrites. Like the Selective Serotonin Reuptake Inhibitors (SSRIs) and in contrast with most tricyclic antidepressant agents, tianeptine does not appear to be associated with adverse cognitive, psychomotor, sleep, cardiovascular or bodyweight effects and has a low propensity for abuse. This study assess the efficacy and safety of tianeptine in patients with FM.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The primary outcome was improvement in the pain score (10 cm Visual Analog Scale [VAS]) at 24 weeks and Fibromyalgia Impact Qiestionnnaire (FIQ) score.</primaryOutcome>
      <secondaryOutcome>1. The tender point score
2. The Hamilton Depression Anxiety inventory (HAD)
3. Short Form (SF-36) health survey.</secondaryOutcome>
      <trialWebsite>http://www.institutferran.es/investigacion.htm</trialWebsite>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Comité Ético de Investigación Clínica de Clínica, International Centre of Advanced Medicine (Centro Internacional de Medicina Avanzada [CIMA]) (Barcelona, Spain) (reference number: 0036/2006CIMA), date of approval is 10th August 2006.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN16400909</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>BP12/2006</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>A prospective double-blind, randomised, single-center, placebo-controlled, parallel group study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-09-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Spain</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="751af0be-406f-4e8b-b597-6f61f5e051c0">
	  <name>Paseo Manuel Girona, 33</name>
	  <address/>
	  <city>Barcelona</city>
	  <state/>
	  <country>Spain</country>
	  <zip>08034</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Aged from 40 to 50 years, both genders
2. Diagnosis of fibromyalgia defined by 1990 American College of Rheumatology (ACR) criteria</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>60</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>60</totalTarget>
      <exclusion>1. Psychiatric illness
2. Major depression
3. Suicidal risk
4. Substance abuse
5. Pulmonary dysfunction
6. Renal impairment
7. Active cardiac disease 
8. Liver disease
9. Autoimmune disease
10. Cancer
11. Sleep apnea
12. Chronic fatigue syndrome
13. Inflammatory bowel disease
14. Contraindications to tianeptine</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-09-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Fibromyalgia (FM)</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Fibromyalgia (FM)</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Group one - intervention group: Three month supply of oral Tianeptine (tablets) 12.5 mg every eight hours.
Group two - control group: Identical placebo every eight hours.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Tianeptine (moxonidine)</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder15405-0</funderId>
      <contactId>Contact53337_15405</contactId>
      <sponsorId>Sponsor51884</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53337_15405">
    <title>Prof</title>
    <forename>Ferran J</forename>
    <surname>García-Fructuoso</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Paseo Manuel Girona, 33 
Servicio de Reumatología
Clínica CIMA</address>
      <city>Barcelona</city>
      <country>Spain</country>
      <zip>08034</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">ferran.garcia@cimaclinic.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51884">
    <organisation>Fundacion para la Fibromialgia y el Síndrome de Fatiga Crónica (Spain)</organisation>
    <website>http://www.fundacionfatiga.org</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>c/o Joan Güell
184  Local 27</address>
      <city>Barcelona</city>
      <country>Spain</country>
      <zip>08028</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">info@fundacionfatiga.org</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.487280.1</gridId>
    <rorId>https://ror.org/03p4nrj93</rorId>
  </sponsor>
  <funder id="Funder15405-0">
    <name>Foundation for Fibromialgia and Chronic Fatigue Syndrome (Fundacion para la Fibromialgia y el Síndrome de Fatiga Crónica) (Spain)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2006-10-04T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2006-10-03T00:00:00.000Z">99850066</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Evaluation of efficacy and safety of aceclofenac injection in the treatment of acute lumbago: a randomised comparative open-labeled multi-centric trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>To evaluate the efficacy and tolerability of aceclofenac injection as compared to diclofenac injection in subjects suffering from acute lumago.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Assessment of overall response to study drugs.
2. Assessment of overall response of subjects to the drug.</primaryOutcome>
      <secondaryOutcome>1. Assessment of changes in VAS pain at 30 minutes, one, two, four, eight, 24 and 48 hours after the treatment compared with the baseline.
2. Assessment to degree of improvement after eight hours, 24 hours and 48 hours of treatment compared to baseline in:
a. pain on movement using a four point scale 
b. functional impairment using a four point scale 
c. pain on pressure in the lumbosacral region using a four point scale 
d. muscle contraction in the lumbosacral region using a four point scale</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Institutional Ethic Committee approval taken for the study.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN99850066</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>ACELO-0605</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Two arm, open-labeled, multi-centric, randomised, comparative trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-05-02T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-08-10T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>India</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="7c010662-c4bd-4a63-95db-6199c0b0381d">
	  <name>A-4, MIG</name>
	  <address/>
	  <city>Madhya Pradesh</city>
	  <state/>
	  <country>India</country>
	  <zip>452001</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients of either sex, aged over 18 years suffering  from acute lumbago (that began less than 48 hours before study entry)
2. Pain intensity more than 50 mm on a 100 mm Visual Analogue Scale (VAS)</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>300</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>300</totalTarget>
      <exclusion>Patients with history of:
1. Recurrent peptic ulcer or duodenal ulcer
2. Gastrointestinal bleeding or other bleeding disorders
3. Significant renal or hepatic impairment
4. Any significant abnormality on preclinical trial screening
5. Pregnant and lactating mothers
6. Patients requiring aspirin at any dose, corticosteroids, anticoagulants, ticlopidine hydrochloride or other drugs affecting platelet  function and coagulation, and patients taking hormonal contraceptives or patients allergic to Non Steroidal Anti-Inflammatory Drugs (NSAIDs)</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-05-02T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-08-10T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Acute Lumbago</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Pain</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Group one - intervention treatment: Aceclofenac injection 150 mg  twice daily (b.i.d) for two days.
Group two - intervention treatment: Diclofenac injection 75 mg b.i.d  for two days.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Aceclofenac</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder15395-0</funderId>
      <contactId>Contact53327_15395</contactId>
      <sponsorId>Sponsor51874</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53327_15395">
    <title>Dr</title>
    <forename>V P</forename>
    <surname>Pandey</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>A-4, MIG
A.B.Road
Indore</address>
      <city>Madhya Pradesh</city>
      <country>India</country>
      <zip>452001</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+91 0731 2532164</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">vppandey@sancharnet.in</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51874">
    <organisation>Venus Remedies Limited (India)</organisation>
    <website>http://www.venusremedies.com</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Intellectual Scientific Division	
Research and Development Centre
51-52 Industrial Area
Phase-1
Panchkula		</address>
      <city>Haryana</city>
      <country>India</country>
      <zip>134113</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+91 17 22561244</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">operations@venusremedies.com</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.465099.7</gridId>
    <rorId>https://ror.org/0169rv113</rorId>
  </sponsor>
  <funder id="Funder15395-0">
    <name>Venus Remedies Limited (India)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2006-09-25T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2006-09-25T00:00:00.000Z">95777169</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Inspiratory airflow limitation during sleep: its relationship to functional complaints</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Patients with Upper Airway Resistance Syndrome (UARS) who are randomised to therapeutic Continuous Positive Airway Pressure (CPAP) will demonstrate reduced pain, fatigue, daytime sleepiness, headache, gastrointestinal discomfort, hyperarousal, and metabolic risk factors after three weeks of treatment compared to UARS patients randomised to sham CPAP.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Fatigue
2. Daytime sleepiness
3. Sleep quality</primaryOutcome>
      <secondaryOutcome>1. Pain
2. Headache
3. Gastrointestinal discomfort
4. Metabolic risk factors
5. Hyperarousal</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Stony Brook University Internal Review Board (reference number: 2006-6309), approved on the 28th August 2006.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN95777169</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>Stony Brook Research Foundation #1051610</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-09-11T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-06-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United States of America</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="c9b35426-9ec2-42cc-958d-0e8cb846a97f">
	  <name>Department of Psychiatry &amp; Behavioral Science</name>
	  <address/>
	  <city>New York</city>
	  <state/>
	  <country>United States of America</country>
	  <zip>11794-8790</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Physician-confirmed diagnosis of UARS
2. Aged between 21 years or over and 65 years or under
3. Able to speak and read English
4. Ability to tolerate only one caffeinated beverage in the morning</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>20</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>20</totalTarget>
      <exclusion>1. Currently taking an opiate, benzodiazepine, sedative, hypnotic, stimulant, or sleeping medication
2. Currently being treated with a lipid lowering or Blood Pressure (BP) medication 
3. Diagnosis and/or treatment for sleep apnea, narcolepsy, or periodic limb movement disorder
4. Diagnosis of diabetes, coronary artery disease, Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS), stroke, or seizures
5. Body Mass Index (BMI) over 32 (no lower limit)
6. Evidence of overt alcohol or other substance abuse
7. History of allergy to lidocaine or similar local anesthestics
8. Presence of an extreme gag reflex
9. Difficulty breathing through nose
10. Smoking
11. Waking after 10:00 a.m. and going to bed after 12:00 a.m</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-09-11T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-06-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Upper airway resistance syndrome</description>
	<diseaseClass1>Respiratory</diseaseClass1>
	<diseaseClass2>Upper airway resistance syndrome</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Following baseline assessment, participants will be randomised to the experimental condition: therapeutic CPAP (n=10) or sham CPAP (n=10). A permuted blocking procedure will be used for the randomisation assignments using two block sizes (four and six). &#147;Allocation concealment&#148; from research assistants conducting outcome assessments will be done to minimise assignment bias and to attempt to maintain blinding of assessors.  The study coordinator, who will not have direct contact with participants, will be responsible for implementing randomisation. 

Per instruction from the study coordinator, one member of the research team will prepare the CPAP device as therapeutic or sham and provide it to another member of the team (blinded) who will interface with the patients to train them in use of the CPAP and answer questions or coach compliance during the trial. Patients will receive treatment for three weeks and then return for post-treatment assessment. The research assistant responsible for gathering pre- and post-treatment data will also be blinded to experimental condition.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder15376-0</funderId>
      <contactId>Contact53308_15376</contactId>
      <sponsorId>Sponsor51855</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53308_15376">
    <title>Dr</title>
    <forename>Joan</forename>
    <surname>Broderick</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Psychiatry &amp; Behavioral Science
Putnam Hall
Stony Brook University
Stony Brook</address>
      <city>New York</city>
      <country>United States of America</country>
      <zip>11794-8790</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor51855">
    <organisation>Respironics, Inc (USA)</organisation>
    <website>http://www.respironics.com</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>1001 Murry Ridge Lane
Murrysville</address>
      <city>Pennsylvania</city>
      <country>United States of America</country>
      <zip>15668-8550</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.417285.d</gridId>
    <rorId>https://ror.org/03kw6wr76</rorId>
  </sponsor>
  <funder id="Funder15376-0">
    <name>Respironics, Inc. (USA)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2006-08-31T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2006-08-31T00:00:00.000Z">44341748</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Optimization of bicycle Ergometer training</title>
      <scientificTitle/>
      <acronym>OpErgo</acronym>
      <studyHypothesis>In accordance with the two training methods there are different training recommendations.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>In accordance with the two training methods there are different training recommendations.</primaryOutcome>
      <secondaryOutcome>Training efficiency is enhanced by the intensity regulation based on metabolic parameters.</secondaryOutcome>
      <trialWebsite>http://www.refonet.de</trialWebsite>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics Commitee of the Ärztekammer Nordrhein approved on the 31st August 2005 (reference number: 2005255).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN44341748</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>03002</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, prospective, controlled trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-11-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-10-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="28130be0-2e49-48c2-bc91-932a1f7465dd">
	  <name>Roderbirken 1</name>
	  <address/>
	  <city>Leichlingen</city>
	  <state/>
	  <country>Germany</country>
	  <zip>42799</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Angiographic proved coronary disease
2. Echocardiogram (ECG) proved normal or slightly limited systolic cardiac function
3. Angina pectoris or acute coronary syndrome more than or equal to ten days before joining the research project
4. Sinus rhythm</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Both</gender>
      <targetEnrolment>340</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>340</totalTarget>
      <exclusion>1. Acute coronary syndrome less than ten days before joining the research project
2. Moderate to severe limited sysolic cardiac function
3. Aorto-coronary bypass operation more than or equal to three months before joining the research project
4. Atrial fibrillations or therapy relevant ventricular arrythmia
5. Clinically limiting peripheral arterial disease
6. Present hypertrophic obstructive cardiac myopathy
7. Non-regulatable arterial hypertonia
8. Haemodynamically relevant cardiac valvular defect
9. Pericarditis, myocarditis and lung embolic more than or equal to six months before joining the research project
10. Limiting orthopaedic secondary disorders
11. Consuming and intercurrent diseases
12. Renal insufficiency (Creatinine &gt; 2.0 mg/dl)
13. Anaemia (haemoglobin [Hb] &lt; 12g/dl)
14. Severe chronic obstructive pulmonary disease (Forced Expiratory Volume in one second [FEV1] &lt; 35%)
15. Respiratory global insufficiency
16. Implantable Cardioverter Defibrillator (ICD) implantation</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-11-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-10-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Coronary heart disease</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Coronary heart disease</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Group one exercises with an intensity of 60% of the symptom-limited performance regulated by heart rate.
Group two exercises metabolically regulated with an intenstity analogous to 60% of the intensity connected with 3 mmol/l lactate in capillary blood.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder15233-0</funderId>
      <contactId>Contact53133_15233</contactId>
      <sponsorId>Sponsor51674</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53133_15233">
    <title>Dr</title>
    <forename>Wolfgang</forename>
    <surname>Mayer-Berger</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Roderbirken 1</address>
      <city>Leichlingen</city>
      <country>Germany</country>
      <zip>42799</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 (0) 217 582 4010</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">wolfgang.mayer-berger@klinik-roderbirken.de</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51674">
    <organisation>Refonet (Germany)</organisation>
    <website>http://www.refonet.de</website>
    <sponsorType>Not defined</sponsorType>
    <contactDetails>
      <address>Burgweg 3</address>
      <city>Bad Neuenahr-Ahrweiler</city>
      <country>Germany</country>
      <zip>53445</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 (0) 264 190 620</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">service@refonet.de</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.487444.f</gridId>
    <rorId>https://ror.org/04yeh2x21</rorId>
  </sponsor>
  <funder id="Funder15233-0">
    <name>Refonet</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2006-09-05T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2006-08-31T00:00:00.000Z">11135486</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Quetiapine versus sertraline as the pharmacological component in a standardised psychopharmacological and psychotherapeutic treatment of borderline personality disorder: a randomised, rater-blinded study</title>
      <scientificTitle/>
      <acronym>QuBor Study</acronym>
      <studyHypothesis>The objective of this randomised, rater blinded study is to compare the efficacy of two currently frequently used substances, the Selective Serotonin Reuptake Inhibitors (SSRI) sertraline and the atypical neuroleptic quetiapine, in the treatment of borderline personality disorder. It is the hypothesis of this study that the atypical neuroleptic quetiapine favorably affects a broader spectrum of the borderline psychopathology than sertraline. The pharmacotherapy should be accompanied by psychotherapy that is based on the dialectical behavior therapy of Linehan. This study will contribute to optimising the medication therapy of borderline personality disorder with respect to efficiency and clarity.

The hypothesis regarding the efficacy comparison of quetiapine and sertraline is that quetiapine is significantly superior to treatment with SSRIs in the therapy of the following target symptoms: impulsivity, aggressiveness, self-inflicted injuries/self-harming and suicidal behavior.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The primary assessment instrument will be the Symptom Check List 90 (SCL-90R) and the primary outcome parameter will be the anger/hostility subscale of the SCL-90R.</primaryOutcome>
      <secondaryOutcome>1. Severity of affective symptoms
2. Anxiety and depressive symptoms
3. Psychotic or psychosis-like symptoms
4. Interpersonal problems
5. Duration of hopsitalisation
6. Co-medication</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval is pending from the University of Duesseldorf.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN11135486</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>D1449L00014</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, rater-blinded trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-10-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-03-15T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="d02fcfb4-e80e-4223-8a93-6e19c2ba09f8">
	  <name>Bergische Landstrasse 2</name>
	  <address/>
	  <city>Duesseldorf</city>
	  <state/>
	  <country>Germany</country>
	  <zip>40629</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Borderline personality disorder according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV)
2. At least 18 years of age
3. Voluntary legal basis
4. Female
5. Written informed consent before entering the study
6. No relevant abnormalities in Electrocardiogram (ECG) and laboratory tests</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Female</gender>
      <targetEnrolment>54</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>54</totalTarget>
      <exclusion>1. Lifetime diagnosis of schizophrenia or schizoaffective disorder according to DSM IV
2. Lifetime diagnosis of bipolar disorder according to DSM IV
3. Current severe major depressive episode according to DSM IV
4. Current severe somatic illness
5. Current psychotic disorder due to substance disorder or a general medical condition
6. Use of drugs that induce or inhibit the metabolising cytochrome 3A4 enzymes within two weeks prior to week zero and during the course of the study (e.g. inducers: phenytoin, carbamazepin, phenobarbital, rifampin, rifabutin, glucocorticoids, thioridazine and St. John´s wort and inhibitors: ketokonazole [except for topical use], itraconazole, fluconazole, erythromycin, fluvoxamin, nefadozone, troleandomycin, indinavir, nelfinavir, ritonavir and saquinavir)</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-10-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-03-15T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Borderline Personality Disorder</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Borderline Personality Disorder</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Intervention group one: Quetiapin 50-800 mg per day orally over 24 weeks.
Intervention group two: Sertralin 25-200 mg per day orally also over 24 weeks.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Quetiapine and sertraline</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder15295-0</funderId>
      <contactId>Contact53199_15295</contactId>
      <sponsorId>Sponsor51745</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53199_15295">
    <title>Dr</title>
    <forename>Jaroslav</forename>
    <surname>Malevani</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Bergische Landstrasse 2</address>
      <city>Duesseldorf</city>
      <country>Germany</country>
      <zip>40629</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor51745">
    <organisation>University of Duesseldorf (Germany)</organisation>
    <website>http://medfak.uniklinikum-duesseldorf.de/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Faculty of Medicine
&#13;c/o Prof Dr Nuernberg
&#13;Universitaetsstrasse 1</address>
      <city>Duesseldorf</city>
      <country>Germany</country>
      <zip>40225</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.411327.2</gridId>
    <rorId>https://ror.org/024z2rq82</rorId>
  </sponsor>
  <funder id="Funder15295-0">
    <name>AstraZeneca</name>
    <fundRef>http://dx.doi.org/10.13039/100004325</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2006-08-23T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2006-08-23T00:00:00.000Z">15188976</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>In situ detection of lung inflammation in chronic obstructive pulmonary disease using 18-fluorodeoxyglucose and positron emission tomography</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Positron Emission Tomography (PET) is a three-dimensional imaging technique that measures physiological effects including metabolism. 18-fluorodeoxyglucose (18FDG) uptake is a well-validated in vivo measure of tissue glucose metabolism using PET and has been extensively used to monitor the metabolic activity of cells in the brain and to detect tumours.  Inflammatory cells utilise glucose as a source of energy during their activation. It is hypothesised that 18FDG uptake by inflammatory cells in the lung could be used as an in vivo measurement of both total and regional lung inflammation.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. 18FDG uptake in the total lung, right and left lung
2. 18FDG uptake in three pre-defined lung regions (central, intermediate and peripheral) using the computerised shell analysis</primaryOutcome>
      <secondaryOutcome>1. Sputum inflammatory cells - Total Cell Count (TCC), Differential Cell Counts (DCC) from induced sputum obtained after 21 minutes nebulised hypertonic saline
2. Spirometry: FEV1, FVC
3. Sputum 18F activity levels post-imaging (COPD only)</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN15188976</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>2004HO0826/GSK SCO103387</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Screening</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-01-02T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-01-02T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Canada</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="4a98169b-7b1d-49fe-84cc-ec7712ea0215">
	  <name>1200 Main St West</name>
	  <address/>
	  <city>Hamilton</city>
	  <state/>
	  <country>Canada</country>
	  <zip>L8N 3Z5</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Healthy volunteer</participantType>
      </participantTypes>
      <inclusion>Inclusion Criteria for Chronic Obstructive Pulmonary Disease (COPD) subjects:
1. Male or Female
2. 40 to 75 years of age
3. COPD, defined as the forced expiratory volume in the first one second to the forced vital capacity of the lungs (FEV1/FVC) being less than 70% that is not fully reversible defined as an increase of less than 15% of predicted FEV1 after inhaling 200 ug salbutamol:
a. mild COPD (Stage I) defined as FEV1 more than 80%, pre-bronchodilator
b. moderate COPD (Stage II) defined as 50% less than FEV1 less than 80%, pre-bronchodilator
c. severe COPD (Stage III) defined as 30% less than FEV1 less than 50%, pre-bronchodilator
4. Current or ex-smokers with more than ten pack year history (i.e. equivalent to 20 cigarettes smoked per day for ten years)
5.	Written informed consent

Inclusion Criteria for COPD subjects during an acute exacerbation:
1. Male or Female
2. 40 to 75 years of age
3. Current or ex-smokers with more than ten pack year history (i.e. equivalent to 20 cigarettes smoked per day for ten years)
4. Written informed consent
5.	Moderate to severe COPD, defined as FEV1/FVC less than 70% that is not fully reversible defined as an increase of less than 15% of predicted FEV1 after inhaling 200 ug salbutamol:
a. moderate COPD (Stage II) defined as 50% less than FEV1 less than 80%, pre-bronchodilator
b. severe COPD (Stage III) defined as 30% less than FEV1 less than 50%, pre-bronchodilator
6. Acute exacerbation, defined as a worsening of the subject’s condition from the stable state and beyond normal day-to-day variation, which is acute in onset and necessitates a change in regular medication

The subject must have two or three of the following clinical findings:
1. Worsening dyspnea
2. New or increased sputum purulence
3. Increased sputum volume
or one of the above clinical findings plus at least one of the following:
1. Upper respiratory tract infection in the past five days
2. Fever without other apparent cause
3. Increased wheezing
4. Increased cough
5. 20% increase in respiratory rate or heart rate above baseline

Subjects with an acute exacerbation must be within the first two to three days post-presentation of symptoms to be enrolled in the study.

Inclusion Criteria for Healthy Volunteers:
1. Male or Female
2. 40 to 75 years of age
3. Non-smoker
4. Written informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>24</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>20 COPD subjects of differing severity and 4 healthy volunteers.</totalTarget>
      <exclusion>Exclusion Criteria for COPD subjects:
1. Other respiratory disorders, including asthma
2. Atopy
3. Other significant disease(s) which may put the subjects at risk or may have influence on the study results
4. Regular use of oxygen therapy
5. Pulmonary exacerbation in the previous four weeks (excluding subjects recruited during an exacerbation of COPD)
6.	Received oral prednisone in the previous four weeks
7. Received antibiotics in the previous four weeks
8. Pregnancy or breastfeeding. If in childbearing years, female subjects will be required to provide a negative urine pregnancy test and must be using an acceptable hormonal or barrier contraceptive method to be included in the study. She must be willing to continue to use this type of contraception for the duration of the study

Exclusion Criteria for Healthy Volunteers:
1. History of respiratory disorders, including asthma
2. Atopy
3. Other significant disease(s) which may put the subjects at risk or may have influence on the study results
4. Received oral prednisone in the previous four weeks
5. Respiratory infection or cold in previous four weeks
6. Received antibiotics in the previous four weeks
7. Pregnancy or breastfeeding. If in childbearing years, female subjects will be required to provide a negative urine pregnancy test and must be using an acceptable hormonal or barrier contraceptive method to be included in the study. She must be willing to continue to use this type of contraception for the duration of the study.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-01-02T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-01-02T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Chronic Obstructive Pulmonary Disease</description>
	<diseaseClass1>Respiratory</diseaseClass1>
	<diseaseClass2>Chronic Obstructive Pulmonary Disease</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The study is an observational study, correlating FDG uptake with other parameters that monitor inflammation.

18FDG injection: The subject will receive an intravenous administration of 18FDG of 3 MBq/kg to a maximum of 300 MBq, followed by PET scanning for 90 min.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>18-fluorodeoxyglucose</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder13484-0</funderId>
      <contactId>Contact51134_13484</contactId>
      <sponsorId>Sponsor49531</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51134_13484">
    <title>Prof</title>
    <forename>Myrna</forename>
    <surname>Dolovich</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>1200 Main St West
&#13;HSC 1V16</address>
      <city>Hamilton</city>
      <country>Canada</country>
      <zip>L8N 3Z5</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 905 521 2100 ext 73454</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">mdolovic@mcmaster.ca</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor49531">
    <organisation>GlaxoSmithKline (Canada)</organisation>
    <website>http://www.gsk.com</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>7333 Mississauga Road</address>
      <city>Mississauga</city>
      <country>Canada</country>
      <zip>L5N 6L4</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.420846.c</gridId>
    <rorId>https://ror.org/02zz8mw60</rorId>
  </sponsor>
  <funder id="Funder13484-0">
    <name>GlaxoSmithKline (Ref No. SCO103387)</name>
    <fundRef>http://dx.doi.org/10.13039/100004330</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2006-07-28T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2006-07-28T00:00:00.000Z">59155637</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Integration of the traditional Chinese medicine into the orthopedic rehabilitation - 
effects on pain and employment prognosis for patients with chronic back pain</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>By additional therapy elements of Traditional Chinese Medicine (TCM) within an orthopedic rehabilitation procedure over four weeks with chronic back pain inpatients, a higher reduction of pain and analgesic consumption can be achieved, as well as a decrease in the amount of times there is an inability to work and improvement of the subjective employment prognosis.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Reduction of the pain
2. Reduction of the analgesic consumption</primaryOutcome>
      <secondaryOutcome>1. Decrease in the amount of times there is an inability to work
2. Improvement of the subjective employment prognosis</secondaryOutcome>
      <trialWebsite>http://www.refonet.de</trialWebsite>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics Committee of the Physicians Chamber, Rheinland-Pfalz, Mainz on 17/11/2005 (reference number 837.258.05).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN59155637</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>04003</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Prospective, randomized controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Other</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-06-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="ef1ca14e-5e90-449e-a270-592586d75cd0">
	  <name>Orthopedic Rehabilitation Center</name>
	  <address/>
	  <city>Bad Ems</city>
	  <state/>
	  <country>Germany</country>
	  <zip>D-56130</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Aged 30 to 55 years
2. Able to gain employment
3. Chronic back pain
4. Medication: not opioid analgesics (World Health Organisation stage I)</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>270</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>270 participants (135 group A, 135 group B)</totalTarget>
      <exclusion>1. Acute slipped disk in the last three months
2. Pension required
3. Spinal column operation in the past</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-06-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Chronic back pain</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Chronic back pain</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The patients of group A are treated exclusively according to schooled medical therapy concept for four weeks. The patients of group B are treated with elements of the TCM additionally. These contain acupuncture and tuina- massage twice in each case per week</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Traditional Chinese medicine</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder15216-0</funderId>
      <contactId>Contact53113_15216</contactId>
      <sponsorId>Sponsor51656</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53113_15216">
    <title>Dr</title>
    <forename>Werner</forename>
    <surname>Kühn</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Orthopedic Rehabilitation Center
&#13;Lahntalklinik Bad Ems
&#13;Adolf-Bach-Promenade 11</address>
      <city>Bad Ems</city>
      <country>Germany</country>
      <zip>D-56130</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 (0) 2603 976 2600</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">w.kuehn@lahntalklinik.de</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51656">
    <organisation>Refonet (Germany)</organisation>
    <website>http://www.refonet.de</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>Burgweg 3</address>
      <city>Bad Neuenahr-Ahrweiler</city>
      <country>Germany</country>
      <zip>D-53445</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 (0) 264 190 620</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">service@refonet.de</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.487444.f</gridId>
    <rorId>https://ror.org/04yeh2x21</rorId>
  </sponsor>
  <funder id="Funder15216-0">
    <name>Refonet, project no. 04003</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2006-07-19T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2006-07-19T00:00:00.000Z">29335793</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Insulin combination therapy in type 2 diabetes</title>
      <scientificTitle/>
      <acronym>DIASULIN</acronym>
      <studyHypothesis>Continuing sulfonylurea in patients without good glycaemic control and using insulin and metformin, will diminish insulin secretion of beta-cells, less than discontinuing sulfonylurea in these patients.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Difference between the two groups in the remaining insulin secretion of the beta-cells, assessed by differences in Homeostasis Model Assessment (HOMA)-beta and in fasting C-peptide.</primaryOutcome>
      <secondaryOutcome>1. Difference in mean daily dosage of insulin glargine in order to reach good glycaemic control (HbA1c &lt;= 7.0%)
2. Percentage of patients with good glycaemic control after 12 months
3. Percentage of patients with good glycaemic control at several intervals within 12 months
4. Frequency of serious and of nocturnal hypoglycaemic episodes
5. Waist circumference
6. Quality of life
7. Patients' treatment satisfaction</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN29335793</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled, parallel group  trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-04-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-04-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="84c55329-684a-47c3-9012-b2c024717a50">
	  <name>University Medical Center Utrecht (UMCU)</name>
	  <address/>
	  <city>Utrecht</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>3508 GA</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Type 2 diabetes patients, male and female, insulin naive, without good glycaemic control for at least three months despite combination of metformin and sulfonylurea therapy and who are referred for insulin therapy by their general practitioner (GP)
2. Aged 40-75 years
3. Haemoglobin HbA1c (HbA1c) &gt;=7.5%</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>200</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>200</totalTarget>
      <exclusion>1. Type 1 diabetes
2. C-peptide &lt;0.50 nmol/l
3. Liver (aspartate aminotransferase [AST] or alanine aminotransferase [ALT] &gt;2 times upper limit of normal) and/or kidney (creatinine &gt;135 in male patients, &gt;110 in female patients) problems
4. Patients who do not read Dutch well enough to answer questionnaires
5. Pregnancy or lactation
6. Amputated leg or arm
7. Intercurrent disease at the discretion of the investigator
8. Short life expectancy
9. Contraindications or intolerancy to metformin, sulfonylurea or insulin glargine</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-04-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-04-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Diabetes mellitus type 2 (DM type II)</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Diabetes</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Continuing sulfonylurea with a combination of metformin and insulin glargine versus discontinuing sulfonylurea with this combination.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Metformin, sulfonylurea, insulin glargine</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder15256-0</funderId>
      <contactId>Contact53159_15256</contactId>
      <sponsorId>Sponsor51703</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53159_15256">
    <title>Dr</title>
    <forename>M.J.P.</forename>
    <surname>Avendonk, van</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>University Medical Center Utrecht (UMCU)
&#13;Julius Center for Health Sciences and Primary Care
&#13;Stratenum 6.131
&#13;P.O. Box 85500</address>
      <city>Utrecht</city>
      <country>Netherlands</country>
      <zip>3508 GA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)30 2538608</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">m.j.p.vanavendonk@umcutrecht.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51703">
    <organisation>Stichting Julius Research (The Netherlands)</organisation>
    <website/>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>P.O. Box 85500</address>
      <city>Utrecht</city>
      <country>Netherlands</country>
      <zip>3508 GA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)30 2509358</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">juliuscenter@azu.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.7692.a</gridId>
    <rorId>https://ror.org/0575yy874</rorId>
  </sponsor>
  <funder id="Funder15256-0">
    <name>Sanofi-Aventis</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2006-07-19T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2006-07-19T00:00:00.000Z">65462262</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Longlasting adduction-related groin injuries in athletes; regular care or a novel treatment approach</title>
      <scientificTitle/>
      <acronym>LIES</acronym>
      <studyHypothesis>Athletes with longstanding groin pain recover faster and more completely if they are treated with specific pelvic stabilizing muscle training compared with regular care.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Severity of the pain over the last three days (11-point visual analogue scale [VAS])
2. Participation in sports (11-point VAS-scale)
3. General disability (adapted Quebec low back pain disability scale)
4. Global change (six-point Likert scale)
5. How long before return to full athletic activity
6. Recurrences of the same complaints
Parameters 1, 2, 3 are measured before and directly after the period of treatment and 26 and 52 weeks after the start of treatment. 
Parameters 4, 5 and 6 are only measured at 26 and 52 weeks after treatment.</primaryOutcome>
      <secondaryOutcome>1. Hip adduction strength (hand-held dynamometer);
2. Contraction pattern of the abdominal musculature (ultrasound echografie);
3. Active straight leg raise test (ASLR).</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN65462262</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>7502.0005</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled, parallel group  trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-03-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-08-15T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="7cc7b46d-4c10-41ca-97fb-446e99698cfe">
	  <name>Heidelberglaan 100</name>
	  <address/>
	  <city>Utrecht</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>3584 CX</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Male athletes, 18-45 years old, hip adduction-related complaints, for a period of at least six weeks, strong desire to compete in sports.</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <upperAgeLimit unit="Years" value="45.0"/>
      <gender>Male</gender>
      <targetEnrolment>80</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>80</totalTarget>
      <exclusion>1. Pain as a result of high-impact trauma, suspicion of fracture, rupture of labrum of the hip, hip arthrosis or arthritis, femoral or inguinal hernia, radicular symptoms, infection of the urinary tract, bursitis, vessel disease, abnormal anatomy
2. Treated for the same (episode of) complaints previously, treated for low back pain with an exercise program in the previous six months, systemic diseases
3. Psychopathology
4. Physical handicaps that make it impossible for the subject to take part of the study</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-03-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-08-15T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Groin pain</description>
	<diseaseClass1>Signs and Symptoms</diseaseClass1>
	<diseaseClass2>Groin pain</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Two different kinds of physiotherapeutic treatments are given for the population. Both treatment strategies are already in use in daily practice.
Patients are randomised to receive either pelvic-stabilizing muscle training or usual care</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder15257-0</funderId>
      <contactId>Contact53160_15257</contactId>
      <sponsorId>Sponsor51704</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53160_15257">
    <title>Dr</title>
    <forename>F. J. G.</forename>
    <surname>Backx</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Heidelberglaan 100</address>
      <city>Utrecht</city>
      <country>Netherlands</country>
      <zip>3584 CX</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)30 2501583</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">fbackx@umcutrecht.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51704">
    <organisation>University Medical Center Utrecht (UMCU) (The Netherlands)</organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>P.O. Box 85500</address>
      <city>Utrecht</city>
      <country>Netherlands</country>
      <zip>3508 GA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.7692.a</gridId>
    <rorId>https://ror.org/0575yy874</rorId>
  </sponsor>
  <funder id="Funder15257-0">
    <name>Netherlands Organisation for Health Research and Development (ZonMw)</name>
    <fundRef>http://dx.doi.org/10.13039/501100001826</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2006-07-19T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2006-07-19T00:00:00.000Z">54551960</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Markers for Acute Chemotherapy-Induced Cardiovascular Changes</title>
      <scientificTitle/>
      <acronym>MACC1</acronym>
      <studyHypothesis>1. The number of circulating endothelial (progenitor) cells may be reduced during chemotherapy and correlate to the development of cardiovascular disease
2. Oxidative stress due to chemotherapy may lead to an increased accumulation of advanced glycation end products (AGEs) in blood vessels, contributing to endothelial damage</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The early effects of cisplatin-based  chemotherapy on the number of circulating endothelial (progenitor) cells and the accumulation of AGEs, and their correlation with cardiovascular damage</primaryOutcome>
      <secondaryOutcome>1. Evaluation of which treatment and patient-related factors (for example chemotherapy dose and presence of cardiovascular risk factors) predispose patients to cardiovascular damage during and after cisplatin-based chemotherapy
2. Determination of circulating apoptosis markers during and after cisplatin-based chemotherapy and their relation to tumor response and cardiovascular damage</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN54551960</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>An observational study</studyDesign>
      <primaryStudyDesign>Observational</primaryStudyDesign>
      <secondaryStudyDesign>Cohort study</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-05-16T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-05-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="a3212a7f-543d-4924-ab57-c0d32a72dc55">
	  <name>Medische Oncologie</name>
	  <address/>
	  <city>Groningen</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>9713 GZ</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients with disseminated testicular cancer who will be treated with cisplatin based chemotherapy
2. Age 18-50 years at start of treatment
3. Written informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <upperAgeLimit unit="Years" value="50.0"/>
      <gender>Male</gender>
      <targetEnrolment>50</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>50</totalTarget>
      <exclusion>1. Medical history of cardiovascular disease
2. Known renal disease or estimated glomerular filtration rate (GFR) &lt;60 ml/min (using Cockcroft-Gault formula)</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-05-16T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-05-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Testicular cancer</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2>Testicular cancer</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The number of circulating endothelial cells, endothelial marker proteins and accumulation of AGEs (estimated by measuring skin autofluorescence with an AGE-reader) will be determined before, during and after chemotherapy.

Cardiovascular status (intima-media thickness of the carotid artery, baroreflex sensitivity and 24-hour ambulatory blood pressure measurement) will be evaluated before start of chemotherapy, within four weeks after completion of chemotherapy and one year after start of chemotherapy.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Cisplatin</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder15259-0</funderId>
      <contactId>Contact53162_15259</contactId>
      <sponsorId>Sponsor51706</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53162_15259">
    <title>Dr</title>
    <forename>E.C.</forename>
    <surname>Haas de</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Medische Oncologie
&#13;University Medical Center Groningen
&#13;Hanzeplein 1</address>
      <city>Groningen</city>
      <country>Netherlands</country>
      <zip>9713 GZ</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)50 3612821</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">e.c.de.haas@int.umcg.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51706">
    <organisation>University Medical Center Groningen (UMCG), Department of Internal Medicine: Division of Medical Oncology (The Netherlands)</organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>P.O. Box 30001</address>
      <city>Groningen</city>
      <country>Netherlands</country>
      <zip>9700 RB</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.4494.d</gridId>
    <rorId>https://ror.org/03cv38k47</rorId>
  </sponsor>
  <funder id="Funder15259-0">
    <name>University Medical Center Groningen (UMCG)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2006-11-10T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2006-07-19T00:00:00.000Z">42388561</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The effectiveness of cognitive behavioural therapy versus interpersonal psychotherapy in panic disorder without agoraphobia</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>To assess the effectiveness of cognitive behavioural therapy (CBT) versus interpersonal psychotherapy (IPT) in panic disorder without agoraphobia.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Panic free status (defined with panic diaries) 
2. Performance on a behavioural test (three situations) 

Panic diaries are completed at zero months (pre-treatment), during treatment, three months (post treatment), four months (follow up one) and nine months (follow up two). 

Performance on the behavioural test is assessed at zero months (pre-treatment), four months (follow up one) and nine months (follow up two).</primaryOutcome>
      <secondaryOutcome>1. A composite measure of panic and agoraphobic measures (the Fear Questionnaire [FQ v+a], main phobia, Anxiety Sensitivity Index [ASI], Fear Of Fear [FOF], etc.,) 
2. A composite measure of cognitive measures (e.g. Body Sensations Interpretation Questionnaire [BSIQ-14], Agoraphobic Cognitions Questionnaire [ACQ]) 
3. An interpersonal measure (the Inventory of Interpersonal Problems [IIP]) 
4. A composite measure of general psychopathology (the Symptom CheckList-90-R [SCL-90], State-Trait Anxiety Inventory [STAI]) 

The outcomes are assessed at zero months (pre-treatment), three months (post treatment), four months (follow up one) and nine months (follow up two).</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics Board of the Community Mental Health Centre Maastricht, ethic approval granted on the 30th September 1996 (ref: GWA 96.070).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN42388561</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1997-06-05T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-01-06T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="b310fea7-1764-45e6-b560-e02c1ede3a73">
	  <name>University Maastricht (UM)</name>
	  <address/>
	  <city>Maastricht</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>6200 MD</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Main diagnosis panic disorder without agoraphobia 
2. Aged between 18 and 60</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <upperAgeLimit unit="Years" value="60.0"/>
      <gender>Both</gender>
      <targetEnrolment>80</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>80</totalTarget>
      <exclusion>1. Co-morbid psychosis or bipolar disorder 
2. The use of psychoactive drugs 
3. Intelligence Quotient (IQ) less than 80 
4. Insufficient knowledge of the Dutch language 
5. Previous formal IPT or CBT received (for the same complaint in the past year) 
6. Alcohol or drugs dependency 
7. Cardiovascular disease 
8. Respiratory disease 
9. Epilepsy</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1997-06-05T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-01-06T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Panic disorder</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Panic disorder</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients will receive 12 therapeutic sessions of either CBT or IPT, one session per week, each session takes one hour</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder15265-0</funderId>
      <contactId>Contact53168_15265</contactId>
      <sponsorId>Sponsor51712</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53168_15265">
    <title>Ms</title>
    <forename>Linsey</forename>
    <surname>Diels</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>University Maastricht (UM)
Research Institute Experimental Psychopathology (EPP)
Department of Clinical, Medical, and Experimental Psychology
P.O.Box 616</address>
      <city>Maastricht</city>
      <country>Netherlands</country>
      <zip>6200 MD</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)43 3881264</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">L.Diels@dmkep.unimaas.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51712">
    <organisation>University Maastricht (UM), Department of Clinical, Medical, and Experimental Psychology (The Netherlands)</organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>P.O.Box 616</address>
      <city>Maastricht</city>
      <country>Netherlands</country>
      <zip>6200 MD</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.5012.6</gridId>
    <rorId>https://ror.org/02jz4aj89</rorId>
  </sponsor>
  <funder id="Funder15265-0">
    <name>University Maastricht (UM), Research Institute Experimental Psychopathology (EPP), Department of Clinical, Medical, and Experimental Psychology (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2006-07-13T00:00:00.000Z" version="17">
    <isrctn dateAssigned="2006-07-13T00:00:00.000Z">46080812</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Effectiveness of Hypericum perforatum and Passiflora incarnata extract combination for treatment of depression and accompanied anxiety</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Ansolin is  equal to placebo in treating depression</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The efficacy of ansolin in mild to moderate severe depressive states.</primaryOutcome>
      <secondaryOutcome>The efficacy of ansolin in the accompained anxiety in depressive states.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Pakistan psychiatric research centre</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN46080812</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>1</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Double blind, randomised, multicentre, placebo controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>GP practice</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-07-03T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-05-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
	<country>Pakistan</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="16c79005-0fac-41ec-94a7-56f3eff96e33">
	  <name>Tolhuislaan 11 - 13</name>
	  <address/>
	  <city>Gorredijk</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>8401 GA</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Male or female patients of eighteen to sixty-five years of age
2. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) diagnosis of mild to moderate (severe) depressive disorder
3. Total severity score of at least 13 and at most 24 at the 17-item Hamilton rating scale for Depression (HAMD) at the entry visit
4. Able to understand the procedures and agreeing to participate by giving written informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>150</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>150</totalTarget>
      <exclusion>1. Patients who respond during the first week with a decrease of the total score of the 17-items HAMD of at least 20%
2. 
Women of child-bearing potential without adequate birth-control measures
3. Women who are pregnant or breast-feeding
4. Treatment with Monoamine Oxidase (MAO) inhibitors during the last two weeks prior to the entry visit
5. Treatment with any psychotropic drug during at least the week preceding the entry visit
6. Contraindication or history of hypersensitivity to the study drugs
7. Unstable and/or severe organ system diseases, e.g. neurological, cardiovascular, pulmonary, hepatic, renal, gastrointestinal, endocrine, metabolic, or other
8. History of organ transplantation or Human Immunodeficiency Virus (HIV) positive
9. Usage of immunomodulators, antiretroviral drugs or digoxine
10. Clinical significant abnormalities observed at screening at the discretion of the investigator
11. Substance dependence or abuse according to DSM-IV criteria
12. Bipolar disorder, psychotic features, or any other psychotic disorder
13. Other principal psychiatric diagnosis judged by the investigator to dominate the clinical picture
14. Significant risk for suicide or significant potential for self-harm as judged by the investigator
15. Significant risk for non-compliance with study procedures or drug intake as judged by the investigator</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-07-03T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-05-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Depressive states</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Depression</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>This is a randomised, double blind, multicentre, parallel group, placebo and active controlled comparison of the efficacy and safety of Ansolin in ambulatory, mildly or moderately depressed patients of eight week duration with a follow-up after four weeks.

After obtaining informed consent patients will complete a pre-study evaluation to assess their suitability to participate. They start with a single-blind placebo period of one week duration and the severity of the depressive symptoms is reassessed thereafter. Eligible patients who do not improve more than 20% on the HAMD-17 will receive one of two treatments: ansolin (containing Hypercicum perforatum and Passiflora incarnata), or a placebo. Patients will be stratified according to their HAMD score (two strata: HAMD total score of 14-17 or 18-24) and centre (three strata). Blindness will be assured by applying the placebo-verum technique.

Treatment with double blind medication will be ended, when the clinical condition worsens during treatment or when improvement stagnates in such a degree that the best interest of the patient is not served by continuation. Both decisions are at the discretion of the investigator. At this moment treatment is initiated with the drugs preferred by doctor and patient. Preferably, after discontinuation of the double-blind medication all assessment will take place as scheduled.

The clinical trial will be ended, when less than 25% of the required number of patients is included within eight months after the initiation of the trial.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Hypericum perforatum (St Johns Wort) and Passiflora incarnata (Passion flower)</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder15166-0</funderId>
      <contactId>Contact53028_15166</contactId>
      <sponsorId>Sponsor51575</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53028_15166">
    <title>Mr</title>
    <forename>Hertzen</forename>
    <surname>Hokwerda</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Tolhuislaan 11 - 13</address>
      <city>Gorredijk</city>
      <country>Netherlands</country>
      <zip>8401 GA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0) 513 469 369</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">h.hokwerda@bional.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51575">
    <organisation>Bional Holding BV (The Netherlands)</organisation>
    <website>www.bional.nl</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Tolhuislaan 11-15</address>
      <city>Gorredijk</city>
      <country>Netherlands</country>
      <zip>8401 GA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0) 513 469 369</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">h.hokwerda@bional.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder15166-0">
    <name>Bional Holding BV</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2006-07-12T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2006-07-12T00:00:00.000Z">82622830</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The effect of ear acupressure on primary insomnia</title>
      <scientificTitle/>
      <acronym>EEAPI</acronym>
      <studyHypothesis>Traditional Chinese Medicine (TCM) ear acupuncture theory</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Actigraphy records</primaryOutcome>
      <secondaryOutcome>Sleep diary</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approved by the Institutional Review Board of Chang Gung Memorial Hospital (IRB/CGMH)  reference number: 94-435</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN82622830</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>CMRPG340501</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Single-blind, placebo-controlled study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-12-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-11-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Taiwan</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="04098956-a826-4461-9390-306e9c00e41b">
	  <name>No.123 Dinghu Road</name>
	  <address/>
	  <city>Taoyuan County</city>
	  <state/>
	  <country>Taiwan</country>
	  <zip>333</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Primary insomnia patients</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>60</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>60</totalTarget>
      <exclusion>Pregnancy</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-12-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-11-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Insomnia</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Insomnia</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Non-invasive ear acupoint acupressure versus placebo</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder15176-0</funderId>
      <contactId>Contact53045_15176</contactId>
      <sponsorId>Sponsor51588</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53045_15176">
    <title>Prof</title>
    <forename>Heng-Hong</forename>
    <surname>Chang</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>No.123 Dinghu Road
&#13;Guishan Shiang</address>
      <city>Taoyuan County</city>
      <country>Taiwan</country>
      <zip>333</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+886 3 3196200</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">tcmchh@adm.cgmh.org.tw</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51588">
    <organisation>Chang Gung Memorial Hospital (Taiwan)</organisation>
    <website>http://www.cgmh.org.tw/index.htm</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>5 Fu-Hsing Street
&#13;Kuei Shan Hsian</address>
      <city>Tauyang Hsien</city>
      <country>Taiwan</country>
      <zip>33375</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.413801.f</gridId>
    <rorId>https://ror.org/02verss31</rorId>
  </sponsor>
  <funder id="Funder15176-0">
    <name>Chang Gung Memorial Hospital</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2006-07-03T00:00:00.000Z" version="19">
    <isrctn dateAssigned="2006-07-03T00:00:00.000Z">17856439</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Pathophysiology of urge incontinence in older women</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Older adults with urge incontinence respond well to generic oxybutynin when it is titrated for physiological differences in older patients. This treatment approach is efficacious even in detrusor hyperreflexia with impaired contractility (DHIC).</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Percentage reduction in incontinence episodes on 4-day bladder diary</primaryOutcome>
      <secondaryOutcome>1. Number of subjects dry at end of study
2. Subjective satisfaction</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approved by Brigham and Women's Hospital Institutional Review Board (IRB) on 26/09/1995, protocol number 94-6641-01</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN17856439</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>1999P-001891</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Double-blind, randomized, placebo-controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1996-03-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-03-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United States of America</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="1da2051b-2b51-4d95-9e89-cc53a70e8912">
	  <name>Suite 500</name>
	  <address/>
	  <city>Pennsylvania</city>
	  <state/>
	  <country>United States of America</country>
	  <zip>15213</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Cognitively intact, community-dwelling persons at least 55 years old with urge incontinence at least every two days</inclusion>
      <ageRange>Senior</ageRange>
      <gender>Female</gender>
      <targetEnrolment>250</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>250</totalTarget>
      <exclusion>1. Significant stress incontinence
2. Outlet obstruction
3. Post-voiding residual (PVR) urine &gt;300 ml
4. Mini mental state examination (MMSE) &lt;24/30
5. Inability to go to the toilet independently
6. Contraindication to antimuscarinic therapy
7. Gastrointestinal obstruction
8. Megacolon
9. Severe liver or renal disease
10. Uncontrolled hyperthyroidism
11. Multiple sclerosis
12. Anteroposterior resection
13. Pelvic radiation
14. Spinal cord disease resulting in para- or quadri-plegia</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1996-03-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-03-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Urge incontinence, detrusor hyperreflexia with impaired contractility (DHIC)</description>
	<diseaseClass1>Urological and Genital Diseases</diseaseClass1>
	<diseaseClass2>Urge incontinence</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Immediate release oxybutynin following treatment of reversible causes, dose titrated for four weeks and maintained for further four weeks
2. Control group: placebo</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Oxybutynin</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder14888-0</funderId>
      <contactId>Contact52668_14888</contactId>
      <sponsorId>Sponsor51201</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52668_14888">
    <title>Dr</title>
    <forename>Neil</forename>
    <surname>Resnick</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Suite 500
&#13;Kaufmann Medical Building
&#13;Pittsburgh</address>
      <city>Pennsylvania </city>
      <country>United States of America</country>
      <zip>15213</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 412 692 2360</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">ResnickNM@dom.pitt.edu</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51201">
    <organisation>National Institutes of Health (USA)</organisation>
    <website/>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>9000 Rockville Pike
&#13;Bethesda</address>
      <city>Maryland</city>
      <country>United States of America</country>
      <zip>20892</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.94365.3d</gridId>
    <rorId>https://ror.org/01cwqze88</rorId>
  </sponsor>
  <funder id="Funder14888-0">
    <name>National Institutes of Health (NIH) (National Institute of Diabetes and Digestive and Kidney Diseases [NIDDK])</name>
    <fundRef>http://dx.doi.org/10.13039/100000002</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2006-06-30T00:00:00.000Z" version="19">
    <isrctn dateAssigned="2006-06-30T00:00:00.000Z">40918692</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Effect of a dietary fiber and magnesium supplement on endothelial dysfunction, inflammation and glycemic control markers in patients with type 2 diabetes mellitus. Randomized, double-blind clinical trial.</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Biomarkers of endothelial dysfunction (selectin 2, vascular cell adhesion molecules [vcam], and intercellular adhesion molecule [icam]) will be lower in the patients with dietary fiber and magnesium supplements than those without them.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Biomarkers of endothelial dysfunction (selectin 2, vascular cell adhesion molecules [vcam]) and intercellular adhesion molecule [icam])</primaryOutcome>
      <secondaryOutcome>1. Serum levels of inflammation markers (interleukin-6, C-reactive protein)
2. Plasma levels of glycemic control markers (glycated hemoglobin and glucose)</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The name of the ethical committee that gave approval for the trial is Ethics Subcommittee of the National Commission for Scientific Research, Institute of Mexican Social Security (Comisión Nacional de Investigación Científica, Subcomité de Ética, Instituto Mexicano del Seguro Social), 14/04/2005; reference number: 09-B5-61-2800/983 2005-785-022</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN40918692</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>2005-785-022</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomized, double-blind, clinical trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-11-28T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-11-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Mexico</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="72963006-7856-4d62-8057-2d382766c528">
	  <name>Ave Cuauhutemoc 330</name>
	  <address/>
	  <city>Mexico Distrito Federal</city>
	  <state/>
	  <country>Mexico</country>
	  <zip>06720</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Having diabetes mellitus type 2 (dm2) according to the American Diabetes Association (ADA) criteria
2. Male or female
3. Up to 48 months of dm2 diagnosis
4. Aged 30-70 years</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>400</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>400</totalTarget>
      <exclusion>1. Clinical evidence of chronic complications at the time of enrolment
2. Chronic diarrhea
3. Renal function impairment</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-11-28T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-11-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Diabetes mellitus type 2</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Diabetes</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>There are four arms of treatment. All four groups received the best therapy available to control dm2 which include the ADA nutrition treatment guidelines. There was a nutritionist that gave specific suggestions according to each patient's needs, with an indication of losing weight if necessary. All patients received oral hypoglycaemic products and antihypertensive therapy as much as was needed to achieve the target levels of glucose and blood pressure. Patients were randomised to receive one of the following interventions:
1. Active cookies and active tablets
2. Combination of placebo and active cookies
3. Combination of placebo and active tablets
4. Control group: placebo cookies and placebo tablets</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder15040-0</funderId>
      <funderId>Funder15040-1</funderId>
      <funderId>Funder15040-2</funderId>
      <contactId>Contact52861_15040</contactId>
      <sponsorId>Sponsor51411</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52861_15040">
    <title>Dr</title>
    <forename>Susana</forename>
    <surname>Castanon</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Ave Cuauhutemoc 330
&#13;Colonia Doctores</address>
      <city>Mexico Distrito Federal</city>
      <country>Mexico</country>
      <zip>06720</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+52 55627690 ext.21507 or 21481</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">susanacast@usa.net</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51411">
    <organisation>Mexican Institute of Social Security (Instituto Mexicano del Seguro Social) (Mexico)</organisation>
    <website>http://www.cis.gob.mx</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>Ave Cuauhutemoc 330
&#13;Colonia Doctores</address>
      <city>Mexico Distrito Federal</city>
      <country>Mexico</country>
      <zip>06720</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+55 56276900 ext 21963</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">mdelpradom@cis.gob</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.419157.f</gridId>
    <rorId>https://ror.org/03xddgg98</rorId>
  </sponsor>
  <funder id="Funder15040-0">
    <name>Mexican Institute of Social Security (Instituto Mexicano del Seguro Social)</name>
    <fundRef/>
  </funder>
  <funder id="Funder15040-1">
    <name>Fabrica de Galletas la Moderna</name>
    <fundRef/>
  </funder>
  <funder id="Funder15040-2">
    <name>Laboratorio Silanes</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2006-06-23T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2006-06-23T00:00:00.000Z">51896330</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Multicentric clinical trial on the efficacy and safety of ceftriaxone and sulbactam in lower respiratory tract infection</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>The increasing rate of the resistance of antibacterials in lower respiratory tract infection (LRTI) pathogens has resulted in the need to consider innovative approaches like combining β-lactam antibiotics with β-lactamase inhibitors. The presence of sulbactam in fixed-dose combination (FDC) along with ceftriaxone could extend the antibiotic spectrum of ceftriaxone to include bacteria normally resistant to it. The aim of our study was to evaluate the efficacy and safety of ceftriaxone and sulbactam in fixed-dose combination in the treatment of  lower respiratory tract infection.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The overall efficacy of fixed dose combination (FDC) of ceftriaxone and sulbactam was excellent. The clinical cure rate was 77.14% and the bacteriological cure rate was 100%. A total of three adverse reactions were noted in 12 of the 105 patients receiving ceftriaxone and sulbactam (FDC) but none of them warranted discontinuation of treatment. Adverse effects noted included: pain at the injection site (5.7%), superficial thrombophlebitis (4.76%), and mild diarrhea (0.95%).</primaryOutcome>
      <secondaryOutcome>Ceftriaxone and sulbactam in fixed dose combination (FDC) is an effective and well-tolerated antimicrobial agent that appears promising for the treatment of serious lower respiratory tract infections</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Independent institutional ethics committee approval of participating centres were taken before initiation, reference number: CT/CS/01</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN51896330</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>CT/CS/01</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Open-label, non-comparative, multicentric study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Multi-centre</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-04-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-09-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>India</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="9bfe5690-2581-471d-895d-14c4b8e7f862">
	  <name>Manas Chest Clinic</name>
	  <address/>
	  <city>Mumbai</city>
	  <state/>
	  <country>India</country>
	  <zip>400022</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Age ≥18 years
2. Fever ≥38°C
3. Sputum pus cells &gt;25 high power fields (HPF)
4. Buccal epithelial cells &lt;10 HPF</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>105</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>105</totalTarget>
      <exclusion>1. Hypersensitivity to ceftriaxone, sulbactam or related drugs
2. Children less than 18 years of age
3. Septicemic shock, active pulmonary malignancies, renal and hepatic insufficiencies</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-04-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-09-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Lower respiratory tract infection</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Respiratory tract infection</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Treatment consisted of 1 g ceftriaxone + 0.5 g sulbactam in intravenous fixed dose combination every eight hours for 7 -10 days</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Ceftriaxone, sulbactam</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder15135-0</funderId>
      <contactId>Contact52990_15135</contactId>
      <sponsorId>Sponsor51538</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52990_15135">
    <title>Dr</title>
    <forename>Milind</forename>
    <surname>Khadke</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Manas Chest Clinic
&#13;301 Marathon Chambers
&#13;P.K. Road
&#13;Paanchrasta
&#13;Mulund (W)</address>
      <city>Mumbai</city>
      <country>India</country>
      <zip>400022</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">milind_khadke@yahoo.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51538">
    <organisation>Venus Remedies Limited (India)</organisation>
    <website>http://www.venusremedies.com</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Intellectual Scientific Division
&#13;Research and Development Centre
&#13;51-52 Industrial Area
&#13;Phase-1
&#13;Panchkula</address>
      <city>Haryana</city>
      <country>India</country>
      <zip>134113</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+91 17 22561244</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">operations@venusremedies.com</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.465099.7</gridId>
    <rorId>https://ror.org/0169rv113</rorId>
  </sponsor>
  <funder id="Funder15135-0">
    <name>Venus Remedies Limited</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2006-06-13T00:00:00.000Z" version="19">
    <isrctn dateAssigned="2006-06-13T00:00:00.000Z">57453322</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Long-term prognosis following cerebrovascular events of different etiologies</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>To determine the rate of recurrence in patients with cerebrovascular events of defined etiology</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Recurrent stroke</primaryOutcome>
      <secondaryOutcome>Mortality of any cause</secondaryOutcome>
      <trialWebsite>http://www.uni-essen.de/neurologie/stroke/</trialWebsite>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics Committee of the University of Essen reviewed the protocol of this trial and confirmed that ethical approval was not required.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN57453322</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>DI 327/9-1</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Prospective observational cohort study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Cohort study</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Diagnostic</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-09-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="e77823bf-db0d-4563-806f-be398f0efb20">
	  <name>Hufelandstr. 55</name>
	  <address/>
	  <city>Essen</city>
	  <state/>
	  <country>Germany</country>
	  <zip>45122</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients with acute cerebrovascular events of defined etiology including:
1. Cardiac right-to-left shunt
2. Transient ischemic attack (TIA) with symptoms lasting &lt;1 hour
3. Intracerebral bleeding
4. Intracranial stenosis
5. Dissection of brain supplying arteries
6. Coagulation disorder
7. Previous history of migraine
8. Basilar artery occlusion
9. Vasculitis
10. Arteriovenous malformation
11. Moyamoya syndrome</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>3000</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>3000</totalTarget>
      <exclusion>Inability or refusal to provide consent for study participation</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-09-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Cerebral stroke and TIA</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Transient ishaemic attack</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients are followed-up via telephone interview to determine the long-term rate of recurrence in patients with predefined stroke etiologies</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder14989-0</funderId>
      <contactId>Contact52800_14989</contactId>
      <sponsorId>Sponsor51345</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52800_14989">
    <title>Dr</title>
    <forename>Christian</forename>
    <surname>Weimar</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Hufelandstr. 55</address>
      <city>Essen</city>
      <country>Germany</country>
      <zip>45122</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 (0)201 723 2495</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">stroke.med@uni-essen.de</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51345">
    <organisation>German Research Foundation (Deutsche Forschungsgemeinsschaft) (DFG)</organisation>
    <website>http://www.dfg.de</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>Kennedeyallee 40</address>
      <city>Bonn</city>
      <country>Germany</country>
      <zip>53175</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">theodora.hogenkamp@dfg.de</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.424150.6</gridId>
    <rorId>https://ror.org/018mejw64</rorId>
  </sponsor>
  <funder id="Funder14989-0">
    <name>German Research Foundation (Deutsche Forschungsgemeinsschaft) (DFG) DI 327/9-1</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2006-06-09T00:00:00.000Z" version="19">
    <isrctn dateAssigned="2006-06-09T00:00:00.000Z">32422510</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A randomized, double-blind, placebo-controlled, multicenter trial to evaluate the clinical efficacy of a single intrapyloric injection of botulinum toxin type A (Botox®) in patients with idiopathic gastroparesis. The BIG study.</title>
      <scientificTitle/>
      <acronym>BIG study</acronym>
      <studyHypothesis>Several open-label pilot studies have shown a promising effect of intrapyloric botulinum toxin injection on symptoms in severe gastroparesis. However, data from randomized, double-blind, placebo-controlled studies are not yet available. We intend to evaluate the clinical efficacy of a single intrapyloric injection of botulinum toxin type A in patients with idiopathic gastroparesis.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Gastric emptying for solids.
1. Half-emptying time at visit 4 (follow-up: week 6) compared to visit 1b (eligibility: week 1)
2. Emptying rate per hour at visit 4 (follow-up: week 6) compared to visit 1b (eligibility: week 1)
3. One, two and four hour meal retention at visit 4 (follow-up: week 6) compared to visit 1b (eligibility week 1). 
Gastroparesis cardinal symptom index (GCSI) outcome
4. Total GCSI score at visit 3, 4, 5 and 6 (follow-up: week 3, 6, 9 and 12) compared to visit 2 (randomization: week 0)
5. Mean GCSI score during follow-up (week 0-12) compared to mean GCSI score during eligibility and randomization (week 10)</primaryOutcome>
      <secondaryOutcome>1. Gastric emptying for liquids; retention of liquid phase at 15, 30, 45, 60, 75, 90, 105 and 120 min
2. Quality of life as measured with the patient assessment of upper gastrointestinal disorders - quality of life (PAGI-QoL), the RAND-36 and EQ-5D questionnaires
3. Psychometric assessment and patient perception of gastrointestinal endoscopy</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN32422510</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>P05.170</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>A randomized, double-blind, placebo-controlled, multicenter trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-06-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-06-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="1f6802e6-0681-4c37-a56f-90cd5cc952fc">
	  <name>Leiden University Medical Center (LUMC)</name>
	  <address/>
	  <city>Leiden</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>2300 RC</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients are eligible to participate in this study if all of the following criteria are met:
1. Presence of clinical symptoms associated with idiopathic gastroparesis: nausea, vomiting, early satiety, postprandial fullness and a Gastroparesis Cardinal Symptom Index (GCSI) score ≥1 at visit 1b (eligibility; week 1)
2. Delayed gastric emptying for solids at visit 1b (eligibility; week 1) as measured with scintigraphy:
a. 2h retention ≥60%; and/or
b. 4h retention ≥10%
3. Absence of an obstructing structural lesion in the stomach or small intestine at prior diagnostic gastrointestinal endoscopy (performed within the previous 5 years) or judged absent by the responsible physician
4. Patients, both male and female, must use adequate means of birth control during the study
5. Patients must provide written informed consent prior to any study procedures being performed
6. Patients aged between 18 and 70 years inclusive
7. Patients, in the opinion of the investigator, must be able to understand the study and comply with the study requirements</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>48</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>48</totalTarget>
      <exclusion>Patients are excluded from the study if any of the following criteria are met:
1. Patients with predominant abdominal pain/discomfort in the opinion of the investigator
2. Presence of an obstructing structural lesion in the stomach or small intestine if observed during treatment gastrointestinal endoscopy (visit 2, randomization; week 0)
3. Patients taking drugs that interfere with the effect of botulinum toxin type A
4. Patients previously treated with intrapyloric injection of botulinum toxin type A;
5. Females who are pregnant or lactating
6. Patients with diabetes mellitus
7. Patients with delayed gastric emptying due to systemic disorders, e.g. systemic lupus erythematosus (SLE), sclerodermia, hypothyroidism
8. Patients with disorders of neuromuscular transmission, e.g. myasthenia gravis and Eaton-Lambert syndrome
9. Patients with abdominal surgery in their medical history, except (laparoscopic) appendectomy, (laparoscopic) cholecystectomy and/or hysterectomy
10. Patients with any condition which, in the opinion of the investigator, makes the patient unsuitable for entry into the study</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-06-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-06-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Idiopathic gastroparesis</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Gastroparesis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Intrapyloric injection of botulinum toxin type A 200 IU single injection or placebo single injection.
Scintigraphy for solid/liquid gastric emptying (before and after treatment).
Gastroparesis cardinal symptom index questionnaire
Quality of life (QOL) questionnaires
Psychometric assessment and patient perception questionnaires</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Botulinum toxin</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder15144-0</funderId>
      <contactId>Contact53000_15144</contactId>
      <sponsorId>Sponsor51548</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53000_15144">
    <title>Dr</title>
    <forename>J.J.L.</forename>
    <surname>Haans</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Leiden University Medical Center (LUMC)
&#13;Department of Gastroenterology and Hepatology C-04-P 
&#13;Room 192
&#13;P.O. Box 9600</address>
      <city>Leiden</city>
      <country>Netherlands</country>
      <zip>2300 RC</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)71 5261104</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">J.J.L.Haans@lumc.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51548">
    <organisation>Leiden University Medical Center (LUMC), Department of Gastroenterology and Hepatology (The Netherlands)</organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>P.O. Box 9600</address>
      <city>Leiden</city>
      <country>Netherlands</country>
      <zip>2300 RC</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.10419.3d</gridId>
    <rorId>https://ror.org/05xvt9f17</rorId>
  </sponsor>
  <funder id="Funder15144-0">
    <name>Leiden University Medical Center (LUMC) Department of Gastroenterology and Hepatology</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2006-06-07T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2006-06-07T00:00:00.000Z">39762831</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Efficacy and safety of ezetimibe in young children with familial hypercholesterolemia</title>
      <scientificTitle/>
      <acronym>EZKIMO</acronym>
      <studyHypothesis>Ezetimibe monotherapy lowers low density lipoprotein-cholesterol (LDL-C) levels, plant sterol levels and inflammatory markers in young children with familial hypercholesterolemia (FH).</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Primary endpoint will be the efficacy towards LDL-C levels and the safety of 10 mg ezetimibe.</primaryOutcome>
      <secondaryOutcome>Secondary endpoint will be the effect of 10 mg ezetimibe on inflammatory markers and plant sterols in plasma.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN39762831</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomized, placebo-controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-08-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-08-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="b3e51c68-8c92-4a28-acb9-10925e773624">
	  <name>Academic Medical Center (AMC)</name>
	  <address/>
	  <city>Amsterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>1100 DD</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Male or female
2. Aged 8-14 years
3. Heterozygous familial hypercholesterolemia defined as:
a. Molecular diagnosis of FH AND LDL-C above 95th percentile for age and sex (LDL-C &gt;3.88 mmol/l) despite a lipid-lowering diet for at least 3 months
b. LDL-cholesterol above 95th percentile for age and sex (LDL-C &gt;3.88 mmol/l) despite a lipid-lowering diet for at least 3 months
c. One parent with either a clinical or molecular diagnosis of FH</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Years" value="8.0"/>
      <upperAgeLimit unit="Years" value="14.0"/>
      <gender>Both</gender>
      <targetEnrolment>70</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>70</totalTarget>
      <exclusion>1. Homozygous familial hypercholesterolemia
2. Diseases that cause a secondary increase in LDL-C, such as diabetes mellitus, anorexia nervosa and renal, hepatic or thyroid disease
3. Length below the 3rd percentile for age and sex
4. Weight-compared-to-length above the 97th percentile for age and sex
5. Serious illness in the previous three months
6. Major surgery in the previous three months 
7. Partial ileal bypass or any gastrointestinal disease that might interfere with drug absorption
8. Plasma triglycerides above 4.0 mmol/l
9. Hypertension (systolic &gt;160 mmHg or diastolic &gt;100 mmHg)
10. Psychological disorders that might interfere with adherence to the protocol
11. Pregnancy at baseline 
12. History of allergy or sensitivity to ezetimibe 
13. Liver function tests, aspartate aminotransferase or alanine aminotransferase (ASAT or ALAT), must be &lt;1.5 times the upper limit of normal (ULN) using the central laboratory reference range
14. Creatinine clearance levels must be &lt;1.5 times the ULN using the central laboratory reference range</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-08-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-08-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Familial hypercholesterolemia (FH)</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Familial hypercholesterolemia</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Ezetimibe 10 mg/day versus placebo treatment for 4 months</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Ezetimibe</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder15118-0</funderId>
      <funderId>Funder15118-1</funderId>
      <contactId>Contact52972_15118</contactId>
      <sponsorId>Sponsor51520</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52972_15118">
    <title>Dr</title>
    <forename>M.D.</forename>
    <surname>Trip</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Academic Medical Center (AMC)
&#13;Department of Cardiology
&#13;F4- 109
&#13;P.O. Box 22660</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1100 DD</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)20 5665882 or 020-5669111</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">m.d.trip@amc.uva.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51520">
    <organisation>Academic Medical Center (AMC) (The Netherlands)</organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>P.O. Box 22660</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1100 DD</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.5650.6</gridId>
    <rorId>https://ror.org/03t4gr691</rorId>
  </sponsor>
  <funder id="Funder15118-0">
    <name>Merck Sharp and Dohme BV (MSD)</name>
    <fundRef/>
  </funder>
  <funder id="Funder15118-1">
    <name>Schering-Plough</name>
    <fundRef>http://dx.doi.org/10.13039/100007110</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2006-06-07T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2006-06-07T00:00:00.000Z">94873343</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Epidural versus intravenous analgesia in children: a double-blind randomized controlled trial.</title>
      <scientificTitle/>
      <acronym>EVIAN</acronym>
      <studyHypothesis>To investigate whether epidural analgesia provides a better postoperative pain control than intravenous (iv) opioid analgesia in children and whether epidural analgesia is associated with reduced postoperative morbidity.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Pain intensity
2. Epidural or iv analgesics consumption
3. Side effects</primaryOutcome>
      <secondaryOutcome>Secondary hyperalgesia</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN94873343</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Double-blind randomized controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-05-08T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-11-08T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="479f9af1-4606-482f-8100-7e65f50a67a2">
	  <name>Erasmus Medical Center</name>
	  <address/>
	  <city>Rotterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>3015 GJ</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. 6-18 years
2. American Society of Anesthesiologists (ASA) I or II</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Years" value="6.0"/>
      <upperAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>60</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>60</totalTarget>
      <exclusion>1. Preoperative use of analgesics or opioids for (chronic) pain syndromes
2. Endocrine and neurological disorders
3. Psychiatric disorders
4. Peripheral neuropathy
5. Mental retardation
6. Medication influencing somatosensory function
7. Indifference or insensitivity to pain
8. Contraindications to epidural analgesia
9. Contraindications to self-administration of opioids</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-05-08T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-11-08T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Pain during thoracic and abdominal surgery</description>
	<diseaseClass1>Surgery</diseaseClass1>
	<diseaseClass2>Pain</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patient controlled intravenous analgesia versus patient controlled epidural analgesia</description>
	<interventionType>Procedure/Surgery</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder15127-0</funderId>
      <contactId>Contact52981_15127</contactId>
      <sponsorId>Sponsor51529</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52981_15127">
    <title>Prof</title>
    <forename>D.</forename>
    <surname>Tibboel</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Erasmus Medical Center
&#13;Sophia Children’s Hospital
&#13;Department of Pediatric Surgical Intensive Care
&#13;Dr. Molewaterplein 60</address>
      <city>Rotterdam</city>
      <country>Netherlands</country>
      <zip>3015 GJ</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)10 4636567</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">j.illsley@erasmusmc.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51529">
    <organisation>Erasmus Medical Center, Department of Anesthesiology (The Netherlands)</organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>P.O. Box 2040</address>
      <city>Rotterdam</city>
      <country>Netherlands</country>
      <zip>3000 CA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.5645.2</gridId>
    <rorId>https://ror.org/018906e22</rorId>
  </sponsor>
  <funder id="Funder15127-0">
    <name>Erasmus Medical Center</name>
    <fundRef>http://dx.doi.org/10.13039/501100003061</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2006-06-07T00:00:00.000Z" version="19">
    <isrctn dateAssigned="2006-06-07T00:00:00.000Z">70542454</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Reduced intensity chemotherapy given with and without imatinib mesylate in patients &gt;/= 60 years considered unfit for standard chemotherapy with previously untreated acute myeloid leukemia (AML) and refractory anemia with excess of blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T): a randomized phase II study</title>
      <scientificTitle/>
      <acronym>HOVON / SAKK AML - 67</acronym>
      <studyHypothesis>The hypothesis to be tested is that the outcome in arm 2 is better than in arm 1.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Complete remission (CR) rate</primaryOutcome>
      <secondaryOutcome>1. Overall survival (time from registration till the death of the patient)
2. Event free survival (i.e. time from registration to induction failure, death or disease progression, whichever occurs first)
3. Adverse events or toxicity.</secondaryOutcome>
      <trialWebsite>http://www.hovon.nl</trialWebsite>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN70542454</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>HO67</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomized phase II study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-01-23T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-04-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="11ae1f05-bbb0-4c9a-8eb1-5df4f73fb3b4">
	  <name>Erasmus Medical Center</name>
	  <address/>
	  <city>Rotterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>3008 AE</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients &gt;/= 60 years
2. Patients considered unfit for standard chemotherapy
3. Patients with a confirmed diagnosis of 
a. Acute myeloid leukemia (M0-M2 and M4-M7, FAB classification)
b. With refractory anemia with excess of blasts (RAEB) or refractory anemia with
excess of blasts in transformation (RAEB-T) with an International Prognostic Scoring System (IPSS) score &gt;/= 1.5
4. Subjects with secondary AML progressing from antecedent (at least 4 months duration) myelodysplasia are also eligible
5. Serum glutamic-oxaloacetic transaminase (SGOT)/aspartate aminotransferase (AST) or serum glutamic pyruvic transaminase (SGPT)/alanine aminotransferase (ALT), total serum bilirubin, serum creatinine, and creatinine clearance not more than 1.5 x the upper limit of normal (ULN) at the laboratory where the analyses were performed
6. Male patients agree to employ an effective barrier method of birth control throughout the study and for up to three months following the discontinuation of study drug
7. Written informed consent</inclusion>
      <ageRange>Senior</ageRange>
      <gender>Both</gender>
      <targetEnrolment>60</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>60</totalTarget>
      <exclusion>1. Patients previously treated for AML (any antileukemic therapy including investigational agents)
2. Patients with cardiac dysfunction as defined by:
a. Myocardial infarction within the last six months prior to study entry
b. Reduced left ventricular ejection fraction of &lt;50% as evaluated by echocardiogram or multiple-gated acquisition left ventricular (MUGA) scan
c. Unstable angina
d. Unstable cardiac arrhythmia
3. Patients with a history of non-compliance to medical regimens or who are considered potentially unreliable
4. Patients with any serious concomitant medical condition, which could, in the opinion of the investigator, compromise participation in the study
5. Patients who have senile dementia, mental impairment or any other psychiatric disorder that prohibits the patient from understanding and giving informed consent</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-01-23T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-04-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Acute myeloid leukemia (AML)</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2>Leukemia</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The reduced intensity chemotherapy will consist of one induction cycle (cycle I) followed by one cycle of consolidation (cycle II).
The chemotherapy regimen for induction is as follows: 
1. Ara-C 100 mg/m^2/day continuous intravenous (iv) infusion, days 1-5
2. Daunorubicin (DNR) 45 mg/m^2/day iv 3h, days 1-2

The chemotherapy regimen for consolidation is as follows: 
1. Ara-C 100 mg/m^2/day iv continuous infusion, days 1-5
2. Daunorubicin (DNR) 45 mg/m^2/day iv 3h, days 1-2

Patients assigned to the imatinib arm, in addition will receive a daily dose of 600 mg imatinib orally (p.o.) from day 1 of the chemotherapy cycle till the end of week 40 (or until disease progression [death], or in case of no complete remission (CR) or no partial remission (PR) after cycle I or II.)</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Phase II</phase>
	<drugNames>Imatinib mesylate</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder15123-0</funderId>
      <contactId>Contact52977_15123</contactId>
      <sponsorId>Sponsor51525</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52977_15123">
    <title>Prof</title>
    <forename>B.</forename>
    <surname>Löwenberg</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Erasmus Medical Center
&#13;Daniel den Hoed Cancer Center
&#13;Department of Hematology
&#13;P.O. Box 5201</address>
      <city>Rotterdam</city>
      <country>Netherlands</country>
      <zip>3008 AE</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)10 4391598</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">b.lowenberg@erasmusmc.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51525">
    <organisation>Dutch Haemato-oncology Association (Stichting Hemato-Oncologie Volwassenen Nederland) (HOVON)</organisation>
    <website/>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>HOVON Data Center
&#13;Erasmus Medical Center
&#13;Daniel den Hoed Cancer Center
&#13;P.O. Box 5201</address>
      <city>Rotterdam</city>
      <country>Netherlands</country>
      <zip>3008 AE</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)10 4391568</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">hdc@erasmusmc.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.476265.4</gridId>
    <rorId>https://ror.org/056kpdx27</rorId>
  </sponsor>
  <funder id="Funder15123-0">
    <name>Dutch Cancer Society</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2006-06-07T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2006-06-07T00:00:00.000Z">86445183</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Alemtuzumab as remission induction for adult patients with acute lymphoblastic leukemia in relapse: a randomized phase II study</title>
      <scientificTitle/>
      <acronym>HOVON 74 ALL</acronym>
      <studyHypothesis>The hypothesis to be tested is that arm A and/or arm B are feasible.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Percentage of patients that reach a complete remission (CR) on induction cycle I in each arm
2. Percentage of patients with severe toxicity on induction cycle I in each arm</primaryOutcome>
      <secondaryOutcome>1. Toxicity profile related to each treatment step and intervals between treatment steps
2. Event-free survival (i.e. time from registration until no CR on protocol, relapse or death, whichever comes first). Event-free survival for patients without a CR is set at one day.
3. Disease-free survival (i.e. time from achievement of CR to date of relapse or death from any cause, whichever occurs first)
4. Overall survival measured from time of registration</secondaryOutcome>
      <trialWebsite>http://www.hovon.nl</trialWebsite>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN86445183</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>HO74</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomized, phase II study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Non randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-05-15T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-04-15T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="fb4e9893-4a7a-41fb-a057-c343853ae666">
	  <name>Leiden University Medical Center (LUMC)</name>
	  <address/>
	  <city>Leiden</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>2300 RC</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Age 18 - 70 years inclusive
2. First or second relapse of precursor B-cell ALL (B-ALL) or T-cell (T-ALL) (including Philadelphia chromosome or BCR-ABL tyrosine kinase positive ALL)
3. Duration of last complete remission at least 6 months
4. World Health Organization (WHO) performance status 0, 1, or 2
5. Negative pregnancy test at inclusion if applicable
6. Written informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>120</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>120</totalTarget>
      <exclusion>1. Mature B-cell ALL, i.e. Burkitt leukemia/lymphoma
2. Acute undifferentiated leukemia (AUL)
3. Treatment with alemtuzumab at any time prior to registration
4. Intolerance of exogenous protein administration
5. Central nervous system (CNS) leukemia
6. Severe cardiovascular disease (arrhythmias requiring chronic treatment, congestive heart failure or symptomatic ischemic heart disease)
7. Severe pulmonary dysfunction (Common Terminology Criteria for Adverse Events [CTCAE] grade III-IV)
8. Severe neurological or psychiatric disease
9. Significant hepatic dysfunction (serum bilirubin or transaminases &gt;/= 3 times normal level)
10. Significant renal dysfunction (serum creatinine &gt;/= 3 times normal level)
11. Patients with active, uncontrolled infections
12. Patients with uncontrolled asthma or allergy, requiring oral steroid treatment at the time of registration
13. Patients known to be human immunodeficiency virus (HIV)-positive
14. Patient is a lactating woman
15. Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-05-15T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-04-15T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Acute lymphoblastic leukemia (ALL)</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2>Leukemia</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Relapsed ALL patients under the age of 71 years will be registered and randomized to receive:
Arm A: prednisone and methotrexate in the pre-phase and thereafter two remission induction courses of alemtuzumab 30 mg

Arm B: prednisone and methotrexate in the pre-phase and thereafter two remission induction courses of alemtuzumab 60 mg</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Phase II</phase>
	<drugNames>Alemtuzumab, prednisone and methotrexate</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder15130-0</funderId>
      <funderId>Funder15130-1</funderId>
      <funderId>Funder15130-2</funderId>
      <funderId>Funder15130-3</funderId>
      <funderId>Funder15130-4</funderId>
      <funderId>Funder15130-5</funderId>
      <contactId>Contact52984_15130</contactId>
      <sponsorId>Sponsor51532</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52984_15130">
    <title>Prof</title>
    <forename>R.</forename>
    <surname>Willemze</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Leiden University Medical Center (LUMC)
&#13;Department of Hematology C2-R
&#13;P.O. Box 9600</address>
      <city>Leiden</city>
      <country>Netherlands</country>
      <zip>2300 RC</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)71 5262267</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">rwillemze@lumc.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51532">
    <organisation>Dutch Haemato-oncology Association (Stichting Hemato-Oncologie Volwassenen Nederland) (HOVON)</organisation>
    <website/>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>HOVON Data Center
&#13;Erasmus Medical Center
&#13;Daniel den Hoed Cancer Center
&#13;P.O. Box 5201</address>
      <city>Rotterdam</city>
      <country>Netherlands</country>
      <zip>3008 AE</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)10 4391568</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">hdc@erasmusmc.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.476265.4</gridId>
    <rorId>https://ror.org/056kpdx27</rorId>
  </sponsor>
  <funder id="Funder15130-0">
    <name>Dutch Cancer Society</name>
    <fundRef/>
  </funder>
  <funder id="Funder15130-1">
    <name>Johnson and Johnson-Orthobiotech</name>
    <fundRef/>
  </funder>
  <funder id="Funder15130-2">
    <name>Schering International</name>
    <fundRef/>
  </funder>
  <funder id="Funder15130-3">
    <name>Novartis Pharma B.V.</name>
    <fundRef/>
  </funder>
  <funder id="Funder15130-4">
    <name>Amgen</name>
    <fundRef>http://dx.doi.org/10.13039/100002429</fundRef>
  </funder>
  <funder id="Funder15130-5">
    <name>Roche Nederland BV</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2006-05-26T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2006-05-26T00:00:00.000Z">06912061</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Prospective, multicenter, double-blind, randomized, cross-over study to evaluate efficacy and safety of sevelamer in the treatment of dyslipidemia in children with persisting proteinuria</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Sevelamer, but not placebo, lowers hypercholesterolemia in children with persisting proteinuria or nephrotic syndrome</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Decrease in serum cholesterol</primaryOutcome>
      <secondaryOutcome>1. Decrease in other lipids
2. Markers of oxidative stress
3. Proteinuria</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics Committee of Charité - University Medicine Berlin on 05/09/2002, reference number 1778/Si 254</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN06912061</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>EK 1656/Si 238</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomized controlled, cross-over, double-blind, multicenter trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="ebfab802-621e-49ef-aff0-d0822ec8b003">
	  <name>Charité - University Medicine Berlin</name>
	  <address/>
	  <city>Berlin</city>
	  <state/>
	  <country>Germany</country>
	  <zip>13353</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Children aged 2-18 years, with persisting proteinuria and hypercholesterolemia.</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Years" value="2.0"/>
      <upperAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>20</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>20</totalTarget>
      <exclusion>1. Chronic renal insufficiency (glomerular filtration rate [GFR] &lt;40 ml/min)
2. Genetic forms of hyperlipidemia
3. Hyperlipidemia due to other causes</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Glomerular diseases with proteinuria</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Proteinuria, hyperlipidemia</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Sevelamer versus placebo</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Sevelamer</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder14929-0</funderId>
      <contactId>Contact52723_14929</contactId>
      <sponsorId>Sponsor51261</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52723_14929">
    <title>Prof</title>
    <forename>Uwe</forename>
    <surname>Querfeld</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Charité - University Medicine Berlin
&#13;Department of Pediatric Nephrology
</address>
      <city>Berlin</city>
      <country>Germany</country>
      <zip>13353</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor51261">
    <organisation>Genzyme Europe</organisation>
    <website/>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>310 Cambridge Science Park</address>
      <city>Cambridge</city>
      <country>United Kingdom</country>
      <zip>CB4 OWG</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.417924.d</gridId>
    <rorId>https://ror.org/02n6c9837</rorId>
  </sponsor>
  <funder id="Funder14929-0">
    <name>Genzyme Europe</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2006-05-15T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2006-05-15T00:00:00.000Z">77165120</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Randomized phase III trial of paclitaxel plus topotecan versus topotecan plus cisplatin in recurrent or persistent cervical cancer stage IVb</title>
      <scientificTitle/>
      <acronym>AGO-Uterus-9</acronym>
      <studyHypothesis>A chemotherapy scheme with topotecan and paclitaxel can be equally or more effective in advanced cervical cancer as a standard chemotherapy scheme</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Overall-survival</primaryOutcome>
      <secondaryOutcome>1. Time to progression
2. Efficacy
3. Therapy tolerance
4. Quality of life</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval details not yet received as of 15/05/2006</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN77165120</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>IFG-01-0106</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Prospective, two-armed, randomised clinical therapy trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-02-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-01-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="adab5438-c2e1-47e9-8367-632aaaf24111">
	  <name>Universitaetsstr. 21-23</name>
	  <address/>
	  <city>Erlangen</city>
	  <state/>
	  <country>Germany</country>
	  <zip>91054</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients with progressive histologically confirmed carcinoma of the cervic uteri and measurable disease (Response Evaluation Criteria in Solid Tumors [RECIST]) without treatment alternatives to chemotherapy</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Female</gender>
      <targetEnrolment>326</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>326</totalTarget>
      <exclusion>Bilateral hydronephrosis, central nervous system (CNS)-metastases or reduced general condition</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-02-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-01-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Advanced carcinoma of the cervix uteri</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2>Cervical cancer</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients are randomised to receive one of the following:
1. Paclitaxel and topotecan
2. Topotecan and cisplatin</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Phase III</phase>
	<drugNames>Paclitaxel, topotecan, cisplatin</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder14625-0</funderId>
      <contactId>Contact52382_14625</contactId>
      <sponsorId>Sponsor50893</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52382_14625">
    <title>Prof</title>
    <forename>Matthias W.</forename>
    <surname>Beckmann</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Universitaetsstr. 21-23</address>
      <city>Erlangen</city>
      <country>Germany</country>
      <zip>91054</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 (0)9131 8533451</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">studienzentrale@gyn.imed.uni-erlangen.de</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50893">
    <organisation>Institute for Women’s Health (Institut fuer Frauengesundheit GmbH) (Germany)</organisation>
    <website>http://www.ifg-erlangen.de</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Universitaetsstr. 21-23</address>
      <city>Erlangen</city>
      <country>Germany</country>
      <zip>91054</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 (0)9131 8533508</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">studienzentrale@gyn.imed.uni-erlangen.de</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.506347.3</gridId>
    <rorId>https://ror.org/01f30wv40</rorId>
  </sponsor>
  <funder id="Funder14625-0">
    <name>Institute for Women’s Health budget supported by GlaxoSmithKline GmbH &amp; Co. KG Germany</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2006-12-22T00:00:00.000Z" version="19">
    <isrctn dateAssigned="2006-05-02T00:00:00.000Z">36275372</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Driving ability after neurological diseases: driving behavior and therapy</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Driving ability, measured by a test of driving behavior after the intervention, improves more after a neuropsychological training with additional individual driving training than after a neuropsychological training with placebo intervention.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite>http://www.refonet.de/projekte/laufendeprojekte_5010.php</trialWebsite>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>University of Bonn, Medical Faculty (under review as of 02/05/2006)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN36275372</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>05010</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised clinical trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-04-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-05-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="778dc887-7f75-484b-a706-f6d83f993e32">
	  <name>Neurological Rehabilitation Center Godeshoehe e.V.</name>
	  <address/>
	  <city>Bonn</city>
	  <state/>
	  <country>Germany</country>
	  <zip>53177</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Neurological, annuity assured patients (phase d, Barthel-Index &gt;80) with stroke or brain injury and written informed consent.</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>60</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>60 participants (30 group A, 30 group B)</totalTarget>
      <exclusion>1. Hemiparesis
2. Seizure disorder
3. Visual field failures in terms of driving licence ordinance (FeV appendix 6)
4. Psychiatric history and important cognitive impairment as orientation disorder and a lack of understanding of instructions
5. Patients with extreme abnormal driving experience (no car driving in the last year or more than 70,000 km per year)</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-04-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-05-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Stroke, brain injury</description>
	<diseaseClass1>Nervous System Diseases</diseaseClass1>
	<diseaseClass2>Stroke, brain injury</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Group A: Individual driving training and neuropsychological training
Group B: Neuropsychological training and placebo intervention (computer education)
Pre/post: test of driving behavior and neuropsychological assessment.
Additional post: interview with patient about compensational strategies and interview with driving instructor concerning patients performance during driving lessons.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder14937-0</funderId>
      <contactId>Contact52735_14937</contactId>
      <sponsorId>Sponsor51274</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52735_14937">
    <title>Prof</title>
    <forename>Dr. Hans</forename>
    <surname>Karbe</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Neurological Rehabilitation Center Godeshoehe e.V.
Section Neuropsychology
Waldstr. 2-10</address>
      <city>Bonn</city>
      <country>Germany</country>
      <zip>53177</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 (0)228 381207</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">h.karbe@godeshoehe.de</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51274">
    <organisation>Refonet (Germany)</organisation>
    <website>http://www.refonet.de/</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>c/o Dr. Hartmut Pollmann
Postfach 10 07 63</address>
      <city>Bad Neuenahr-Ahrweiler</city>
      <country>Germany</country>
      <zip>53445</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 (0)264 1906212</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">service@refonet.de</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.487444.f</gridId>
    <rorId>https://ror.org/04yeh2x21</rorId>
  </sponsor>
  <funder id="Funder14937-0">
    <name>Rehabilitations - Research Network of the German Pension Insurance Fund Rhineland - Refonet Germany (Forschungsnetzwerk der Deutschen Rentenversicherung Rheinland - Refonet) Project number: 05010</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2006-04-28T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2006-04-28T00:00:00.000Z">75768415</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Pharmacological treatment of Depression: Phase II Lithium addition</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>The two strategies (Venlafaxine and subsequent Lithium addition in non-responders to Venlafaxine; Imipramine and subsequent Lithium addition in non-responders to Imipramine) are comparable in efficacy and time to response.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Change in HRSD scores
2. Change in CGI scores</primaryOutcome>
      <secondaryOutcome>Adverse effects.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN75768415</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>A double blind, randomized single-centre study with a washout period, comparing 2 treatment strategies.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-06-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-06-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="80e12255-ba7e-4379-981e-8cab7d91f6ae">
	  <name>Erasmus Medical Center</name>
	  <address/>
	  <city>Rotterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>3000 CA</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>All non-responders in phase I. 
In phase I inclusion criteria were:
1. Age 18-65
2. Major depressive disorder, single or recurrent episode (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition [DSM-IV])
3. Hamilton Rating Scale for Depression  (HRSD) (17 item) greater than or equal to 14
4. Written informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <upperAgeLimit unit="Years" value="65.0"/>
      <gender>Both</gender>
      <targetEnrolment>69</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>69</totalTarget>
      <exclusion>Any of the following is regarded as a criterion for exclusion from the trial:
1. Patients who are incapable of understanding the information and of giving informed consent. Also, patients who are unable to read or write  
2. Major depression with psychotic features (separate study)
3. Bipolar I or II disorder
4. Schizophrenia or other primary psychotic disorder
5. Treatment of current episode with adequate trial of Imipramine or Venlafaxine
6. Drug/alcohol dependence in the last 3 months
7. Mental retardation (IQ &lt;80)
8. Women: pregnancy or possibility for pregnancy and no adequate contraceptive measures. Breastfeeding.
9. Serious medical illness affecting central nervous system (CNS) e.g. M. Parkinson, systemic lupus erythematosus (SLE), brain tumor, cerebrovascular accident (CVA)
10. Relevant medical illness as contra-indications for the use of study medication (Venlafaxine and Imipramine), such as recent myocardial infarction and severe liver or kidney failure
11. Medication affecting CNS e.g. antidepressants and/or antipsychotics other than study medication, steroids (prednison), mood stabilisers, benzodiazepines (if not being tapered): &gt;3 mg lorazepam (or equivalent)
12. Direct electroconvulsive therapy (ECT) indication (e.g. very severely suicidal or refusal of food and drinking resulting in life threatening situation)
13. Contra-indications for Lithium (Moleman, 1998):
a. Kidney failure
b. Acute myocardial infarction
c. Myasthenia gravis
d. Breastfeeding</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-06-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-06-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Depression</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Depression</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Venlafaxine (maximum dose 375 mg) and subsequent Lithium addition;
Imipramine (dose adjustment to adequate plasma levels of 200-300 µg/l) and subsequent Lithium addition.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Venlafaxine, Lithium, Imipramine</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder15029-0</funderId>
      <contactId>Contact52849_15029</contactId>
      <sponsorId>Sponsor51398</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52849_15029">
    <title>Dr</title>
    <forename>W.W.</forename>
    <surname>Broek, van den</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Erasmus Medical Center
&#13;Department of Psychiatry
&#13;P.O. Box 2040</address>
      <city>Rotterdam</city>
      <country>Netherlands</country>
      <zip>3000 CA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">w.w.vandenbroek@erasmusmc.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51398">
    <organisation>Erasmus Medical Center (The Netherlands)</organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>P.O. Box 2040</address>
      <city>Rotterdam</city>
      <country>Netherlands</country>
      <zip>3000 CA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.5645.2</gridId>
    <rorId>https://ror.org/018906e22</rorId>
  </sponsor>
  <funder id="Funder15029-0">
    <name>Wyeth</name>
    <fundRef>http://dx.doi.org/10.13039/100004342</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2006-04-28T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2006-04-28T00:00:00.000Z">36704940</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Metabolic effects of Diabecinn (oral cinnamon extract) in diabetes type 2, a placebo-controlled randomized clinical trial</title>
      <scientificTitle/>
      <acronym>Diabecinn trial</acronym>
      <studyHypothesis>The main objective of this randomized, placebo-controlled trial is to determine the effects of cinnamon extract on HbA1c and lipid profiles in type 2 diabetic patients.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>HbA1c.</primaryOutcome>
      <secondaryOutcome>1. Lipid profile
2. 6 point glucose profile
3. Hypoglycemia
4. Body weight
5. Free fatty acids
6. C-reactive protein (CRP)</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN36704940</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised placebo-controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-05-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="ac7e789d-64cb-442b-8d93-a1de5482eb42">
	  <name>Academic Medical Center</name>
	  <address/>
	  <city>Amsterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>1100 DD</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Type 2 diabetes patients
2. Age 35-70 years inclusive
3. HbA1c between 7 and 12% inclusive</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>120</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>120</totalTarget>
      <exclusion>1. Pregnancy
2. Breast-feeding</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-05-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Diabetes Mellitus type 2 (DM type II)</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Diabetes</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Diabecinn three times a day (tid) or placebo</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Diabecinn</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder15031-0</funderId>
      <contactId>Contact52851_15031</contactId>
      <sponsorId>Sponsor51400</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52851_15031">
    <title>Dr</title>
    <forename>J.H.</forename>
    <surname>DeVries</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Academic Medical Center
&#13;Department of Internal Medicine, F4-222
&#13;P.O. Box 22660</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1100 DD</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)20 5669111</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">j.h.devries@amc.uva.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51400">
    <organisation>Academic Medical Center (AMC) (The Netherlands)</organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>P.O. Box 22660</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1100 DD</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.5650.6</gridId>
    <rorId>https://ror.org/03t4gr691</rorId>
  </sponsor>
  <funder id="Funder15031-0">
    <name>OTC Pharma</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2006-04-28T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2006-04-28T00:00:00.000Z">61458115</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The effect of Continuous Positive Airway Pressure (CPAP) on the collapsed lung during single-lung-ventilation in patients undergoing robot-assisted thoracoscopic esophageal resection: pulmonary complications, local and systemic cytokine production</title>
      <scientificTitle/>
      <acronym>COCTAIL</acronym>
      <studyHypothesis>Continuous positive airway pressure on the deflated lung prevents total alveolar collapse, resulting in less local and systemic cytokine response, causing less pulmonary complications.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Local and systemic cytokine production.</primaryOutcome>
      <secondaryOutcome>1. Pulmonary complications
2. Ventilation time
3. Intensive care unit (ICU) stay
4. Hospital stay</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN61458115</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-04-05T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-04-05T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="aa079704-8eb1-4d46-a8eb-07f2ba571d9d">
	  <name>University Medical Center Utrecht (UMCU)</name>
	  <address/>
	  <city>Utrecht</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>3584 CX</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients with resectable carcinoma of the esophagus or junction that will undergo robot-assisted thoracoscopic esophago-lymphadenectomy with gastric conduit formation
2. American Society of Anesthesiologists (ASA) classification &lt;4
3. Written informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>30</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>30</totalTarget>
      <exclusion>1. Moderate/severe lung function impairment ascertained by pulmonary function tests, requiring high dose steroid therapy
2. No epidural catheter</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-04-05T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-04-05T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Esophageal cancer</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2>Oesophageal</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Continuous Positive Airway Pressure (CPAP) to the collapsed lung during single-lung-ventilation versus no CPAP.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder15036-0</funderId>
      <contactId>Contact52856_15036</contactId>
      <sponsorId>Sponsor51405</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52856_15036">
    <title>Dr</title>
    <forename>R.</forename>
    <surname>Hillegersberg, van</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>University Medical Center Utrecht (UMCU)
&#13;Department of Surgery, G04.228
&#13;Heidelberglaan 100</address>
      <city>Utrecht</city>
      <country>Netherlands</country>
      <zip>3584 CX</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)30 2506968</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">r.vanhillegersberg@umcutrecht.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51405">
    <organisation>University Medical Center Utrecht (UMCU), Department of Surgery (The Netherlands)</organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Heidelberglaan 100</address>
      <city>Utrecht</city>
      <country>Netherlands</country>
      <zip>3584 CX</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.7692.a</gridId>
    <rorId>https://ror.org/0575yy874</rorId>
  </sponsor>
  <funder id="Funder15036-0">
    <name>Comprehensive Cancer Centre (Integraal Kankercentrum)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2006-05-02T00:00:00.000Z" version="18">
    <isrctn dateAssigned="2006-04-27T00:00:00.000Z">36282240</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A single-center, double-blind, randomized, placebo-controlled, 13-week study to evaluate the efficacy and safety of one capsule of XTEND-LIFE compared to placebo, and an extended four-week trial to assess its benefit when combined with ezetimibe 10 mg per day</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>XTEND-LIFE treatment for 12 weeks results in significantly greater reduction in low-density lipoprotein (LDL-C) than treatment with placebo. The addition of ezetimibe further enhances the efficacy of XTEND-LIFE to lower LDL-C.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>To compare the low density lipoprotein cholesterol (LDL-C) lowering efficacy of XTEND-LIFE to placebo in patients with hypercholesterolemia</primaryOutcome>
      <secondaryOutcome>1. To evaluate the effect of XTEND-LIFE compared to placebo on total cholesterol (TC), high density lipoprotein cholesterol (HDL-C), triglycerides, non-HDL-C, LDL-C:HDL-C ratio, apolipoprotein-B, apolipoprotein-A1, and high sensitivity C reactive protein
2. To evaluate the effect of XTEND-LIFE plus ezetimibe compared to ezetimibe and placebo on total cholesterol (TC), LDL-C, high density lipoprotein cholesterol (HDL-C), triglycerides, non-HDL-C, LDL-C:HDL-C ratio, apolipoprotein-B, apolipoprotein-A1, and high sensitivity C reactive protein
3. To explore the safety and tolerability of XTEND-LIFE with and without ezetimibe</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approved by the Western Institutional Review Board (WIRB) on 29/09/2005, study number: 1069148, WIRB protocol number: 20051297</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN36282240</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>CCR-XL001</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomized, double-blind, placebo-controlled study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-10-10T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-07-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United States of America</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="efdc4ecb-86d3-4754-8659-c7dd1314e67f">
	  <name>4675 Main Street</name>
	  <address/>
	  <city>Bridgeport</city>
	  <state/>
	  <country>United States of America</country>
	  <zip>06606</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Men and women greater than 18 years of age with LDL-C greater than or equal to 130 mg/dl
2. Have not received any cholesterol lowering medication for 8 weeks
3. Patients with coronary heart disease or coronary heart disease risk equivalents and with documented intolerance or reluctance to take Hydroxamethylglutaryl-CoA (HMG-CoA) reductase inhibitors will be included, however, patients being treated with and who are tolerant of HMG-CoA reductase inhibitors will not be considered</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>60</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>60</totalTarget>
      <exclusion>1. Plasma triglycerides &gt;400 mg/dl
2. Congestive Heart Failure (CHF) with New York Heart Association (NYHA) class 3 or 4
3. Hemoglobin A1C &gt;9%
4. Ileal bypass or gastrointestinal (GI) disorder that can impair absorption of study drugs
5. Impaired renal function - aspartate aminotransferase (AST) or alanine transaminase (ALT) &gt;2 times the upper limit of normal
6. Uncontrolled endocrine disorder
7. Alcohol consumption &gt;14 drinks per week
8. Lipid lowering medication within 8 weeks
9. Treatment with oral corticosteroids, immunosuppressants, androgens or warfarin</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-10-10T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-07-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Hypercholesterolemia</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Hypercholesterolemia</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The study will compare 12 weeks of treatment with one capsule of XTEND-LIFE to placebo. After 12 weeks, ezetimibe 10 mg/day will be added.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>XTEND LIFE Capasule and ezetimibe</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder14930-0</funderId>
      <contactId>Contact52724_14930</contactId>
      <sponsorId>Sponsor51262</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52724_14930">
    <title>Dr</title>
    <forename>Edward</forename>
    <surname>Kosinski</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>4675 Main Street</address>
      <city>Bridgeport</city>
      <country>United States of America</country>
      <zip>06606</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 203 683 5111</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">edward_kosinski@med3000.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51262">
    <organisation>Connecticut Clinical Research LLC (USA)</organisation>
    <website/>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>4675 Main Street</address>
      <city>Bridgeport</city>
      <country>United States of America</country>
      <zip>06606</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 203 683 5130</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">maria_capasso@med3000.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder14930-0">
    <name>Connecticut Clinical Research, LLC</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2006-04-11T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2006-04-11T00:00:00.000Z">95689523</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Neurocognitive and health-related quality of life outcomes of nocturnal oxygen supply in chronic obstructive pulmonary disease patients with sleep-related oxygen desaturation</title>
      <scientificTitle/>
      <acronym>GIRON</acronym>
      <studyHypothesis>Nocturnal oxygen supply will prevent the consequences of sleep-related hypoxemia (i.e. neurocognitive and health-related quality of life decline) in severe to very severe chronic obstructive pulmonary disease (COPD) patients presenting sleep-related oxygen desaturation. This decline will become similar to that seen in those severe to very severe COPD patients without nocturnal desaturation.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Neurocognitive function by means of a battery of tests:
1. Trail making test
2. Wechsler adult intelligence scale (WAIS)
3. Wechsler memory scale-revised (WMSR) test
4. Verbal fluency test
5. Rey complex figure test (RCFT)
6. Rey auditory verbal learning test (RAVLT)
7. National adult reading test (NART)
8. Repeatable battery for the assessment of neuropsychological status (RBANS)
9. Luria's premotor test performance</primaryOutcome>
      <secondaryOutcome>1. Health-related quality of life (St. George’s respiratory questionnaire)
2. Anxiety (state-trait anxiety inventory [STAI])
3. Depression (Beck depression inventory [BDI])
4. Exercise capacity (walking test)
5. Sleepiness (Epworth scale)
6. Dyspnea (Medical Research Council [MRC] scale)
7. Diurnal oxygen and carbonic anhydride blood pressures
8. Nocturnal urinary norepinephrine
9. Exacerbation rate
10. Hospitalization days
11. Mortality</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approved by the Institute of Health Assistance (Institut d'Assistència Sanitària) (IAS), Institutional Review Board (IRB) reviewed the protocol and reported its approval on 27/04/2004, reference number: CEIC-IAS 06/2004</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN95689523</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>IAS-PnN1-2006</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Prospective, randomised clinical trial and prospective case-control study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-03-08T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-03-07T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Spain</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="7223f716-d0fe-457f-8bde-362dd64875a9">
	  <name>Hospital Santa Caterina</name>
	  <address/>
	  <city>Salt</city>
	  <state/>
	  <country>Spain</country>
	  <zip>17019</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Severe to very severe stable COPD
2. Age 60 to 80 years
3. With a resting awake pO2 between 60 and 80 mmHg, with (cases) or without (controls) sleep-related oxygen desaturation</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>216</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>216 (144 nocturnal desaturators)</totalTarget>
      <exclusion>1. Clinically significant obstructive sleep apnea-hypopnea syndrome
2. Alcoholism
3. Anemia
4. Dementia
5. Cirrhosis
6. Obesity
7. Active psychiatric disease
8. Abnormal thyroid function
9. Stroke
10. Chronic systemic steroid therapy
11. Malignancy</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-03-08T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-03-07T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>COPD with and without nocturnal desaturation</description>
	<diseaseClass1>Respiratory</diseaseClass1>
	<diseaseClass2>COPD with and without nocturnal desaturation</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>All patients will receive standard care, but nocturnal desaturators will be randomized to receive oxygen during sleep or standard care only. Neurocognitive function, blood/urine analysis and electrocardiogram will be assessed at baseline and at 18 months. Health-related quality of life, lung function, six-minute walking test, nocturnal oxymetry and respiratory and sleep-related symptoms will be assessed at baseline and at six-month intervals.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder14871-0</funderId>
      <funderId>Funder14871-1</funderId>
      <funderId>Funder14871-2</funderId>
      <funderId>Funder14871-3</funderId>
      <funderId>Funder14871-4</funderId>
      <contactId>Contact52649_14871</contactId>
      <sponsorId>Sponsor51182</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52649_14871">
    <title>Dr</title>
    <forename>Susana</forename>
    <surname>Mota</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Hospital Santa Caterina
&#13;Hospital de Dia
&#13;Dr. Castany, s/n</address>
      <city>Salt</city>
      <country>Spain</country>
      <zip>17019</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+34 (0)97 218 26 00</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">susana.mota@ias.scs.es</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51182">
    <organisation>Institute of Health Assistance (Institut d'Assistència Sanitària [IAS]) (Spain)</organisation>
    <website>http://www.ias.scs.es</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Parc Hospitalari Marti i Julia
&#13;Dr. Castany, s/n</address>
      <city>Salt</city>
      <country>Spain</country>
      <zip>17019</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+34 (0)97 218 26 00</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">recerca@ias.scs.es</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.425907.d</gridId>
    <rorId>https://ror.org/058css875</rorId>
  </sponsor>
  <funder id="Funder14871-0">
    <name>IAS</name>
    <fundRef/>
  </funder>
  <funder id="Funder14871-1">
    <name>Grants from:</name>
    <fundRef/>
  </funder>
  <funder id="Funder14871-2">
    <name>Catalan Society of Pneumology 2005 (Societat Catalana de Pneumologia [SOCAP] 2005)</name>
    <fundRef/>
  </funder>
  <funder id="Funder14871-3">
    <name>Spanish Society of the Pathology of the Respiratory System 2005 (Sociedad Española de Patología del Aparato Respiratorio [SEPAR] 2005)</name>
    <fundRef/>
  </funder>
  <funder id="Funder14871-4">
    <name>Spanish Company of Air Products and Chemicals Inc.  (Sociedad Española de Carburos Metálicos S.A.)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2006-03-31T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2006-03-31T00:00:00.000Z">14732774</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Adoptive immunotherapy for adenovirus (AdV)-associated complications post transplantation</title>
      <scientificTitle/>
      <acronym>GAP-Protocol</acronym>
      <studyHypothesis>Allogeneic AdV-specific T lymphocytes (ASTL) can be generated and used therapeutically with a low risk of graft versus host disease (GVHD)</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>To determine the treatment related mortality (TRM), this will come into effect if:
1. TRM exceeds 35%
2. Acute GVHD III/IV exceeds 25%
3. Chronic GVHD II exceeds 25%
4. Non-hematopoietic toxicity 3-5 (according to NCI CTEP reporting criteria) exceeds 40%</primaryOutcome>
      <secondaryOutcome>1. Acute and chronic GVHD assessed by standard clinical grading scheme
2. Early non-hematopoietic toxicity grade according to NCI CTEP common terminology criteria for adverse events
3. Frequency and duration of AdV reactivations</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethical approval not yet received as of 31/03/2006</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN14732774</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Prospective, randomized, double-blind, placebo-controlled, phase III multicenter trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-07-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2011-07-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="f9935390-ce81-4976-ba4e-f1c829142d78">
	  <name>Department of General Pediatrics</name>
	  <address/>
	  <city>Berlin</city>
	  <state/>
	  <country>Germany</country>
	  <zip>13353</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Pediatric patients, aged 2 to 18 years with:
1. Acute leukemias (ALL)
2. Acute myeloid leukemia (AML)
3. Chronic myeloid leukemia (CML)
4. Myelodysplastic syndromes (MDS)</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Years" value="2.0"/>
      <upperAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>306</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>306</totalTarget>
      <exclusion>1. Patients in relapse or progress of AML or ALL and blast crisis of CML at the time of randomization
2. All second transplants
3. AdV seronegative recipients with seronegative matched related donors (MRD)
4. Patients with severe non-hematopoietic organ toxicity grade 3-5 (according to the National Cancer Institute [NCI] and Cancer Therapy Evaluation Program [CTEP] reporting criteria) at the time of randomization</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-07-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2011-07-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Pediatric patients with ALL, AML, CML or MDS following hematopoietic stem cell transplantation</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2>Paediatric leukaemia</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Treatment group will receive ASTL as prophylaxis and cidofovir as intervention.
2. Control group will receive placebo as prophylaxis and cidofovir as intervention.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Phase III</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder14832-0</funderId>
      <funderId>Funder14832-1</funderId>
      <contactId>Contact52604_14832</contactId>
      <sponsorId>Sponsor51137</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52604_14832">
    <title>Dr</title>
    <forename>Sebastian</forename>
    <surname>Voigt</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of General Pediatrics
&#13;Augustenburger Platz 1</address>
      <city>Berlin</city>
      <country>Germany</country>
      <zip>13353</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor51137">
    <organisation>Charité - University Medicine Berlin (Germany)</organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Augustenburger Platz 1</address>
      <city>Berlin</city>
      <country>Germany</country>
      <zip>13353</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.6363.0</gridId>
    <rorId>https://ror.org/001w7jn25</rorId>
  </sponsor>
  <funder id="Funder14832-0">
    <name>German Research Foundation (Deutsche Forschungsgemeinsschaft) (DFG)</name>
    <fundRef/>
  </funder>
  <funder id="Funder14832-1">
    <name>Vo 774/4-1</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2006-03-24T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2006-03-24T00:00:00.000Z">47228763</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Influence of different types of dialysis membranes on parameters of chronic inflammation</title>
      <scientificTitle/>
      <acronym>INFLUX</acronym>
      <studyHypothesis>The aim of the study is to evaluate the influence of dialysis membrane permeability on biological parameters that predict morbidity and mortality of hemodialysis patients with moderate chronic inflammation</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Plasma concentration of C-reactive protein</primaryOutcome>
      <secondaryOutcome>Advanced glycation end products, carboxymethyl lysine, asymmetric dimethyl arginine, fibrinogen, albumin and prealbumin, phosphate</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Consulting committee for the protection of people in biomedical research, Bordeaux A (Comité Consultatif pour la Protection des Personnes dans la Recherche Biomédicale [CCPPRB] de Bordeaux A) - number 2004/49, June 18, 2004.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN47228763</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>POL-FRA-1</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Prospective, multicenter, randomised</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-02-10T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>France</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="a5b5552c-6f55-4575-84b3-c9684d27a46e">
	  <name>Hôpital Pellegrin</name>
	  <address/>
	  <city>Bordeaux</city>
	  <state/>
	  <country>France</country>
	  <zip>33076</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Medically stable end-stage renal disease patients on hemodialysis for 6 months or more
2. Age ≥18 years
3. C-reactive protein between 5 and 50 mg/l maximum one week before inclusion
4. Human immunodeficiency virus (HIV) and hepatitis C virus (HCV) serologies negative
5. Not under guardianship
6. AgHbs negative
7. Absence of vascular access thrombosis
8. Absence of clinically identifiable cause of chronic inflammation
9. Treatment in a dialysis unit providing water quality according to the European Pharmacopoeia
10. Statin medication allowed, but no introduction or modification during the study
11. Hemodialysis blood flow rates between 200 and 500 ml/min possible
12. Dialysis frequency 3-4 per week</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>180</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>180</totalTarget>
      <exclusion>1. Age &gt;75 years
2. Known pregnancy
3. Severe comorbidities with life expectancy &lt;1 year
4. Cancer except skin cancer
5. Severe digestive pathologies
6. Chronic inflammatory diseases
7. Medication interfering with nutritional or inflammatory status
8. Treatment or intention to treat with immunosuppressive medication
9. Dialysis dose Kt/V &lt;1.2, and dialysis time &lt;10 hours per week
10. Treatment with hemofiltration or hemodiafiltration
11. Participation in another study during the preceding 30 days
12. Physically or mentally disabled patients</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-02-10T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>End-stage renal disease</description>
	<diseaseClass1>Urological and Genital Diseases</diseaseClass1>
	<diseaseClass2>Renal disease</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Hemodialysis treatment with high-flux versus low-flux dialysers of the same type of chemical composition</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder14909-0</funderId>
      <contactId>Contact52700_14909</contactId>
      <sponsorId>Sponsor51238</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52700_14909">
    <title>Prof</title>
    <forename>Christian</forename>
    <surname>Combe</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Hôpital Pellegrin
&#13;Service de Néphrologie
&#13;Place Amélie Raba-Léon</address>
      <city>Bordeaux</city>
      <country>France</country>
      <zip>33076</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">christian.combe@chu-bordeaux.fr</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51238">
    <organisation>Gambro SAS (France)</organisation>
    <website/>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>1-3, Boulevard Charles-de-Gaulle</address>
      <city>Colombes</city>
      <country>France</country>
      <zip>92707</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">georges.martin@gambro.com</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.487322.8</gridId>
    <rorId>https://ror.org/01mgtdr23</rorId>
  </sponsor>
  <funder id="Funder14909-0">
    <name>Gambro SAS</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2006-03-24T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2006-03-24T00:00:00.000Z">81821807</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Clinical assessment of a new catheter surface coating with antimicrobial properties: safety - handling - efficacy</title>
      <scientificTitle/>
      <acronym>Care BioBac</acronym>
      <studyHypothesis>Show that safety, handling and efficacy of a new temporary hemodialysis catheter with antibacterial/anti-biofilm coating is equal or superior compared to standard catheters of same type</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Safety (early removal due to catheter failure)
2. Handling (implantation, removal)
3. Efficacy (hemodialysis blood flow rate, pressure)</primaryOutcome>
      <secondaryOutcome>1. Frequency of exit site and catheter-related bloodstream infections
2. Bacterial growth on the catheter
3. Inflammatory and coagulation parameters in plasma</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Primary vote given by Charite, Berlin on 08/03/2004, reference number: 30/2004; secondary votes given by Arztekammer Westfalen-Lippe on 04/05/2004, reference number: 4/134 and Technical University Munich on 02/06/2004, reference number: 1080/04.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN81821807</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>2005-MBR-001</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Controlled, randomised, 2 parallel groups, multicenter</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-05-24T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-07-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="83cb7e0c-e9b3-4542-b2c0-d3cb57f3bdfb">
	  <name>Charité Campus Virchow-Klinikum</name>
	  <address/>
	  <city>Berlin</city>
	  <state/>
	  <country>Germany</country>
	  <zip>13353</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Need for renal replacement therapy
2. Age ≥18 years
3. Written informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>100</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>100</totalTarget>
      <exclusion>1. Known acute hepatitis B virus (HBV), hepatitis C virus (HCV) or human immunodeficiency virus (HIV)
2. Age &gt;75 years
3. Any infection associated wtih one or more positive blood cultures within 10 days prior to planned implantation
4. Any bacteremia associated with a previous catheter
5. Known pregnancy
6. Hospitalisation for more than 14 days
7. Respiratory assist
8. Use of antibiotics
9. Participation in another study during the preceding 30 days</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-05-24T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-07-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>End-stage renal disease patients with need for a temporary hemodialysis catheter</description>
	<diseaseClass1>Urological and Genital Diseases</diseaseClass1>
	<diseaseClass2>Renal disease</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Comparison of standard temporary hemodialysis catheter with a new catheter with antibacterial/anti-biofilm coating</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder14911-0</funderId>
      <contactId>Contact52701_14911</contactId>
      <sponsorId>Sponsor51239</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52701_14911">
    <title>Prof</title>
    <forename>Ralf</forename>
    <surname>Schindler</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Charité Campus Virchow-Klinikum
&#13;Innere Medizin
&#13;Nephrologie und Internistische Intensivmedizin
&#13;Augustenburger Platz 1</address>
      <city>Berlin</city>
      <country>Germany</country>
      <zip>13353</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">ralf.schindler@charite.de</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51239">
    <organisation>Gambro Corporate Research (Germany)</organisation>
    <website/>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Holger-Crafoord Street 26</address>
      <city>Hechingen</city>
      <country>Germany</country>
      <zip>72379</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">reinhold.deppisch@gambro.com</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.473105.4</gridId>
    <rorId>https://ror.org/05jgtkc28</rorId>
  </sponsor>
  <funder id="Funder14911-0">
    <name>Gambro Corporate Research</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2006-03-16T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2006-03-16T00:00:00.000Z">37522543</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The Impacts of a Visiting Companion Animal Program on the Health and Wellbeing of Patients whilst Residing in an Acute Care Setting</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>The implementation of a companion animal program has significant potential for enhancing the wellbeing of neurological unit patients within a hospital setting</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Assessment of wellbeing due to interventions
2. Assessment of quality of life due to interventions</primaryOutcome>
      <secondaryOutcome>Assessing the influence of the interventions on patients within the neurological ward</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approved by the Melbourne Health Ethics Committee, Deakin University (DU-HREC) on 20/09/2004, reference number: 212-2004</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN37522543</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>The study is an open randomised controlled trial using an interventional technique. Measurement involves quality of life and wellbeing scales, a pet attitude scale and observation.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Quality of life</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-02-14T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-02-14T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Australia</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="ce3eaffb-5665-4edc-bc76-745751d9ca87">
	  <name>221 Burwood Highway</name>
	  <address/>
	  <city>Burwood</city>
	  <state/>
	  <country>Australia</country>
	  <zip>3125</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Participants in the study must be a patient on the stroke ward at Western Hospital</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>80</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>80</totalTarget>
      <exclusion>Participants who are unable to complete the measures for the study</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-02-14T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-02-14T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Neurological disorder</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Neurological disorder</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Experimental group receive visitations from a companion animal program. Control group receive visitations without a companion animal program.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder14202-0</funderId>
      <contactId>Contact51918_14202</contactId>
      <sponsorId>Sponsor50348</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51918_14202">
    <title>Ms</title>
    <forename>Lauren</forename>
    <surname>Prosser</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>221 Burwood Highway</address>
      <city>Burwood</city>
      <country>Australia</country>
      <zip>3125</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+61 (0)3 9244 6452</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">lauren.prosser@deakin.edu.au</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50348">
    <organisation>Deakin University (Australia)</organisation>
    <website>http://www.deakin.edu.au/hbs/hsd/research/niche</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>221 Burwood Highway</address>
      <city>Burwood</city>
      <country>Australia</country>
      <zip>3125</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+61 (0)3 9244 6452</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">lauren.prosser@deakin.edu.au</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.1021.2</gridId>
    <rorId>https://ror.org/02czsnj07</rorId>
  </sponsor>
  <funder id="Funder14202-0">
    <name>Deakin University</name>
    <fundRef>http://dx.doi.org/10.13039/501100001778</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2006-03-17T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2006-03-16T00:00:00.000Z">70123783</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Brazilian conjugated meningococcal C vaccine: safety and immunogenicity</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Vaccine adverse events occur in acceptable levels for human use</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Safety assessment 30 days after immunization</primaryOutcome>
      <secondaryOutcome>Immunogenicity 30 days after immunization</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approved by the Committee of Evandro Chagas Clinical Research Institute on 8/08/2005, reference number: CAAE-0060.0.009.000-05</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN70123783</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>0060.0.009.000-05</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Open, phase 1 trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Prevention</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-01-02T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-04-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Brazil</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="73ddbbd3-cc2a-4f30-aa73-972c89d40f43">
	  <name>Av. Brasil 4365</name>
	  <address/>
	  <city>Rio de Janeiro</city>
	  <state/>
	  <country>Brazil</country>
	  <zip>21040-900</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Healthy volunteer</participantType>
      </participantTypes>
      <inclusion>1. 18-44 years of age
2. Willingness to comply with protocol requirements
3. Healthy volunteers
4. Ability to understand consent form
5. Human Immunodeficiency Virus (HIV) negative
6. Non-pregnant</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <upperAgeLimit unit="Years" value="44.0"/>
      <gender>Both</gender>
      <targetEnrolment>30</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>30</totalTarget>
      <exclusion>1. Nursing women
2. Use of different substances in the previous 14-60 days such as immunosupressive therapy and other vaccines
3. Prior history of serious adverse event to vaccines
4. Prior history of chronic diseases such as hypertension and diabetes
5. Alcohol and drug abuse</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-01-02T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-04-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Meningococcal disease serogroup C</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Meningococcal disease serogroup C</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Brazilian conjugate meningococcal C vaccine
2. Blood, urine, faeces specimens
3. Electrocardiogram (ECG), x-ray</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Phase I</phase>
	<drugNames>Brazilian conjugated meningococcal C vaccine</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder14815-0</funderId>
      <contactId>Contact52587_14815</contactId>
      <sponsorId>Sponsor51112</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52587_14815">
    <title>Dr</title>
    <forename>Andre</forename>
    <surname>Perisse</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Av. Brasil 4365</address>
      <city>Rio de Janeiro</city>
      <country>Brazil</country>
      <zip>21040-900</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+55 21 3882 9479</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">areynaldo@bio.fiocruz.br</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51112">
    <organisation>Bio-Manguinhos/Fiocruz (Brazil)</organisation>
    <website>http://www.bio.fiocruz.br</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Av. Brasil 4365</address>
      <city>Rio de Janeiro</city>
      <country>Brazil</country>
      <zip>21040-900</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+55 21 3882 9305</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">akira@bio.fiocruz.br</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.424703.6</gridId>
    <rorId>https://ror.org/05gj5j117</rorId>
  </sponsor>
  <funder id="Funder14815-0">
    <name>Bio-Manguinhos/Fiocruz</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2006-03-17T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2006-03-16T00:00:00.000Z">75538667</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Brazilian Meningococcal B Vaccine: Safety and Immunogenicity Study</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Vaccine adverse events occur in acceptable levels for human use</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Safety 30 days after immunization</primaryOutcome>
      <secondaryOutcome>Immunogenicity 30 days after immunization</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approved by the Committee of Evandro Chagas Clinical Research Institute on 28/02/2005, reference number: CAAE-0047.0.009.000-05</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN75538667</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>0047.0.009.000-05</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Open, phase 1 trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Prevention</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-01-02T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-12-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Brazil</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="4c32454f-bb97-4731-9740-5c841e5f6fe6">
	  <name>Av. Brasil 4365</name>
	  <address/>
	  <city>Rio de Janeiro</city>
	  <state/>
	  <country>Brazil</country>
	  <zip>21040-900</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Healthy volunteer</participantType>
      </participantTypes>
      <inclusion>1. 18-44 years of age
2. Willingness to comply with protocol requirements
3. Healthy volunteers
4. Ability to understand informed consent form
5. Human Immunodeficiency Virus (HIV) negative
5. Non-pregnant</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <upperAgeLimit unit="Years" value="44.0"/>
      <gender>Both</gender>
      <targetEnrolment>30</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>30</totalTarget>
      <exclusion>1. Nursing women
2. Use of different substances in the previous 14-60 days such as immunosuppressive therapy and other vaccines
3. Prior history of serious adverse event to vaccines
4. Prior history of chronic diseases such as hypertension and diabetes
5. Autoimmune diseases
6. Alcohol and drug abuse</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-01-02T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-12-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Meningococcal disease serogroup B</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Meningococcal disease serogroup B</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Three doses of three different concentrations of Brazilian meningococcal B vaccine
2. Blood, urine, faeces specimens
3. Electrocardiogram (ECG), x-ray</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Phase I</phase>
	<drugNames>Vaccine for meningococcal B disease</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder14818-0</funderId>
      <contactId>Contact52591_14818</contactId>
      <sponsorId>Sponsor51118</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52591_14818">
    <title>Dr</title>
    <forename>Andre</forename>
    <surname>Perisse</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Av. Brasil 4365</address>
      <city>Rio de Janeiro</city>
      <country>Brazil</country>
      <zip>21040-900</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+55 21 3882 9479</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">areynaldo@bio.fiocruz.br</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51118">
    <organisation>Bio-Manguinhos/Fiocruz (Brazil)</organisation>
    <website>http://www.bio.fiocruz.br</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Av. Brasil 4365</address>
      <city>Rio de Janeiro</city>
      <country>Brazil</country>
      <zip>21040-900</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+55 21 3882 9305</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">akira@bio.fiocruz.br</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.424703.6</gridId>
    <rorId>https://ror.org/05gj5j117</rorId>
  </sponsor>
  <funder id="Funder14818-0">
    <name>Bio-Manguinhos/Fiocruz</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2006-03-13T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2006-03-10T00:00:00.000Z">68990076</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Randomised controlled trial for the treatment of hand arthrosis with prednisolone and naproxen</title>
      <scientificTitle/>
      <acronym>BELIOA2</acronym>
      <studyHypothesis>The primary hypothesis is that patients with hand arthrosis treated with prednisolone for one week (3 days 50 mg, 4 days 25 mg) will improve significantly in different clinical parameters</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Pain in the target hand measured on a 100 mm VAS</primaryOutcome>
      <secondaryOutcome>1. Morning stiffness
2. VAS for disease activity
3. Tender and swollen joint counts (inflammatory and bony swelling)
4. Functioning measured with:
a. Health Assessment Questionnaire (HAQ)
b. Score for Assessment and Quantification of Chronic Rheumatic Affections of the Hands (SACRAH)
c. Arthritis Impact Measurement Scales 2 - Short Form (AIMS2-SF)
d. Grip strength
e. Moberg picking-up test</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The study was approved by the Internal Review Board and Ethical Committee of the Vienna Medical University on 14/02/2006, reference number 481/2005</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN68990076</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>IDS 04-05</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Single-centre, randomised, double-blind, placebo-controlled clinical trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-12-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-12-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Austria</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="8f183a80-36b8-4da6-bcc3-3af542e241bc">
	  <name>Department of Internal Medicine III</name>
	  <address/>
	  <city>Vienna</city>
	  <state/>
	  <country>Austria</country>
	  <zip>A-1090</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Hand arthrosis
2. Age over 18 years
3. Pain on a 100 mm Visual Analogue Scale (VAS) in the target hand more than 40 mm
4. Willingness to comply with the protocol</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>246</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>246</totalTarget>
      <exclusion>1. Current treatment with steroids
2. Cardiac insufficiency
3. Infection
4. Uncontrolled hypertension
5. History of gastrointestinal bleeding
6. Diabetes mellitus
7. Allergy against study medication
8. Pregnancy</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-12-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-12-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Hand arthrosis</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Hand arthrosis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients are randomised to receive treatment with either prednisolone or naproxen or placebo</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Prednisolone and naproxen</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder14233-0</funderId>
      <contactId>Contact51954_14233</contactId>
      <sponsorId>Sponsor50384</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51954_14233">
    <title>Prof</title>
    <forename>Josef</forename>
    <surname>Smolen</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Internal Medicine III
&#13;Division of Rheumatology
&#13;Wahringer Gurtel 18-20</address>
      <city>Vienna</city>
      <country>Austria</country>
      <zip>A-1090</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+43 (0)140 400 4381</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">josef.smolen@wienkav.at</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50384">
    <organisation>Vienna Medical University (Austria)</organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Department of Internal Medicine III
&#13;Division of Rheumatology
&#13;Wahringer Gurtel 18-20</address>
      <city>Vienna</city>
      <country>Austria</country>
      <zip>A-1090</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.22937.3d</gridId>
    <rorId>https://ror.org/05n3x4p02</rorId>
  </sponsor>
  <funder id="Funder14233-0">
    <name>Vienna Medical University (Austria)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2006-03-01T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2006-03-01T00:00:00.000Z">72526711</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A randomized, open-labelled, parallel, comparative study of the efficacy and tolerability of rosuvastatin in low-density lipoprotein-cholestrol reduction using different dosing regimens of 5 mg daily, 10 mg daily and 10 mg on alternate days in Hong Kong Chinese type 2 diabetic patients</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Alternate day dosing of rosuvastatin 10 mg is comparable to daily dosing of rosuvastatin 5 mg</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Percentage change of LDL-Cholesterol at 12 weeks and 24 weeks from baseline parameter in the three study arms using different dosing regimes of rosuvastatin</primaryOutcome>
      <secondaryOutcome>1.  Percentage change of total cholesterol, triglyceride levels and High-Density Lipoprotein-Cholesterol (HDL-C) at 12 weeks and 24 weeks from baseline parameters in the three study arms using different dosing regimes of rosuvastatin
2.  Effects on glycemic control as determined by fasting glucose and HbA1c at 12 weeks and 24 weeks
3.  Effects on insulin resistance as determined by Homeostasis Model Assessment (HOMA) at 12 and 24 weeks
 4.  Effects on urinary albumin excretion and creatinine clearance as assessed at 12 and 24 weeks</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Study protocol, informed consent documents, any addenda or amendments have been reviewed and approved jointly by the Chinese University of Hong Kong, New Territories and the East Cluster Clinical Research Ethics Committee, reference number CRE-2005.095-T</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN72526711</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomized, open-labelled, parallel-group study using rosuvastatin 5 mg daily, 10 mg daily or 10 mg on alternate days in patients with Low-Density Lipoprotein (LDL) Cholesterol &gt;/= 2.6 mmol/l after following a standard lipid lowering diet</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-06-18T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-12-18T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Hong Kong</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="ac5a51d2-adb2-486d-b585-85a260480dea">
	  <name>Flat 8A</name>
	  <address/>
	  <city>Shatin, New Territories</city>
	  <state/>
	  <country>Hong Kong</country>
	  <zip>-</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Type 2 diabetic patients 18 to 75 years of age
2. Treated with diet alone, oral hypoglycemic agents and/or insulin
3. LDL-Cholesterol &gt;/= 2.6 mmol/l
4. Dyslipidaemia persisting after diet control for eight weeks or more
5.  Alcohol consumption &lt;50 g/day
6.  Not on treatment with drugs known to interfere with glucose tolerance or drugs that have a major effect on lipid metabolism e.g. thiazide diuretics and beta-blockers
7.  Good compliance to diet and drugs
8.  HbA1c &lt;9% (glucosylated haemoglobin &lt;9%)
9.  Blood pressure &lt;160/95 mmHg</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>120</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>120</totalTarget>
      <exclusion>1.  Significantly impaired renal function (plasma creatinine &gt;150 micromol
2.  Impaired liver function (Serum Glutamic Pyruvic Transaminase [SGPT] or alanine aminotransferase [ALT] twice the upper limit of normal)
3.  Secondary dyslipidaemia, diabetic dyslipidaemia
4.  Pregnant women or those planning a pregnancy
5.  Lactation
6.  Progressive fatal disease
7.  History of drug or alcohol abuse
8.  History of hypersensitivity to study medication or drugs with a similar chemical structure
9.  Likelihood of requiring treatment during the study period with the following drugs: cyclosporine, erythromycin</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-06-18T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-12-18T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Dyslipidaemia</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Dyslipidaemia</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Drug intervention: rosuvastatin 5 mg daily or 10 mg daily or 10 mg on alternate days</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Rosuvastatin</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder14601-0</funderId>
      <contactId>Contact52351_14601</contactId>
      <sponsorId>Sponsor50841</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52351_14601">
    <title>Dr</title>
    <forename>Francis C.C.</forename>
    <surname>Chow</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Flat 8A
&#13;Block B
&#13;Staff Quarters
&#13;Prince of Wales Hospital</address>
      <city>Shatin, New Territories</city>
      <country>Hong Kong</country>
      <zip>-</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor50841">
    <organisation>Chinese University of Hong Kong</organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Flat 8A
&#13;Block B
&#13;Staff Quarters
&#13;Prince of Wales Hospital</address>
      <city>Shatin, New Territories</city>
      <country>Hong Kong</country>
      <zip>-</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.10784.3a</gridId>
    <rorId>https://ror.org/00t33hh48</rorId>
  </sponsor>
  <funder id="Funder14601-0">
    <name>Chinese University of Hong Kong (investigator-initiated study)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2006-03-01T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2006-02-28T00:00:00.000Z">76036162</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A randomized, double blind, placebo-controlled trial on the effect of rosiglitazone in reversing newly diagnosed type 2 diabetes to non-diabetic status</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Rosiglitazone will be effective in reversing newly diagnosed mild diabetes to non-diabetic status</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Glycaemic status as assessed by 75 g OGTT at 52 weeks</primaryOutcome>
      <secondaryOutcome>1.  Change of insulin resistance and insulin reserve as assessed by Homeostasis Model Assessment (HOMA) at 52 weeks
2.  Cardiovascular risk factors assessed at 52 weeks
3.  Treatment effect 13 weeks after treatment stopped</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Study protocol, informed consent documents, any addenda or amendments have been reviewed and approved jointly by the Chinese University of Hong Kong, New Territories and the East Cluster Clinical Research Ethics Committee, reference number CRE-2003.111-T</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN76036162</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomized, double-blind, placebo-controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-09-09T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-01-25T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Hong Kong</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="725c9611-cabf-441d-b711-52aa43f0ca3d">
	  <name>Flat 8A</name>
	  <address/>
	  <city>Shatin, New Territories</city>
	  <state/>
	  <country>Hong Kong</country>
	  <zip>-</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1.  Type 2 diabetic patients above 18 years of age
2.  Newly diagnosed diabetes within one year with HbA1c &lt;7% at the time of entry to the study
3.  No history of exposure to any anti-diabetic medications except diet control or insulin during period of gestational diabetes
4.  Alcohol consumption less than 50 g/day</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>80</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>80</totalTarget>
      <exclusion>1.  Significantly impaired renal function with plasma creatinine &gt;200 mmol/l
2.  Known case of liver cirrhosis (Child’s B grading or above) or significantly impaired liver function (alanine aminotransferase [ALT] or aspartate aminotransferase [AST], greater than two times the upper limit of normal) 
3.  Congestive heart failure of class III or IV by the New York Heart Association classification (NYHA) 
4.  Progressive fatal disease
5.  History of drug or alcohol abuse
6.  History of hypersensitivity to study medication or drugs with similar chemical structure to rosiglitazone
7.  Pregnant women or those planning a pregnancy
8.  Lactation
9.  Known severe non-compliance to medication or any factor, which will affect the completion of the study as judged by the investigator
10.  Need of any medication, which will affect interpretation of Oral Glucose Tolerance Test (OGTT) such as regular oral steroid or episodic high dose steroid</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-09-09T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-01-25T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Diabetes mellitus (type 2)</description>
	<diseaseClass1>Urological and Genital Diseases</diseaseClass1>
	<diseaseClass2>Diabetes mellitus (type 2)</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Primary intervention: rosiglitazone versus placebo for 52 weeks
Secondary intervention: standard lifestyle modification advice</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Rosiglitazone</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder14594-0</funderId>
      <funderId>Funder14594-1</funderId>
      <contactId>Contact52337_14594</contactId>
      <sponsorId>Sponsor50826</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52337_14594">
    <title>Dr</title>
    <forename>Francis C.C.</forename>
    <surname>Chow</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Flat 8A
&#13;Block B
&#13;Staff Quarters
&#13;Prince of Wales Hospital</address>
      <city>Shatin, New Territories</city>
      <country>Hong Kong</country>
      <zip>-</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor50826">
    <organisation>Chinese University of Hong Kong</organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Flat 8A
&#13;Block B
&#13;Staff Quarters
&#13;Prince of Wales Hospital</address>
      <city>Shatin, New Territories</city>
      <country>Hong Kong</country>
      <zip>-</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.10784.3a</gridId>
    <rorId>https://ror.org/00t33hh48</rorId>
  </sponsor>
  <funder id="Funder14594-0">
    <name>Chinese University of Hong Kong</name>
    <fundRef/>
  </funder>
  <funder id="Funder14594-1">
    <name>(investigator-initiated study)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2006-12-22T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2006-02-28T00:00:00.000Z">02674550</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Pilot, prospective, multicentric, open study: use of a new Prismaflex filter (coated with heparin) without any addition of heparin in the extracorporeal circuit. Study with direct individual benefit.</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Evaluation of heparin-free treatment</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Evaluation of filters&#146; lifespan in patients treated by CRRT with the new products without any addition of heparin in the extracorporeal circuit</primaryOutcome>
      <secondaryOutcome>Safety assessment of heparin-free treatment</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approved by the Committee for the Protection of Persons (CPP) on 06/12/2005, reference number 2005/063B</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN02674550</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>1439</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Pilot, prospective, multicentric, open study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-11-30T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-08-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>France</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="cbfd5549-5cf6-4764-beab-4ef83fc925c4">
	  <name>Hôpital Edouard Herriot</name>
	  <address/>
	  <city>Lyon</city>
	  <state/>
	  <country>France</country>
	  <zip>69437</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1.  Patients requiring Continuous Renal Replacement Therapy (CRRT)
2.  Patients aged 18 and over
3.  Patients weighing 30-120 kg
4.  Patients having signed a written consent (informed consent) to participate in the study or written consent from a relative or, failing which, a person of trust in case the patient is unconscious</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>30</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>30</totalTarget>
      <exclusion>1.  History of heparin antibodies or heparin-induced thrombocytopenia
2.  Known hypersensitivity to any dialysis membrane
3.  Pregnancy
4.  Current enrolment in another trial which could impact the successful completion of this study
5.  Patients under guardianship
6.  Patients anticipated to require transportation outside the unit for diagnostic or therapeutic procedures in the coming first week
7.  Unconscious patients for whom no relative or person of trust can give consent for treatment. In the absence of any relative or person of trust, the patient in question cannot be included in the study.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-11-30T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-08-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Continuous Renal Replacement Therapy (CRRT)</description>
	<diseaseClass1>Urological and Genital Diseases</diseaseClass1>
	<diseaseClass2>Continuous Renal Replacement Therapy (CRRT)</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients are treated with a maximum five filters. 

Please note that the study period of this trial has been extended to December 2007.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder14734-0</funderId>
      <contactId>Contact52498_14734</contactId>
      <sponsorId>Sponsor51013</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52498_14734">
    <title>Prof</title>
    <forename>Bernard</forename>
    <surname>Allaouchiche</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Hôpital Edouard Herriot
Service d&#146;Anesthésie-Réanimation
Pavillon G
5 Place d&#146;Arsonval
</address>
      <city>Lyon</city>
      <country>France</country>
      <zip>69437</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor51013">
    <organisation>Gambro Industries (France)</organisation>
    <website/>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>61 Avenue Tony Garnier</address>
      <city>Lyon</city>
      <country>France</country>
      <zip>69357</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.487322.8</gridId>
    <rorId>https://ror.org/01mgtdr23</rorId>
  </sponsor>
  <funder id="Funder14734-0">
    <name>Gambro Industries</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2006-03-22T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2006-02-07T00:00:00.000Z">14523624</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Is beta-lactam therapy, until the patient has been afebrile for 48 hours (at least 5 days), sufficient for the treatment of community-acquired pneumonia?</title>
      <scientificTitle/>
      <acronym>PNEITID</acronym>
      <studyHypothesis>Is beta-lactam therapy until the patient has been afebrile for 48 hours (and been treated for at least 5 days) as effective as beta-lactam therapy for 10 days in uncomplicated community-acquired pneumonia?</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Clinical cure at the four-week-visit
2. Recurrence of pneumonia within one month</primaryOutcome>
      <secondaryOutcome>1. Resolution of X-ray infiltrates
2. C-reactive protein-level at the four-week-visit
3. Reported fever, cough and of physical and mental condition at the telephone conversation or at the follow-up visit</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Yes, by the Ethics Committee of the Orebro County Council, number 965-1999 (Sweden)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN14523624</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Prospective, randomised, open-label, multi-center (4 centres) study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1999-12-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-05-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Sweden</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="bba64d8d-8626-4863-8be8-8f376b206a6a">
	  <name>Department of Infectious Diseases</name>
	  <address/>
	  <city>Orebro</city>
	  <state/>
	  <country>Sweden</country>
	  <zip>SE-70185</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Adult patients with uncomplicated febrile community-acquired pneumonia, with chest X-ray infiltrates, who initially experience improvement with beta-lactam monotherapy</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>200</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>200</totalTarget>
      <exclusion>Nursing home resident, hospitalisation during the preceding month, antibiotic treatment for any reason during the preceding week, ongoing antipyretic medication. Inability to make a telephone conversation or to attend to a follow-up visit</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1999-12-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-05-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Community-acquired pneumonia</description>
	<diseaseClass1>Respiratory</diseaseClass1>
	<diseaseClass2>Pneumonia</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients who experience improvement with beta-lactam monotherapy are randomised, on treatment day 2-5, to receive this medication for either 10 days or until he/she has been afebrile for 48 hours (and has been treated for at least 5 days).

The body temperature is measured rectally three times daily and the patient is considered afebrile after a second consecutive temperature read at =/&lt; 37.8 °C. Two weeks from the start of antibiotic treatment, a study nurse will have a telephone conversation with the patient, and four weeks from start of treatment, a follow-up visit, including a chest X-ray, is performed.

At hospital discharge, at the telephone conversation, and at the follow-up visit, the patient is asked if he/she has experienced cough or fever and is asked to describe his/her physical and mental condition. C-reactive protein and a serum for serological tests are taken on treatment day 3 and at the follow-up visit. Serological tests for Mycoplasma pneumoniae, Chlamydophila pneumoniae, Chlamydophila psittaci, and other respiratory viruses are performed.

At presentation, patients suitable for the study are subjected to cultures from blood, sputum, and nasopharyngeal secretions. Since 2005, the Binax NOW® Streptococcus pneumoniae urinary antigen test is also used to establish the pneumonia aetiology.


If a patient experiences fever, increasing dyspnoea, or increasing cough during the first month after inclusion in the study, careful analysis, including radiological investigations, microbiological investigations, and other laboratory investigations, is performed.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>beta-lactam</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2004 Other publications in https://doi.org/10.1086/381761 Stralin et al. Clinical Infectious Diseases, ;38:766-7.</publicationDetails>
      <publicationStage/>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="bac8445f-d524-4185-a089-8ee87da357c6" outputType="otherpublications" artefactType="ExternalLink" dateCreated="2004-03-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://doi.org/10.1086/381761"/>
	<description>Stralin et al. Clinical Infectious Diseases, ;38:766-7.</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder14616-0</funderId>
      <contactId>Contact52371_14616</contactId>
      <sponsorId>Sponsor50881</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52371_14616">
    <title>Dr</title>
    <forename>Hans</forename>
    <surname>Holmberg</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Infectious Diseases
&#13;Orebro University Hospital</address>
      <city>Orebro</city>
      <country>Sweden</country>
      <zip>SE-70185</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+46 19 6021863</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">hans.holmberg@orebroll.se</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50881">
    <organisation>The Research Committee of Orebro County Council (Sweden)</organisation>
    <website/>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>c/o Carl-Goran Ohlson MD, PhD
&#13;Assistant Professor
&#13;Clinical Research Centre
&#13;Orebro University Hospital</address>
      <city>Orebro</city>
      <country>Sweden</country>
      <zip>SE-70185</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+46 19 6022468</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">carl-goran.ohlson@orebroll.se</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.451792.c</gridId>
    <rorId>https://ror.org/00maqj547</rorId>
  </sponsor>
  <funder id="Funder14616-0">
    <name>The Research Committee of Orebro County Council and The Orebro University Hospital Research Foundation (Sweden)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2006-01-12T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2006-01-11T00:00:00.000Z">19584965</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A Prospective Randomized Double-Blind Study on Prevention of Urethral Restenosis by Radiotherapy</title>
      <scientificTitle/>
      <acronym>RADIUS</acronym>
      <studyHypothesis>Postoperative endourethral radiotherapy after urethrotomy may reduce rate of restenosis</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Prevention of urethral restenosis after internal urethrotomy by radiotherapy</primaryOutcome>
      <secondaryOutcome>Toxicity</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN19584965</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Prevention</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-02-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-02-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="83922f15-8b02-4980-819c-f621c17cb02b">
	  <name>Klinik für Strahlentherapie</name>
	  <address/>
	  <city>Düsseldorf</city>
	  <state/>
	  <country>Germany</country>
	  <zip>40225</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Peak flowrate &lt;15 ml/s

2. Age &gt;30 

3. Stenosis suitable for internal urethrotomy 

4. Written consent</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Male</gender>
      <targetEnrolment>180</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>180</totalTarget>
      <exclusion>1. Prior radiotherapy in this area (penis, prostate, bladder)

2. Cancer of the prostate or urethra or bladder

3. Congenital stenosis

4. Greater than three prior urethrotomies

5. Traumatic genesis 

6. Stenosis &gt;2 cm</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-02-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-02-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Urethral stenosis</description>
	<diseaseClass1>Urological and Genital Diseases</diseaseClass1>
	<diseaseClass2>Urethral stenosis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Internal urethrotomy followed by postoperative single shot endourethral Ir-192- High Dose Rate (HDR)-brachytherapy within 24 hours. The prescribed dose is 15 Gy/2 mm depth. The control group receives sham brachytherapy.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder13527-0</funderId>
      <contactId>Contact51189_13527</contactId>
      <sponsorId>Sponsor49588</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51189_13527">
    <title>Dr</title>
    <forename>Stephan</forename>
    <surname>Gripp</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Klinik für Strahlentherapie
&#13;Universitätsklinikum Düsseldorf
&#13;Moorenstrasse 5</address>
      <city>Düsseldorf</city>
      <country>Germany</country>
      <zip>40225</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 (0)2118118992</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">Gripp@uni-duesseldorf.de</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor49588">
    <organisation>University of Düsseldorf (Germany)</organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Klinik für Strahlentherapie
&#13;Universitätsklinikum Düsseldorf
&#13;Moorenstrasse 5</address>
      <city>Duesseldorf</city>
      <country>Germany</country>
      <zip>40225</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 (0)2118118992</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">Gripp@uni-duesseldorf.de</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.411327.2</gridId>
    <rorId>https://ror.org/024z2rq82</rorId>
  </sponsor>
  <funder id="Funder13527-0">
    <name>University of Düsseldorf (Germany)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2006-04-07T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2006-01-09T00:00:00.000Z">25391663</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Cristalloid versus colloid in patients with severe sepsis and septic shock</title>
      <scientificTitle/>
      <acronym>KRISCOLL (in Dutch: KRIStalloid versus COLLoid)</acronym>
      <studyHypothesis>To demonstrate whether there is difference in tissue oxygen tension and extravascular lung water while patients are being resuscitated with cristalloids or colloids combined with cristalloids.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The relation between the resuscitation regime and the tissue oxygen tension.
Furthermore the relation between the resuscitation regime and the amount of extravascular lung water, as well as the relation between the amount of extravascular lung water and the tissue oxygen tension.</primaryOutcome>
      <secondaryOutcome>1. Subcutaneous temperature
2. Laboratory findings: hemoglobin, hematrocrite, albumin, arterial and venous blood gasses
3. Hemodynamic parameters: cardiac output, VO2, DO2
4. Respiratory parameters: PEEP, PaO2/FiO2 ratio; inotropes</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN25391663</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-11-14T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="6988cb0b-634b-4f04-ac1d-59b7811226f8">
	  <name>University Medical Centre Utrecht</name>
	  <address/>
	  <city>Utrecht</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>3584 CX</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Sever sepsis or septic shock (according to the criteria of the American College of Chest Physicians/Society of Critical Care Medicine) in a mechanically ventilated ICU patient.</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>60</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>60</totalTarget>
      <exclusion>Patients under the age of 18 years and patients with a sensitivity to starch-products.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-11-14T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Sepsis, Septic shock</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Septicemia</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Subjects are assigned to be resuscitated either with cristalloids (sodium chloride 0.9%) or cristalloid combined with colloids (polyhydroxyethylstarch 10%) until resuscitation endpoints have been established.
Endpoints are an intrathoracal blood volume of &gt;850 ml/m^2, a mean arterial pressure of &gt;70 mmHg and a cardiac index of &gt;3.0 l/min/m^2.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder14579-0</funderId>
      <contactId>Contact52330_14579</contactId>
      <sponsorId>Sponsor50807</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52330_14579">
    <title>Prof</title>
    <forename>L.P.H.</forename>
    <surname>Leenen</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>University Medical Centre Utrecht
&#13;Department of Surgery HP G04.228
&#13;P.O. Box 85500</address>
      <city>Utrecht</city>
      <country>Netherlands</country>
      <zip>3584 CX</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)30 2509882</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">lleenen@chir.azu.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50807">
    <organisation>University Medical Center Utrecht (The Netherlands)</organisation>
    <website/>
    <sponsorType>Not defined</sponsorType>
    <contactDetails>
      <address>P.O. Box 85500</address>
      <city>Utrecht</city>
      <country>Netherlands</country>
      <zip>3508 GA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.7692.a</gridId>
    <rorId>https://ror.org/0575yy874</rorId>
  </sponsor>
  <funder id="Funder14579-0">
    <name>University Medical Centre Utrecht, Department of Surgery</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2006-04-03T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2006-01-09T00:00:00.000Z">55471205</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Radiotherapy with or without ibandronate in the treatment of painful bone metastases of prostate cancer</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>The purpose of this study is to evaluate the efficacy of oral ibandronate (versus placebo) added to the standard radiotherapy regimen for painful bone metastases to reduce pain, to reduce the need of analgesics, and to reduce skeletal-related events (impending fractures, need of repeated radiotherapy, or surgery).</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Primary objective will be pain reduction on the pain scale (scale 0-10) at 12 weeks of treatment. Response of treatment will be defined as a reduction of at least two points of the pain scale.</primaryOutcome>
      <secondaryOutcome>1. Pain reduction on the pain scale at 4-8-16-20-24 weeks of treatment. Use of analgesics at 4-8-12-16-20-24 weeks of treatment.
2. New skeletal-related events (= time to progression, including fractures, need of repeated radiotherapy, surgery)
3. Side effects at 4-8-12-16-20-24 weeks of treatment
4. Quality of Life, as measured by the EORTC-QLQ-C30 and EQ-5D, at 12-24 weeks</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN55471205</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-12-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-12-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="9cf38302-62dd-43a9-88b9-af36416f2879">
	  <name>Erasmus Medical Center</name>
	  <address/>
	  <city>Rotterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>3008 AE</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Karnofsky score &gt;60% 
2. Written informed consent
3. Histologically proven PC with documented (bone scintigraphy, CT scan, MRI, or conventional X-Ray) bone metastases, without spinal cord/cauda equina compression
4. Indication for analgesic radiotherapy
5. Estimated life expectancy of &gt;6 months
6. Clinically documented painful bone metastases
7. Indication for analgesic radiotherapy for the painful bone metastases</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>80</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>80</totalTarget>
      <exclusion>1. Previous treatment with any kind of bisphosphonates or radionuclides
2. Hypercalcemia (serum calcium level &gt;2.65 mmol/l), hypocalcemia (serum calcium level &lt;2.2 mmol/l), impaired renal function (creatinine &gt;266 µmol/l; albumin &gt;50 g/l), according to the medical charts
3. Investigational drugs within 30 days before study entry
4. Paget's disease
5. Untreated esophagitis or gastric ulcer</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-12-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-12-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Prostate Cancer</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2>Prostate</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Ibandronate tablet or placebo</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>ibandronate</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder14580-0</funderId>
      <contactId>Contact52321_14580</contactId>
      <sponsorId>Sponsor50808</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52321_14580">
    <title>Dr</title>
    <forename>L.</forename>
    <surname>Incrocci</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Erasmus Medical Center
&#13;Daniel den Hoed Cancer Center
&#13;P.O. Box 5201</address>
      <city>Rotterdam</city>
      <country>Netherlands</country>
      <zip>3008 AE</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)10 4391421</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">l.incrocci@erasmusmc.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50808">
    <organisation>Erasmus Medical Center (The Netherlands)</organisation>
    <website/>
    <sponsorType>Not defined</sponsorType>
    <contactDetails>
      <address>Dr. Molewaterplein 40/50</address>
      <city>Rotterdam</city>
      <country>Netherlands</country>
      <zip>3000 CA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.5645.2</gridId>
    <rorId>https://ror.org/018906e22</rorId>
  </sponsor>
  <funder id="Funder14580-0">
    <name>Roche Nederland BV</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2006-08-24T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2005-12-19T00:00:00.000Z">23561723</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Immediate optimal endocrine adjuvant therapy versus standard chemotherapy followed by the same endocrine therapy in pre- or peri-menopausal patients with early hormone receptor-positive breast cancer - the Promise study</title>
      <scientificTitle/>
      <acronym>PROMISE, BOOG 2002-01</acronym>
      <studyHypothesis>To compare the efficacy and tolerability of immediate optimal endocrine adjuvant therapy versus standard chemotherapy (five courses FE90C) followed by the same endocrine therapy in pre- and peri-menopausal patients with ER and/or PR positive primary breast cancer.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Relapse-free survival (RFS)</primaryOutcome>
      <secondaryOutcome>1. Overall survival (OS), the incidence of contralateral breast cancer
2. Safety and longterm tolerability of both treatment regimens</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN23561723</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-07-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2011-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="565d861d-ff3d-4d75-95a5-339d52a94615">
	  <name>Erasmus Medical Center</name>
	  <address/>
	  <city>Rotterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>3008 AE</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Pre-/peri-menopausal patients aged less than 60 years at entry of the trial. Patients must have had their last menstrual period less than two years before surgery of the primary tumor. In previously hysterectomised patients, women with both post-menopausal plasma Follicle Stimulating Hormone (FSH) and estradiol concentrations will be excluded.
1.a. Any N+ subgroup (N1-3, N4-9, N10)
b. Any high-risk N0 subgroup which meets one of the following criteria:
i. Tumor size more than or equal to 3 cm
ii. Tumor size 2-3 cm with grade II or III
iii. Tumor size 1-2 cm with grade III
iv. Patients under 35 years of age (with exception in case of tumors less than or equal to 1 cm, grade I)
3. Estradiol Receptors (ER) and Progesterone Receptors (PgR)status positive as defined by local hospital criteria (as cut-off levels are advised minimally more than or equal to 10% positively staining tumor cell by immunohistochemistry or more than or equal to 10 fmol/mg protein by ligand binding assay). ER-positive, PgR-negative patients are eligible
4. Patients with either Her2/neu negative or positive tumors are eligible
5. No previous systemic therapy for breast cancer
6. Adequate hematological-, renal- and hepatic function (defined as PLT more than 100 x 10^9/l, white blood cell count (WBC) more than 3 x 10^9/l, Creatinine less than 1.5 Upper Normal Limit (UNL) and SGOT (Aspartate Aminotransferase [AST]) or SGPT (Alanine Aminotrasferase [ALT]) less than 2.5 UNL)
7. Accessible for follow-up for the duration of the trial
8. Eastern Cooperative Oncology Group (ECOG) performance status zero or one
9. Written informed consent (according to International Conference on Harmonisation [ICH]/Good Clinical Practice [GCP] and local Institutional Review Board [IRB] guidelines)</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>25</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>25</totalTarget>
      <exclusion>Those patients who did not undergo intended curative primary treatment or who fulfilled one of the following criteria:
1. Inflammatory breast cancer
2. Positive supraclavicular nodes
3. Ulceration/infiltration of local skin metastasis
4. Primary surgery was completed more than 12 weeks before starting the randomised treatment
5. Both ER negative and PgR negative primary tumor
6. Evidence of distant metastases (M1)
7. Patients who have received previous systemic endocrine and/or chemotherapeutic treatment for breast cancer
8. Uncontrolled cardiac disease including unstable angina, Chronic Heart Failure (CHF) or arrhythmia requiring medical therapy or with a history of myocardial infarction within the past three months or any other serious concomitant disease
9. Psychiatric disorders preventing proper informed consent
10. Tumor with a size less than 1cm and N0 and age more than 35 years
11. Tumor size 1-2 cm, N0 with grade I or II and age over 35 years
12. Tumor size 2-3 cm, N0 with grade I and age over 35 years
13. Concomitant malignancies except for adequately treated carcinoma in situ of the uterine cervix or basal squamous cell carcinoma of the skin, unless agreed by the Steering Committee. Subjects with other malignancies must be disease-free for at least five years. Patients with a history of breast cancer should be excluded
14. Other serious illnesses that may interfere with subject compliance, adequate informed consent or determination of causality of adverse events
15. Patients who are using contraceptive pills or receiving any Hormone Replacement Therapy (HRT) for treatment of peri-/post-menopausal symptoms should stop taking these endocrine agents at least four weeks prior to randomisation
16. Pregnancy or breast feeding
17. In case a germline BRCA1 or BRCA2 mutation is known in the family of the patient, it is advised not to include such patients in the study because of the different management of these patients and the increased risks of contralateral breast cancer and ovarian cancer (it is not warranted to perform standardly a Deoxyribonucleic Acid (DNA) test within the context of this trial)</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-07-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2011-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Breast cancer</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2>Breast cancer</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>A: goserelin + anastrozole for 5 years (experimental arm)
B: 5 courses of FEC90 followed by goserelin + anastrozole for five years
Goserelin is available as four weeks depot (Zoladex 3.6 mg) and as three month depot (Zoladex 10.8 mg). Zoladex 3.6 mg depot will be administered subcutaneously every 28 days. The Zoladex 10.8 mg depot will be administered every 12 weeks.
Anastrozole 1 mg/day
FEC90 (standard dose, day 1, every 21 days): Cyclophosphamide 500 mg/m^2 intravenously (iv) (push), Epidoxorubicine 90 mg/m^2 iv (push), 5-Fluorouracil 500 mg/m^2 iv (push)</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Goserelin, anastrozole</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder14324-0</funderId>
      <contactId>Contact52074_14324</contactId>
      <sponsorId>Sponsor50535</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52074_14324">
    <title>Prof</title>
    <forename>J.G.M.</forename>
    <surname>Klijn</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Erasmus Medical Center
&#13;Daniel den Hoed Kliniek
&#13;Department of Medical Oncology
&#13;P.O. Box 5201</address>
      <city>Rotterdam</city>
      <country>Netherlands</country>
      <zip>3008 AE</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)10 4391733</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">j.g.m.klijn@erasmusmc.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50535">
    <organisation>Breast Cancer Study Group (BOOG) (The Netherlands)</organisation>
    <website/>
    <sponsorType>Not defined</sponsorType>
    <contactDetails>
      <address>P.O. Box 9236</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1006 AE</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)20 3462547</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">boog@ikca.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.476173.0</gridId>
    <rorId>https://ror.org/04cr37s66</rorId>
  </sponsor>
  <funder id="Funder14324-0">
    <name>CKTO, Astra Zeneca</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2006-09-29T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2005-09-29T00:00:00.000Z">87057460</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Effectiveness of the Dual Serotonin Norepinephrine Reuptake Inhibitor Venlafaxine in Depressed Patients</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Tyramine is well known by clinicians for its capacity to increase blood pressure, typically in patients treated with monoamine oxidase inhibitors. The finding that pretreatment with reserpine, which induces a depletion of catecholamines, abolishes the effect of Tyramine on blood pressure suggests that Tyramine acts indirectly as a sympathomimetic agent. It has been shown that Tyramine is taken up in NE neurons by the NE transporter and that by stochiometric displacement, it then releases NE from intraneuronal stores (Hoffman and Lefkowitz 1990). Blood pressure is increased by the release of NE; therefore, blood pressure serves as a simple and reliable index of the action of Tyramine. The Tyramine test (Ghose and Turner 1975) consists of measuring the transient increase in the blood pressure of patients after a Tyramine load. It can be carried out either by determining the dose of Tyramine required to induce a fixed increase in systolic blood pressure (SBP) (for example, 30 mmHg,) or by measuring the effect of a fixed dose of Tyramine. Pretreatment with Tomoxetine (now called Atomoxetine), a relatively potent and selective inhibitor of NE uptake, has been reported to decrease the transient elevation in blood pressure produced by Tyramine administration (Zerbe et al. 1985). In recent work, we have demonstrated that transient blood pressure elevation in response to Tyramine is reduced by pretreating subjects with Desipramine, Nortriptyline, Clomipramine and Reboxetine, three NE uptake inhibitors, but not by pretreating with Paroxetine, a selective 5-HT uptake inhibitor (Blier et al. 1997; Slater et al. 2000; Turcotte et al. 2001). In the proposed study, if treated subjects decrease their pressor response to Tyramine, it will be interpreted as evidence of NE uptake inhibition.
In this study, the 5-HT content of the whole blood will be used as an index of 5-HT uptake in depressed patients and will be measured before and after each week of treatment. Since more than 90% of the 5-HT in the blood is in platelets, it is not necessary to correct this value for the platelet count. Notably, Flament et al. (1987) found that the mean level of 5-HT did not change significantly after 5 weeks of placebo whereas it dropped by 95% after 5 weeks of treatment with clomipramine. In this study, the use of each subject as his own control will allow the use of covariance analysis, increasing the likelihood of detecting a statistically significant difference between the different groups at the end of the treatments.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The primary objective of this study is to find evidence of a dose-dependent inhibition of NE reuptake starting of Venlafaxine at 150 mg/day.</primaryOutcome>
      <secondaryOutcome>A secondary objective of this study is to show a lack of effect of Paroxetine on NE reuptake at doses of up to 50 mg/day. Another secondary objective is to show a lack of effect of Atomoxetine on 5-HT reuptake and a similar action of higher doses of Venlafaxine and Atomoxetine on NE reuptake. A third secondary objective is to show a marked effect of Paroxetine and Venlafaxine on 5-HT reuptake starting at low doses.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN87057460</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-08-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-04-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Canada</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="8f810a2d-e014-4d69-95d4-4e999a1b3770">
	  <name>1145 Carling Avenue</name>
	  <address/>
	  <city>Ottawa</city>
	  <state/>
	  <country>Canada</country>
	  <zip>K1Z 7K4</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Male or female patients between 18 and 65 years of age
2. Diagnosis of major depression according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) (American Psychiatry Association, 1994) using the Structured Clinical Interview for Depression (SCID) (Spitzer 1992)
3. Initial global score 18 on the 17-item Hamilton depression rating scale
4. Written informed consent signed by the patient</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>40</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>40</totalTarget>
      <exclusion>1. Evidence of significant physical illness contraindicating the use of Venlafaxine, Paroxetine or Atomoxetine found on physical or in the laboratory data obtained during the first week of the study
2. Evidence of suicidality or severity of depression precluding safe participation in the study
3. Mental retardation (IQ lower than 80) rendering the response to investigators unreliable
4. Pregnancy, or absence of adequate contraceptive method in women with childbearing potential
5. Concurrent use of psychotropic medication such as antipsychotics, mood stabilizers or regular use of high doses of benzodiazepines
6. Lack of response or intolerance to optimal doses of Paroxetine, Venlafaxine or Atomoxetine
7. Participation in another clinical trial within 30 days of entry into the current study</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-08-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-04-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Major Depression</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Depression</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>This is a three-arm, randomized, parallel study designed to assess the inhibition of NE and 5-HT uptake by Venlafaxine, Paroxetine and Atomoxetine. Approximately 40 depressed patients will be randomized to one of three treatment groups with the goal of having at least 10 subjects complete the study in each group. The investigators involved in the Tyramine test or the collecting of biochemical data will be blind to the medications used by patients. This study will be conducted on an outpatient basis.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Venlafaxine, Paroxetine and Atomoxetine</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder13532-0</funderId>
      <contactId>Contact51194_13532</contactId>
      <sponsorId>Sponsor49593</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51194_13532">
    <title>Prof</title>
    <forename>Pierre</forename>
    <surname>Blier</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>1145 Carling Avenue
Room LG2043</address>
      <city>Ottawa</city>
      <country>Canada</country>
      <zip>K1Z 7K4</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 613 722 6521 (6908)</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">pblier@rohcg.on.ca</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor49593">
    <organisation>Wyeth Pharmaceuticals (Canada)</organisation>
    <website>http://www.wyeth.com</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>50 Minthorn Boulevard</address>
      <city>Markham, Ontario</city>
      <country>Canada</country>
      <zip>L3T 7Y2</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.421137.2</gridId>
    <rorId>https://ror.org/059g90c15</rorId>
  </sponsor>
  <funder id="Funder13532-0">
    <name>Wyeth Pharmaceuticals</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2006-11-16T00:00:00.000Z" version="17">
    <isrctn dateAssigned="2005-09-21T00:00:00.000Z">86563511</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Investigating cognitive effects of aromatherapy on people with dementia living in residential care facilities</title>
      <scientificTitle/>
      <acronym>Aromatherapy trial</acronym>
      <studyHypothesis>Twelve weeks of aromatherapy treatment with the active oil blend will show a statistically significant improvement in participants&#146; cognitive ability and behavioural characteristics compared to baseline</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The primary outcome measure will be the difference in mean baseline and endpoint scores on the standardised Mini-Mental State Examination (MMSE) (Molloy et al., 1991). The MMSE is the standard scale used by aged care facilities for assessing the stage of dementia and cognitive function of their residents.

The annual rate of change on the MMSE for people with a base-line score between 7-28 is a decrease of 3.6 points per year, or about 0.9 points per 12 weeks (Swanwick et al., 1998). A typical Alzheimer's drug trial reports a mean MMSE increase over 12 weeks between 0.8 and 2.3 points for a similar population.</primaryOutcome>
      <secondaryOutcome>Secondary outcome measures will be:
1. Difference in baseline, repeated measures and endpoint scores on the Nurses&#146; Observation Scale for Geriatric Patients (NOSGER) (Spiegel et al. 1991)
2. Changes in the use of other medications related to cognitive and behavioural functions (for example, anti-depressants, anti-psychotics)
3. Correlation between ability to smell the treatments and end-point scores on MMSE and NOSGER</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at registration time</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN86563511</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>ECN-04-201</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Other</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-04-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-09-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Australia</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="fea9a1ac-0a6d-495a-998d-877e2e75e323">
	  <name>P.O. Box 157</name>
	  <address/>
	  <city>Lismore</city>
	  <state/>
	  <country>Australia</country>
	  <zip>2480</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Residents in good health will be invited to participate in the treatment arms of the study if they also comply with the following criteria. They must:
1. Have been living in the nursing home for more than 3 months
2. Be more than 65 years old
3. Already be on an aromatherapy care plan; or deemed by the Director of Care or the care staff to be unlikely to be disturbed by the use of the aromatherapy lotion in place of their normal skin integrity lotion
4. Have English as their first language

They must also have:
5. A Mini-Mental State Examination (MMSE) score of 10-26
6. A diagnosis of dementia, short-term memory loss or cognitive impairment that is not caused by any other diagnosis of mental illness

7. Residents with non-acute concomitant diseases may participate if their disease is medically controlled.</inclusion>
      <ageRange>Senior</ageRange>
      <gender>Both</gender>
      <targetEnrolment>130</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>100-130 people</totalTarget>
      <exclusion>1. Had a myocardial infarction or stroke in previous 3 months
2. Epilepsy
3. Current treatment with anti-cholinesterase or anti-cholinergic drugs
4. Eczema, psoriasis or dermatitis around the neck and shoulders area
5. Known allergy to Eucalyptus, Cypress, Ginger, Lemongrass, Lime or Mandarin essential oils or aqueous cream
6. An adverse reaction to treatment patch-tests given during screening process
7. Vision or hearing impairments that prevent them from undertaking the cognitive test</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-04-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-09-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Dementia</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Dementia</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The 'active' treatment will contain 1 ml each of Cypress (Cupressus sempervirens), Lime (Citrus latifolia) and Eucalyptus (Eucalyptus globulus) essential oils, diluted in a non-fragranced aqueous cream lotion.

The 'inactive' preparation will contain 1 ml each of Ginger (Zingiber officinalis), Lemongrass (Cymbopogon citratus) and Mandarin (Citrus recticulata) essential oils, diluted in a non-fragranced aqueous cream lotion.

The placebo preparation will contain only non-fragranced aqueous cream lotion and will be used during the washout periods. An important purpose of the placebo is to control for the possible effect of touch.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Cypress (Cupressus sempervirens), Lime (Citrus latifolia) and Eucalyptus (Eucalyptus globulus)</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder13146-0</funderId>
      <contactId>Contact50698_13146</contactId>
      <sponsorId>Sponsor49084</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50698_13146">
    <title>Prof</title>
    <forename>Stephen</forename>
    <surname>Myers</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>P.O. Box 157</address>
      <city>Lismore</city>
      <country>Australia</country>
      <zip>2480</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+61 (0)2 66 20 3403</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">smyers@scu.edu.au</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor49084">
    <organisation>Australian Centre for Complementary Medicine, Education and Research (ACCMER)</organisation>
    <website/>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>P.O. Box 157</address>
      <city>Lismore</city>
      <country>Australia</country>
      <zip>2480</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">joconnor@scu.edu.au</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder13146-0">
    <name>Post graduate funding from Australian Centre for Complementary Medicine, Education and Research (ACCMER) and the School of Natural and Complementary Medicine</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2006-12-15T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2004-08-09T00:00:00.000Z">75804878</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Single versus Dual Incision Minimally Invasive Hip Arthroplasty</title>
      <scientificTitle/>
      <acronym>Mini hip</acronym>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN75804878</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>2003-025</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-07-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Australia</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="43109cfd-76bb-465a-93fb-fe9494a526ef">
	  <name>Perth Orthopaedic Institute</name>
	  <address/>
	  <city>Perth</city>
	  <state/>
	  <country>Australia</country>
	  <zip>6009</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Not provided at time of registration</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>0</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Not provided at time of registration</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-07-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Osteoarthritis</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Osteoarthritis (OA)</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Total hip arthroplasty: single versus dual incision minimally invasive hip arthroplasty</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder5718-0</funderId>
      <contactId>Contact7149_5718</contactId>
      <sponsorId>Sponsor5312</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact7149_5718">
    <title>Prof</title>
    <forename>Bo</forename>
    <surname>Nivbrant</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Perth Orthopaedic Institute
Gate 3
Verdun St
Nedlands</address>
      <city>Perth</city>
      <country>Australia</country>
      <zip>6009</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor5312">
    <organisation>Perth Orthopaedic Institute</organisation>
    <website/>
    <sponsorType>Not defined</sponsorType>
    <contactDetails>
      <address>Gate 3
Verdun St
Nedlands</address>
      <city>Perth</city>
      <country>Australia</country>
      <zip>6009</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+61 8 9346 6211</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">nivbrant@cyllene.uwa.edu.au</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder5718-0">
    <name>Perth Orthopaedic Institute</name>
    <fundRef/>
  </funder>
</fullTrial></allTrials>